How Process Intensification and Continuous Manufacturing are Reshaping the Economics of Clinical and Commercial Biologics Supply

Robert Valdes
John Valdes
BIOTECH RESOURCES GROUP, LLC

BRG
GMP IS IN OUR DNA(R)

How Process Intensification and Continuous Manufacturing are Reshaping the Economics of Clinical and Commercial Biologics Supply

Robert Valdes John Valdes

Biotech Resources Group, LLC

BRG
BIOTECH RESOURCES GROUP

GMP IS IN OUR DNA(R)

This first edition published June 26, 2026

Limit of Liability

Although the authors have made every effort to ensure that the information in this book was correct, the authors do not assume and hereby disclaim any liability to any party for any loss, damage, or disruption caused by errors or omissions, whether such errors or omissions result from negligence, accident, or any other cause.

Front Cover: by Biotech Resources Group, LLC
Back Cover: by Biotech Resources Group, LLC
Icons, logo: by Biotech Resources Group, LLC
Font: Montserrat

Trademarks: Created and Owned by Biotech Resources Group, LLC
Slogans: Biotech Resources Group, LLC
No ISBN as of June 2026 / E-Book/pdf is the only format created

- **Effort**: The authors searched and read more than 2500 pages of brochures, white papers, journal articles, textbook chapters.
- **E-Book #1 creation**: 7 months
- **E-Book #2**: Completion data to be announced
- **Software**: MS word, MS excel, MS Visio, Kofax PowerPDF
- **Software**: Colossyan, Chrome, Perplexity

To those who shaped me by example:

If you learn a lot, pass it on.
If you earn a lot, give back.
If you've been lucky, stay humble.
And remember—time always wins,
so do something fun today.

Smile big!

Robert Valdes

Biotechnology Consultant | Biotech Resources Group, LLC | Maryland, EU, APAC

Robert (Bob) Valdes is a biomanufacturing executive and GMP consultant with over 25 years of experience leading global biotechnology operations. As cofounder of Biotech Resources Group (BRG), he advises CDMOs and innovators including Thermo, Lonza, GSK, and Wuxi on driving GMP batch success, increasing capacity, and scaling reliably across multiple regions. Previously, he served as Director of Large-Scale Manufacturing at Human Genome Sciences, where he oversaw production readiness for Benlysta®, the first new lupus therapy approved in more than 50 years. His earlier roles at Lonza Biologics (US/UK) spanned biologics manufacturing, design, and engineering, giving him a deep understanding of end-to-end commercial production. Bob holds an M.Sc. from the University of Massachusetts, an MBA from the Johns Hopkins Carey Business School, and a B.A. in Microbiology from the University of New Hampshire. Outside of work he is an avid cyclist, hockey player, mentor, and fountain pen enthusiast.

John Valdes

Supply Chain Consultant | Biotech Resources Group, LLC | Boston Metro Area

As a dedicated leader in operational excellence, John specializes in transforming complex, chaotic environments into streamlined engines of innovation, accountability, and excellence. His leadership philosophy is rooted in driving cultural shifts that empower teams to embrace data-driven decision-making and sustainable growth.
By integrating rigorous Lean and Six Sigma methodologies, John executes comprehensive strategic plans designed to assess and elevate organizational processes. John's commitment to continuous improvement is not just about the metrics; it is about building a scalable culture where process efficiency directly contributes to increased value for both the organization and the customer.

"Biologics manufacturing is entering a decade in which cost, capacity, and flexibility will determine who remains competitive, particularly as originator products lose exclusivity and biosimilars reshape global price expectations. Traditional fed-batch platforms and incremental debottlenecking can no longer reliably deliver the economics and agility that portfolios of mid-volume biologics, biosimilars, and regionally supplied products require. Process intensification and continuous manufacturing have moved from interesting pilots to proven options in commercial settings, yet many organizations remain in a sustained "wait and see" posture.

"The expectation is not that every reader will become a subject-matter expert in process intensification and/or continuous manufacturing. Rather, by the end of the book, a COO or technical leader should be able to articulate why PI/CM is strategically relevant to their own portfolio and network, distinguish between incremental optimization and step-change redesign, identify a small number of credible starting points, and ask sharper questions of internal teams and external partners. In short, this e-book is designed to move leadership from general awareness to a deliberate, defensible decision about when and how to act. It should make you think a little differently."

BRG TEAM 2026

Expectation Management:

"The expectation is not that every reader will become a subject-matter expert in process intensification and/or continuous manufacturing. Rather, by the end of the book, a COO or technical leader should be able to articulate why PI/CM is strategically relevant to their own portfolio and network, distinguish between incremental optimization and step-change redesign, identify a small number of credible starting points, and ask sharper questions of internal teams and external partners. In short, this e-book is designed to move leadership from general awareness to a deliberate, defensible decision about when and how to act.
It should make you think a little differently."

— BRG Team 2026

Executive Summary: Why will PI/CM Reshape Biologics Manufacturing?

Biologics manufacturing is entering a decade in which cost, capacity, and flexibility will determine who remains competitive, particularly as originator products lose exclusivity and biosimilars reshape global price expectations. Traditional fed-batch platforms and incremental debottlenecking can no longer reliably deliver the economics and agility that portfolios of mid-volume biologics, biosimilars, and regionally supplied products require. Process intensification and continuous bioprocessing have moved from interesting pilots to proven options in commercial settings, yet many organizations remain in a sustained "wait and see" posture.

This e-book is written for senior leaders who find themselves in that position. It is aimed at Chief Operating Officers, Heads of Technical Operations, Site Heads, Manufacturing and MSAT leaders, and CDMO executives who must make high-stakes decisions about platforms, facilities, and partnerships. It is equally relevant to strategy, finance, and business development leaders who evaluate major capital projects and CDMO arrangements and need a sharper understanding of how intensified and continuous architectures change the economics of biologics.

The purpose of this book is to translate process intensification and continuous bioprocessing from technical concepts into board-level decisions about cost of goods, capacity, capital efficiency, and risk. Rather than cataloging every available technology, the focus is on the questions a cautious leadership team must answer why the timing for intensification is different now; what realistic options exist between "do nothing" and fully end-to-end continuous plants; how these options affect cost, throughput, and footprint; and what levels of digital, regulatory, and organizational maturity are actually required. The goal is to reframe inaction as a deliberate, quantifiable strategic choice, not a neutral default.

Readers will find a clear explanation of why process intensification has become strategically urgent, weaving together biosimilars, Loss of Exclusivity (LOE) cliffs, portfolio fragmentation, regionalization, and policy trends. The main process archetypes—intensified seed trains, intensified fed-batch, production perfusion, and intensified downstream processing—are described in business terms: what they are, where they fit, and what they change in practice. Economic and capacity impacts are made explicit by comparing conventional, hybrid PI, and end-to-end PI configurations in terms of productivity, cost of goods, footprint, and return on investment. Common barriers and risks—technical, regulatory, digital, and cultural—are treated directly rather than minimized, with an emphasis on concrete mitigation strategies for risk-averse organizations.

The book also lays out a phased implementation roadmap that can be lifted into internal playbooks and governance decks. It describes how to start with a small number of high-value use cases, how to progress through lab models and integrated pilots, how to make credible go/no-go decisions, and how to align facility design, automation, and PAT with the chosen process concepts.

Different archetypes are mapped to different company profiles: large innovators with stainless cathedrals, single-use-heavy or greenfield CDMOs, biosimilar-focused players, and organizations working with more complex or unstable modalities.

Different readers will approach the information provided with different priorities. Early chapters orient executives on the strategic "why" and the main options available, while later chapters serve as references when reviewing internal PI proposals or CDMO offerings. The final sections consolidate the content into checklists, example decision paths, and questions that can structure governance discussions and board updates.

This is not a technology catalog or a vendor brochure. It is a decision guide for leaders who already suspect that intensified and continuous manufacturing will be part of their future, but who have not yet seen a clear, de-risked path for their own organizations. By the end of the book, a COO or Head of Technical Operations should be able to articulate why process intensification and continuous bioprocessing matter for their specific portfolio and network, distinguish between incremental optimization and step-change redesign, identify a small number of credible starting points, and ask sharper questions of internal teams and external partners.

The Competitive Imperative

Biologics manufacturing stands at an inflection point. Traditional fed-batch platforms—built around large stainless-steel bioreactors and discrete batch operations—no longer meet the combined demands of cost, capacity, flexibility, and sustainability.

Process intensification (PI) has moved from niche innovation to mainstream strategy, enabling 3–8× higher productivity, 40–60% smaller facility footprints, and dramatic reductions in cost of goods. Less than 20% of companies have moved beyond pilots, creating a widening competitive gap between early adopters and conservative organizations. For innovators, CDMOs, and biosimilar manufacturers, the strategic question is no longer *if* to adopt PI, but *where*, *when*, and *how* to deploy it most effectively.

What Is Process Intensification / Continuous Manufacturing ?

Process Intensification (PI) and Continuous Manufacturing (CM) are the key components of a modular toolbox of technologies and strategies that increase volumetric productivity and reduce facility footprint:

- **Upstream:** N-1 perfusion seed trains, high-inoculation fed-batch, production perfusion—delivering 2–8× higher titers and cumulative output
- **Downstream:** Multicolumn chromatography (MCC), membrane capture, continuous viral inactivation, flow-through polishing, single-pass TFF—reducing resin consumption 50–70% and buffer volumes 40–60%
- **Digital backbone:** Process analytical technology (PAT), real-time control, integrated automation, and data platforms enabling closed-loop optimization
- **Facility concepts:** Modular POD cleanrooms, buffer inline conditioning (BIC), and hybrid single-use/stainless designs—cutting capital by 30–50% and deployment time from 3–5 years to 6–12 months

PI/CM is not a single monolithic continuous process. Organizations implement PI/CM incrementally—starting with N-1 perfusion or MCC capture, then adding perfusion or continuous polishing as experience, expertise, and business cases justify.

Why Now - 5 Converging Forces Making PI/CM Urgent

1. Market fragmentation

Biosimilars, regional supply chains, and niche indications demand smaller, more flexible manufacturing nodes rather than single mega-facilities.

2. Cost pressure

Payer scrutiny and competitive biosimilar launches are driving required mAb cost of goods below $50/g—unattainable with conventional platforms.

3. Modality complexity

Unstable proteins, bispecifics, viral vectors, and cell therapies benefit from shorter residence times, higher control granularity, and minimal hold steps that PI enables.

4. Regulatory clarity

ICH Q13 (Continuous Manufacturing guideline, Jan 2023) and FDA/EMA guidances explicitly endorse PI and continuous manufacturing when supported by robust control strategies.

5. Technology readiness

Single-use perfusion systems, continuous chromatography skids, PAT sensors, and digital platforms have matured from R&D curiosities to validated, scalable commercial tools.

Business Impact: Real-World Outcomes

Early adopters report compelling gains across multiple dimensions. See table below.

Metric	Fed-Batch	Pi/Cm (Hybrid/E2E)
Volumetric productivity	Baseline	3–8× higher
Cost of goods (mAb)	$80–150/g	$40–70/g
Facility footprint	3,000–5,000 m²	800–2,000 m²
Campaign duration	14–21 days	21–60 days (perfusion)
Resin consumption	Baseline	50–70% reduction
Buffer volumes	Baseline	40–60% reduction
Capital deployment	3–5 years	6–18 months (modular)

These improvements translate into:

- **Capacity unlocking:** 50–80% more throughput from existing plants without adding bioreactor volume
- **Capital efficiency:** $100–300M savings vs. traditional greenfield builds for equivalent capacity
- **Sustainability:** 30–50% lower process mass intensity (PMI), energy, and CO_2e per kg product
- **Agility:** Faster tech transfer, multi-product flexibility, and regional manufacturing viability

Implementation Roadmap

Successful PI/CM programs follow a structured four-phase approach:

Phase 0 – Strategy & Scoping (0–6 months)

Define business case, select target products, establish cross-functional governance (PD, MSAT, QA/QC, Regulatory, Engineering, Digital/Automation, Finance).

Phase 1 – Lab Development (6–18 months)

Build robust scale-down models for intensified upstream (N-1 perfusion, high-density seed) and downstream (MCC, membranes, continuous VI). Establish PAT and data foundations.

Phase 2 – Pilot Integration (12–30 months)

Demonstrate integrated PI/CM flows at 50–500 L scale. Execute robustness testing, FMEA, and regulatory alignment (control strategy, batch definition, comparability).

Phase 3 – Commercial Deployment (≥24 months)

Finalize facility design (PODs, automation, utilities), technology transfer, operator training, and lifecycle management. Track realized CoG and capacity gains vs. business case.

Critical success factors:

- Named PI Champion with cross-functional authority
- All seven functions engaged from Phase 0 (not bolted on later)
- Digital/automation specified in equipment selection, not retrofitted
- QA drafts sampling and quality strategy in Phase 1, not at pilot launch
- MSAT adequately resourced (3–5 FTE for pilot execution)

Who Should Read This Wonderful E-Book?

- **Innovators (biotech, biopharma):**CMC, Technical Operations, and Strategy leaders evaluating PI/CM for pipeline molecules or capacity-constrained assets

- **CDMO's:** Technical, Commercial, and Facility leaders designing next-generation platforms and positioning PI/CM capabilities competitively

- **Biosimilar Manufacturers:** Operations and Finance leaders seeking cost structures that enable regional manufacturing and market competitiveness

- **Engineering & Digital Teams:** Facility designers, automation architects, and PAT specialists implementing PI/CM-ready infrastructure

- **Regulatory & Quality Leaders:** Professionals navigating ICH Q13 implementation, batch definition, and continuous process validation

The Bottom Line

Process intensification is no longer experimental. It is a proven, regulator-endorsed strategy that fundamentally changes the economics, agility, and sustainability of biologics manufacturing.

ONE: From Awareness to Decision

1.1 The Leadership Dilemma

Most senior leaders in biologics manufacturing are no longer debating whether process intensification and continuous bioprocessing (PI/CM) are technically possible. They are debating whether now is the right moment to commit, how far to go, and what happens if they wait. Mild awareness of benefits, case studies, and regulatory endorsements has not translated into decisive movement in many organizations, especially where existing plants are still "good enough" on paper.

That gap between awareness and action matters because facility, platform, and partnership choices made in the next 24–36 months will determine whether a company can compete on cost, speed, and flexibility through the coming wave of loss-of-exclusivity (LOE) events and biosimilar launches. "Wait and see" is not a neutral holding pattern; it is a strategic decision with financial and operational consequences over the next decade.

1.2 The Cost of Inaction

From a distance, Process Intensification (PI) and Continuous Manufacturing (CM) can look like optional upgrades—attractive, but not strictly necessary this year. That framing breaks down under LOE, biosimilar, and capital-allocation pressure.

For many biologics portfolios, the difference between conventional and intensified or continuous architectures is measured in multiples, not percentage:

- Several-fold differences in space-time yield and annual throughput per bioreactor
- Double-digit percentage reductions in cost of goods per gram
- The ability to add the equivalent of a new line's capacity inside existing walls rather than building a new facility

Every year without a clear PI roadmap increases the likelihood that:

- Stainless or first-generation single-use assets become locked into structurally uncompetitive CoG's for key biologics and biosimilars
- Capacity constraints are "solved" by more of the same—extra tanks, incremental debottlenecking, or one-off single-use suites—rather than by architectures that change the productivity baseline

Once price pressure intensifies post-LOE, this structural disadvantage cannot be corrected quickly. A PI/CM program started only when margins are already eroding will deliver meaningful benefits years after competitors that moved earlier. This is called late-mover risk.

1.3 Why Awareness Hasn't Become Action

If the advantages are recognized, why do many organizations still hesitate? Across Innovators, CDMOs, Joint-Ventures (JV), and Academia, similar themes persist.

First, perceived risk outweighs visible upside. Intensified and continuous architectures are seen as introducing new single points of failure—cell-retention devices, integrated skids, extended campaigns—and deeper dependence on automation, data integrity, and PAT. Leaders worry that deviations in a long campaign could compromise large volumes of product or overwhelm operations and QA.

Second, internal business cases are often underspecified. Proposals for PI/CM can emphasize 2-10× fold-changes in titer and space-time yield but fail to tie them clearly to NPC, NPV, IRR, Pricing, Formulary, Payback, and network strategy. They sometimes present PI/CM as an all-or-nothing leap to fully end-to-end (e2e) continuous manufacturing, rather than as a spectrum of options from N-1 perfusion and intensified fed-batch through hybrid lines. For a cautious executive team, this makes PI/CM look like a binary bet rather than a set of staged, testable moves.

Third, regulatory and organizational myths persist. Despite guidance such as ICH Q13, Q9, and multiple commercial precedents, there is lingering concern that regulators will treat intensified or continuous processes as inherently higher risk, that QA/QC will be overwhelmed by new control strategies and batch definitions, and that operations teams will struggle to move from batch-campaign thinking to flow-oriented oversight. These concerns are not imaginary; they reflect real implementation challenges. But they are also manageable, provided the adoption path is phased, cross-functional, and explicit.

Let's jump to Chapter Two.

TWO: Why Now?

2.1 The Strategic Inflection Points in Biologics

Biologics manufacturing has passed the point where incremental platform tweaks on large, batch-based plants are enough to stay competitive. Traditional stainless-steel fed-batch facilities, originally optimized for a handful of blockbuster monoclonal antibodies, now struggle to provide the flexibility and economics required for portfolios dominated by mid-volume biologics, biosimilars, and regionally supplied products. As shown in Figure 2-1, the industry is already shifting from a single "cathedral" facility model toward a spectrum of PI/CM-enabled intermediate and small-scale nodes better aligned with this reality.



Figure 2-1: Evolution from large, centralized fed-batch facilities to a spectrum of PI/CM-enabled intermediate and small-scale nodes, including portable and personalized facilities. Note the factories situated on continents notoriously dependent on external suppliers for most therapeutics

At the same time, the conditions that once justified waiting have largely disappeared. Regulatory agencies have clarified expectations for continuous manufacturing; single-use perfusion systems, intensified downstream operations, and PAT have matured; and early adopters have demonstrated compelling gains in productivity, cost, and footprint at commercial scale.

The strategic question for Innovators and CDMOs is therefore no longer whether to adopt process intensification, but where, when, and how aggressively to deploy it in their networks. Senior manufacturing and technical leaders must decide which parts of the network should move first, which archetypes of intensified processes and facility to prioritize, and how to balance risk, speed, and capital across a multi-product portfolio.

2.2 Market and Portfolio Pressures

For many years, biologics manufacturing was built around a simple pattern: a small number of very large-volume products with relatively stable demand, justifying large, hard-piped plants with long campaigns and slow changeovers. Today, most organizations manage dozens of monoclonal antibodies, bispecifics, fusion proteins, and other modalities across different lifecycle stages, often with lower and more uncertain peak volumes. Leaders face a persistent tension between keeping facilities highly utilized and accommodating frequent product switches, tech transfers, and late lifecycle changes.

Biosimilars make this tension particularly visible. As originator products lose exclusivity, biosimilar manufacturers are forced to compete primarily on cost and speed while serving fragmented regional markets and demand that is often lower than early forecasts suggested. For both originators defending share and biosimilar players attacking it, process intensification and continuous manufacturing offer a way to reconcile these constraints: higher productivity from smaller, more flexible assets that can support a mix of products without locking capital into single-product configurations.

In parallel, governments and health systems are pushing for more resilient and regionalized supply chains, particularly in the wake of COVID-19 disruptions and geopolitical shocks. This often translates into a shift from a single mega-facility shipping globally to multiple, smaller nodes located closer to patients, a pattern captured in the BPOG "biomanufacturing scenarios" view adapted in Figure 2-1.

Intensified processes, especially when embedded in modular facilities and pod-based cleanrooms, align naturally with this direction by enabling compact, right-sized capacity in each region without replicating the full cost and complexity of a traditional large plant.

2.3 Economics: From Marginal to Step-Change

Historically, many leadership teams have treated process intensification as a tactical way to "add a bit of capacity" or trim cost at the margin. In practice, the combination of high cell densities, perfusion or intensified fed-batch, and streamlined downstream trains can move productivity and cost of goods by multiples rather than percentages.

These step-changes matter particularly in mid-volume and late-lifecycle settings where traditional stainless capacity is under-utilized. In such scenarios, a well-designed intensified single-use train can deliver equivalent output at a fraction of the footprint, with lower capital at risk and more resilient operating economics across a range of demand outcomes. Even when peak volume initially appears to justify a large stainless facility, portfolio and loss of exclusivity (LOE) dynamics often erode utilization over time; PI/CM provides a structural hedge against that erosion.

For CDMOs, intensified architecture also changes the underlying business model. Higher throughput per square meter and faster changeovers translate into more billable campaigns per line per year, smoother capacity expansion via scale-out rather than lumpy scale-up, and a more attractive cost position in competitive biosimilar and mid-volume innovator markets. These economics are central to the arguments captured in Figure 2-1 and reinforced by multi-scenario analyses in adjacent viral vector and advanced therapy platforms.

2.4 Technology, Regulation, and Risk Perception

Ten years ago, hesitancy around process intensification and continuous bioprocessing was often grounded in genuine technology and regulatory uncertainty.

Today, the picture is more nuanced: upstream and downstream technologies have matured, regulatory expectations are clearer, and multiple case studies and roadmaps have codified best practices for design, control strategies, and lifecycle management.

At the same time, industry analyses highlight that the dominant barriers to adoption are increasingly business, cultural, and organizational rather than purely technical.

Concerns about being "first," about integrating new technologies into existing assets, and about cross-site portability often slow decisions more than any specific gap in equipment or guidance. Initiatives such as Biomanufacturing Readiness Levels, NIIMBL and BioPhorum testbeds, and collaborative case studies are explicitly designed to address these perceived risks, creating shared evidence that de-risks adoption across companies and sites.

From a regulatory standpoint, continuous manufacturing guidances now provide concrete expectations for control strategies, material traceability, disturbance management, and model lifecycle management. When PI/CM is framed as part of a structured control strategy within ICH Q8/Q9/Q10/Q12/Q13 and an agile, data-driven pharmaceutical quality system, it becomes easier for both regulators and manufacturers to view it as a disciplined evolution of existing practice rather than as an experimental outlier.

2.5 Convergence of Drivers: Why "Optional" Is No Longer Realistic

Individually, none of these forces—cost pressure, portfolio complexity, biosimilars, regionalization, technology maturity, regulatory clarity—would necessarily make process intensification inevitable. Taken together, they form a coherent pattern in which maintaining a conventional, batch-centric network becomes increasingly misaligned with both competitive and policy realities. Table 1.0 brings these drivers together, adapting the BPOG roadmap vision to show how market trends, performance requirements, and enabling technologies converge on intensified, modular, and increasingly continuous biomanufacturing as the logical response.

For innovators, this convergence manifests as a growing gap between the economics and responsiveness of intensified versus non-intensified assets, particularly in late development and lifecycle management. For biosimilar and LOE players, it shows up as a cost-of-goods and speed-to-market race that cannot be won sustainably with legacy architectures, especially when competing across multiple regions. For CDMOs, it underpins the strategic choice between being a capacity provider in a price-compressed, commoditized environment and being a technology-differentiated partner with structurally advantaged economics.

In that sense, the core argument of this chapter is not that every asset must become fully continuous or that intensification is risk-free. Rather, it is that the convergence of external pressures and internal economics makes a thoughtful, staged adoption of process intensification a strategic necessity rather than a discretionary optimization.

THREE: The PI/CM Toolbox – Architectures, Archetypes, and Flow Paths

3.1 Architecture Spectrum

Process intensification in biologics spans a spectrum from "better batch" all the way to fully integrated continuous lines. The architecture choice determines not just productivity, but also facility design, automation strategy, and regulatory posture. This chapter translates the main PI archetypes into business language—what they are, where they fit, and what they change in real facilities[1][2].

3.2 Upstream Building Blocks

3.2.1 Intensified Seed and N-1 Strategies

Most successful PI programs start upstream, in the seed train. Intensified N-1 or N-2 stages are used to reach much higher cell densities before inoculation of the production bioreactor, enabling either higher starting viable cell densities (VCD) in fed-batch or cleaner transition into perfusion[3][4].

Key patterns include:

High-inoculation fed-batch (IFB):

- Use enriched media or fed-batch at N-1 to reach 20–30 × 10^6 cells/mL, then inoculate the production bioreactor at 5–10× higher VCD than a conventional process[5][6]
- **Benefits:** 2–4× higher titer in the same vessel, shorter overall culture duration, and better use of existing stainless assets[7]

N-1 perfusion:

- Maintain the N-1 stage in perfusion (alternating tangential flow or tangential flow filtration) to achieve very high viable cell densities and a metabolically "clean" inoculum[8][9]
- **Benefits:** Robust high-inoculation without over-stressing cells, smoother operation when feeding a production perfusion reactor, and easier scale-down modeling of intensified seeds[10]

These approaches can usually be implemented with limited facility changes (additional single-use equipment, media capacity, and gas/harvest handling), making them attractive "first steps" along the architecture spectrum[11].

3.2.2 Production Bioreactor Modes

At the production stage, the main choices are:

Intensified fed-batch (IFB):

- Standard stirred-tank reactors (STRs), but with higher inoculation, optimized feeds, and potentially shorter runs
- Well aligned with current regulatory expectations and validation approaches, especially for monoclonal antibodies and robust Fc-fusion proteins[12][13]

Perfusion (steady-state or dynamic):

- Continuous media exchange with cell retention; can be run at near-steady state or with controlled rate changes[14][15]
- **Advantages:**
  - High space-time yields, especially for unstable molecules and viral vectors
  - More consistent culture conditions and often more consistent product quality attributes (e.g., glycosylation) due to reduced feast-and-famine cycles[16]
- **Trade-offs:** Higher media consumption, need for robust cell retention, and more sophisticated control[17]

Some emerging "hybrid" modes deliberately combine perfusion and fed-batch behavior—for example, perfuse during growth, then transition to a production phase with less media exchange—to balance productivity, media use, and control complexity[18][19].

3.3 Downstream Building Blocks

3.3.1 Capture and Primary Purification

Downstream architectures lag upstream in many organizations, but intensified and semi-continuous options are now well established for mAbs and many recombinant proteins[20][21].

Core capture options include:

High-productivity single-column operation:

Improved resins, higher binding capacities, and optimized loading/wash/elution strategies raise productivity without changing the basic batch paradigm[22]

Multicolumn chromatography (MCC):

- Multiple smaller columns operated in sequence allow near-continuous loading and elution, dramatically increasing resin utilization and reducing column sizes[23][24]
- Typically implemented first at Protein A capture, then extended downstream as needed

Membrane capture:

Protein A or other affinity membranes offer high throughput and low pressure drop, making them attractive for intensified or continuous capture in single-use flow paths[25][26]

These capture options are modular; MCC or membrane capture can be deployed as stand-alone "islands of continuity" even when the rest of downstream processing (DSP) remains batch[27].

3.3.2 Viral Inactivation, Intermediate Steps, and Polishing

PI-aligned DSP architectures often use:

Continuous or plug-flow viral inactivation:

Uses hold loops or dedicated reactors to maintain a defined residence time distribution, enabling continuous operation while meeting regulatory expectations for inactivation time and conditions[28][29]

Flow-through polishing:

Anion exchange (AEX) and mixed-mode media in flow-through mode remove impurities while the product passes without binding, reducing cycle times and simplifying integration with continuous upstream steps[30]

Single-pass tangential flow filtration (SPTFF) and inline conditioning:

Single-pass TFF and inline buffer conditioning reduce tankage and hold-up volumes, which is especially important for integrated lines and modular facilities[31][32].

Together, these elements support semi-continuous DSP architectures that can be tuned to match either intensified fed-batch or perfusion upstream[33][34].

3.4 Integration Patterns and Control Concepts

3.4.1 Integration Patterns

In practice, few organizations jump directly to fully continuous upstream (USP) plus downstream (DSP). More common integration patterns are:

Islands of Continuity:

- **Example:** Batch fed-batch upstream feeding MCC capture, then batch viral inactivation and polishing
- **Benefit:** Local gains in resin utilization and throughput, minimal impact on existing batch validation paradigms[35]

USP continuous, DSP batch:

- Perfusion or highly intensified upstream feeding periodic, larger batch DSP operations
- Requires surge tanks or hold bags and careful management of residence time and product stability[36][37]

End-to-End continuous:

- Perfusion upstream directly feeding continuous capture, continuous viral inactivation, and at least semi-continuous polishing, with integrated control across the chain[38][39]
- Best suited to high-value products where the business case justifies the complexity and to facilities built around single-use, modular architectures

3.4.2 Control and ICH Q13 Concepts

Regardless of architecture, integration raises control and regulatory questions that ICH Q13 is designed to address[41][42].

Key control concepts include:

Residence time distribution (RTD) and material traceability:

Understanding RTD through connected unit operations and being able to trace material segments is essential for defining batch boundaries, diversion strategies, and stability justifications[43][44]

Active process controls:

Feedforward and feedback loops across unit operations (e.g., adjusting perfusion rates based on downstream column loading, or modulating capture load based on upstream titer)[45]

Disturbance management and diversion:

Pre-defined criteria and logic for when to divert material (e.g., during startup, control excursions, PAT failures) and how to define the affected segment in a continuous run[46][47]

3.5 Matching Architectures to Use Cases

Choosing among these architectures is not an abstract exercise; it depends on product, portfolio, facility, and business constraints[49][50].

Typical decision drivers:

Volume and lifecycle stage:

- **Early-phase or uncertain-demand products:** Favor architectures that minimize initial capital expenditure (CapEx) and allow flexible scale-out (e.g., intensified fed-batch with MCC capture in single-use)[51]
- **Established high-volume products or biosimilars:** Stronger business case for perfusion and more integrated DSP to drive down cost of goods (CoG) and maximize facility throughput[52][53]

Modality and product sensitivity:

- **Robust mAbs with high stability:** Can exploit high-inoculation fed-batch and MCC without necessarily needing perfusion[54][55]
- **Unstable proteins or viral vectors:** Benefit more from perfusion and minimized hold times, pushing the architecture toward more continuous USP and at least semi-continuous DSP[56]

Facility starting point:

- **Stainless brownfield:** Start with N-1 intensification and DSP islands of continuity that fit within existing utilities and layouts [57][58]
- **Greenfield single-use:** Design for perfusion and modular continuous DSP from the outset; use scale-out and template pods for replication across regions[59][60]

Innovator vs CDMO:

- **Innovators:** Optimize around portfolio and lifecycle dynamics, often with a limited number of large assets
- **CDMOs:** Prioritize flexible, platformized architectures (e.g., standardized intensified trains with configurable "modules" for capture and polishing) that can be repurposed across clients and molecules [61]

3.6 Chapter Summary: The PI Toolbox

This chapter has laid out the core building blocks of process intensification:

Upstream: From high-inoculation fed-batch through N-1 perfusion to production perfusion, each step unlocks productivity gains but requires progressively more sophisticated control and facility support.

Downstream: Intensified capture (MCC, membranes), continuous viral inactivation, flow-through polishing, and single-pass TFF form a modular toolkit that can be assembled into islands of continuity or full end-to-end trains.

Integration patterns: Most organizations implement PI incrementally, starting with discrete improvements (N-1 perfusion, MCC capture) before progressing to more integrated continuous flows.

Control strategy: ICH Q13 provides the regulatory framework for residence time distribution, material traceability, active controls, and disturbance management that make continuous manufacturing credible and approvable.

Use case matching: The right architecture depends on your specific product, portfolio priorities, facility constraints, and risk tolerance—there is no single "best" PI configuration.

The next chapter (Chapter 4) quantifies how these architectural choices translate into concrete business outcomes: cost of goods reductions, capacity gains, capital efficiency, and return on investment.

Chapter 3 References (62)

[1] Tsang V, et al. Biomanufacturing evolution from conventional to intensified processes. *Biotechnol Bioeng*. 2020;117(11):3359-3372. PMC7531520

[2] Karst N, et al. Reviewing the process intensification landscape through the life cycle lens. *Biotechnol Bioeng*. 2024;121(4):1123-1140

[3] Yang WC, et al. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality. *Biotechnol Prog*. 2014;30(3):616-625

[4] WuXi Biologics. Stepwise cell culture process intensification platform. White paper. August 2024

[5] Huang YM, et al. Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. *Biotechnol Prog*. 2010;26(5):1400-1410

[6] Padawer I, et al. Case study: An accelerated 8-day monoclonal antibody production process based on high seeding densities. *Biotechnol Prog*. 2013;29(3):829-832

[7] Yongky A, et al. Process intensification in fed-batch production bioreactors using non-perfusion seed cultures. *mAbs*. 2019;11(8):1502-1514. PMC6844383

[8] Yang WC, et al. Cell bank manufacturing and perfusion seed train process intensification. *BioProcess Int*. 2019

[9] Walther J, et al. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production. *J Biotechnol*. 2015;213:3-12

[10] Clincke MF, et al. Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor. Part I: Effect of the cell density on the process. *Biotechnol Prog*. 2013;29(3):754-767

[11] BioPhorum Operations Group. Biomanufacturing technology roadmap: Executive summary. 2017. https://www.biophorum.com/download/executive-summary/biophorum

[12] Li F, et al. Cell culture processes for monoclonal antibody production. *mAbs*. 2010;2(5):466-477. PMC2958571

[13] Rathore AS, Winkle H. Quality by design for biopharmaceuticals. *Nat Biotechnol*. 2009;27(1):26-34

[14] Warikoo V, et al. Integrated continuous production of recombinant therapeutic proteins. *Biotechnol Bioeng*. 2012;109(12):3018-3029

[15] Konstantinov KB, Cooney CL. White paper on continuous bioprocessing. *J Pharm Sci*. 2015;104(3):813-820

[16] Hossler P, et al. Optimal and consistent protein glycosylation in mammalian cell culture. *Glycobiology*. 2009;19(9):936-949

[17] ICH Q13. Continuous Manufacturing of Drug Substances and Drug Products. Final guideline. January 2023

[18] Ozturk SS. Cell culture technology—an overview. In: *Cell Culture Technology for Pharmaceutical and Cell-Based Therapies*

[19] Bielser JM, et al. Perfusion mammalian cell culture for recombinant protein manufacturing. *Biotechnol Adv*. 2018;36(4):1328-1340. CRC Press; 2005:1-46

[20] Jungbauer A, Hahn R. Ion-exchange chromatography. *Methods Enzymol*. 2009;463:349-371

[21] Steinebach F, et al. Design and operation of a continuous integrated monoclonal antibody production process. *Biotechnol Prog*. 2017;33(5):1303-1313

[22] Guiochon G, Lin B. *Modeling for Preparative Chromatography*. Academic Press; 2003

[23] Godawat R, et al. Periodic counter-current chromatography—design and operational considerations for integrated and continuous purification of proteins. *Biotechnol J*. 2012;7(12):1496-1508

[24] Waghmare R, et al. Multi-column chromatography: A review. *Prep Biochem Biotechnol*. 2019;49(5):413-425

[25] Orr V, et al. Recent advances in bioprocessing application of membrane chromatography. *Biotechnol Adv*. 2013;31(4):450-465

[26] Ghosh R. Protein separation using membrane chromatography: opportunities and challenges. *J Chromatogr A*. 2002;952(1-2):13-27

[27] Pollock J, et al. Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. *Biotechnol Prog*. 2017;33(4):854-866

[28] Xenopoulos A. A new, integrated, continuous purification process template. *BioProcess Int*. 2015;13(7):S18-S25

[29] Hammerschmidt N, et al. Economics of recombinant antibody production processes at various scales. *Biotechnol J*. 2014;9(6):766-775

[30] Gottschalk U. The renaissance of protein purification. *BioPharm Int*. 2008;21(6):S4-S9

[31] van Reis R, Zydney A. Bioprocess membrane technology. *J Membr Sci*. 2007;297(1-2):16-50

[32] Azevedo AM, et al. Chromatography-free recovery of biopharmaceuticals through aqueous two-phase processing. *Trends Biotechnol*. 2009;27(4):240-247

[33] Steinebach F, et al. Process intensification in biologics manufacturing. *Chem Eng Process*. 2019;141:107265

[34] Xenopoulos A, Pattnaik P. Production and purification of plasmid DNA vaccines. *Rev Med Virol*. 2014;24(5):321-340

[35] Arnold L, et al. Implementation of fully integrated continuous antibody processing: Effects on productivity and COGm. *Biotechnol J*. 2019;14(2):e1800061

[36] Bausch M, et al. Recommendations for comparison of productivity between fed-batch and perfusion processes. *Biotechnol J*. 2019;14(2):e1700721

[37] Walther J, et al. Perfusion cell culture decreases process and product heterogeneity in a head-to-head comparison with fed-batch. *Biotechnol J*. 2019;14(2):e1700733

[38] Warikoo V, et al. Integrated continuous production of recombinant therapeutic proteins. *Biotechnol Bioeng*. 2012;109(12):3018-3029

[39] Zydney AL. Continuous downstream processing for high value biological products: A review. *Biotechnol Bioeng*. 2016;113(3):465-475

[40] Karst DJ, et al. Process performance and product quality in an integrated continuous antibody production process. *Biotechnol Bioeng*. 2017;114(2):298-307

[41] ICH Q13. Continuous Manufacturing of Drug Substances and Drug Products. Final guideline. January 2023

[42] FDA. Continuous Manufacturing of Drug Substances and Drug Products. Draft Guidance. April 2023

[43] Lopes AG. Integrating predictive models into control strategies for continuous biomanufacturing. *Curr Opin Chem Eng*. 2020;27:87-93

[44] Lee SL, et al. Modernizing pharmaceutical manufacturing: From batch to continuous production. *J Pharm Innov*. 2015;10(3):191-199

[45] Rehm B, et al. Advanced process monitoring and feedback control to enhance cell culture process efficiency and product quality. *Curr Opin Biotechnol*. 2018;53:11-19

[46] FDA. Quality Considerations for Continuous Manufacturing. Guidance for Industry. February 2019

[47] Rogers RS, et al. Diversion and hold strategies for continuous manufacturing of monoclonal antibodies. *mAbs*. 2019;11(8):1466-1475

[48] Narayanan H, et al. Bioprocessing in the digital age: The role of process models. *Biotechnol J*. 2020;15(1):e1900172

[49] Steinwandter V, et al. Data science tools and applications on the way to pharma 4.0. *Drug Discov Today*. 2019;24(9):1795-1805

[50] National Academies of Sciences, Engineering, and Medicine. *Continuous Manufacturing for the Modernization of Pharmaceutical Production*. National Academies Press; 2019

[51] Farid SS. Process economic drivers in industrial monoclonal antibody manufacture. In: Gottschalk U, ed. *Process Scale Purification of Antibodies*. Wiley; 2009:239-261

[52] Walther J, et al. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production. *J Biotechnol*. 2015;213:3-12

[53] Kelley B. Industrialization of mAb production technology: The bioprocessing industry at a crossroads. *mAbs*. 2009;1(5):443-452

[54] Shukla AA, Thömmes J. Recent advances in large-scale production of monoclonal antibodies and related proteins. *Trends Biotechnol*. 2010;28(5):253-261

[55] Li F, et al. Current therapeutic antibody production and process optimization. *BioProcessing J*. 2006;5(4):16-25

[56] Wright D, et al. Continuous viral production systems: Opportunities and challenges. *Curr Opin Biotechnol*. 2021;67:141-148

[57] Croughan MS, et al. The future of industrial bioprocessing: Batch or continuous? *Biotechnol Bioeng*. 2015;112(4):648-651

[58] BioPhorum Operations Group. Process intensification roadmap for biologics manufacturing. Technical report. 2023

[59] Hummel J, et al. Modular facility concepts for biopharmaceutical manufacturing. In: *Single-Use Technology in Biopharmaceutical Manufacture*. Wiley; 2011:333-351

[60] Langer E, Rader RA. Continuous bioprocessing and perfusion: Wider adoption coming as bioprocessing matures. *BioProcess Int*. 2014;12(6):S23-S28

[61] Chopda VR, et al. Recent advances in integrated process analytical techniques, modeling, and control strategies to enable continuous biomanufacturing of monoclonal antibodies. *J Chem Technol Biotechnol*. 2022;97(11):2867-2886

[62] Steinebach F, et al. Design of a prototype process for integrated continuous manufacturing of clinical-stage antibodies. *Biotechnol Prog*. 2019;35(1):e2765



FOUR: Chasing R.O.I.

Process intensification and Continuous Manufacturing (PI/CM) changes not only how biologics are made, but also fundamentally alters the economics that determine competitive positioning. This chapter translates PI/CM's technical capabilities into financial metrics that matter at the board level: cost of goods (CoG's), capacity throughput, capital efficiency, and return on investment. For sponsors and senior leaders, PI/CM is valuable when it improves time-to-milestone, total program economics, or market access without adding disproportionate technical or regulatory risk. For CDMOs, PI/CM becomes a commercial offering—a platform that can deliver structurally lower CoG's and more flexible capacity to multiple clients while maintaining robust, inspection-ready control strategies.

Understanding these trade-offs is essential because PI/CM's value proposition varies by molecule, portfolio, facility type, and organizational maturity. Early adopters report 3–8× productivity gains and 30–60% reductions in cost of goods, but these outcomes depend on disciplined execution across process, automation, digital, and regulatory domains.

4.1 PI/CM Upsides

4.1.1 Faster Timelines Without New Facilities

PI/CM enables a CDMO to unlock roughly 50–80% more throughput from existing suites via N-1 perfusion and hybrid downstream trains, which can translate into earlier slot availability or overlapping campaigns for your program.

Client value: If your CDMO can fit eight campaigns per year instead of five in the same suite, you move up the queue—critical for Phase II/III transitions where slot delays cost months.

4.1.2 Lower CoG's / Competitive Pricing

Intensified upstream and downstream processes can reduce CoG's into the $20–$80 USD/g range for monoclonal antibodies (mAbs) and biosimilars, enabling more aggressive tender pricing or improved margins on existing list prices.

Client value: For biosimilars targeting about 40 USD/g economics, PI-based CDMOs are structurally positioned to support your pricing strategy.

For innovators, lower CoG's translate into better portfolio economics or pricing flexibility in competitive markets.

4.1.3 More Options for Regional Supply

Compact, modular PI/CM facilities can be replicated regionally with 40–60% smaller footprints and roughly 20–50% of the capex of traditional plants, supporting local-for-local supply strategies.

Client value: If you need commercial capacity in Europe, Asia–Pacific, and North America, your CDMO can deploy standardized PI PODs in 6–12 months per region instead of building three "cathedral" facilities over 3–5 years.

4.1.4 Improved Quality Control and Data Packages

Rich process analytical technology (PAT) and continuous data streams support strong Quality by Design (QbD) narratives, robust continued process verification (CPV), and clearer linkages between critical process parameters (CPPs) and critical quality attributes (CQAs) in regulatory filings.

Client value: Real-time Raman, capacitance, and biolayer interferometry (BLI) data enable defensible control strategies for pre-approval inspections and post-approval changes, reducing Chemistry, Manufacturing, and Controls (CMC) supplement risk.

4.2 Where PI Creates New Questions for CDMO Clients

4.2.1 Campaign Risk and Batch Definition

Long perfusion runs and connected downstream processing create larger "campaigns" and different batch boundaries, which change how deviations, rework, and release decisions affect your supply.

Questions to ask your CDMO:

- How do you define batch boundaries in perfusion campaigns (time-based, volume-based, or both)?
- What is your deviation rate for perfusion versus fed-batch campaigns over the past 12 months?
- How do you handle mid-campaign equipment failures without losing the entire pool?
- What redundancy exists (dual alternating tangential flow [ATF] systems, backup PAT sensors)?

4.2.2 Media, Buffer, and Logistics Dependencies

Perfusion and continuous DSP shift constraints to media, buffers, and utilities; CDMOs must show that tankage, buffer inline conditioning (BIC), storage, and waste handling are sized and validated to support your projected demand.

Questions to ask your CDMO:

- Is buffer inline conditioning validated and operational, or are you still using batch prep or inline dilution?
- What is your peak media consumption rate per bioreactor, and do you have cold-chain capacity for three to four parallel perfusion runs?
- How do you manage waste streams from continuous DSP, especially spent buffers?
- Are utilities (water for injection [WFI], chilled water, compressed air) sized for continuous operation, or will they bottleneck at scale?

4.2.3 Automation and Digital Maturity

The value of PI depends on robust automation, PAT integration, and data management; sponsors should expect to see architecture, cybersecurity, and data integrity clearly documented, not treated as a black box.

Questions to ask your CDMO:

- What percentage of your PI/CM platform is automated end-to-end without manual interventions?
- Which communication standards do you use (OPC UA, other standards, or proprietary interfaces)?
- How do you ensure data integrity (21 CFR Part 11) across multi-vendor equipment?
- Is your historian integrated with MES/QMS, or do you manually reconcile batch records?
- What is your cybersecurity posture for networked bioreactors and skids?

4.2.4 Fit to Asset Stage and Modality

For very early-stage assets where speed-to-first-in-human dominates long-term CoG's, or where cell line and formulation are still fluid, full end-to-end PI/CM may not be the right starting point.

When to prioritize conventional over PI/CM:

- Phase I, dose-finding: Speed and flexibility trump CoG's; batch processes support rapid protocol changes.
- Unstable cell lines: If titer or productivity is still evolving, perfusion investment may be premature.
- Novel modalities without precedent: For first-in-class molecules, conventional platforms with extensive comparability data may reduce regulatory friction.

When PI/CM is ideal from Phase I onward:

- High-volume mAbs/biosimilars: Where target dose, annual demand, and commercial CoG's requirements are clear from the outset.
- Fragile modalities: Viral vectors or unstable fusion proteins, where continuous harvest and reduced hold times are scientifically justified.
- Portfolio programs: Where the CDMO's PI platform will serve multiple molecules in your pipeline, amortizing learning-curve costs.

4.3 How to Read a CDMO's PI/CM Offering

When CDMO's present "intensified platforms," sponsors can use three questions to cut through the marketing language.

Question 1: Which PI/CM archetypes are actually implemented today, and at what scale? Examples include:

- N-1 perfusion feeding 200–2,000 L reactors
- Multicolumn chromatography (MCC) or membrane capture
- Continuous viral inactivation
- Single-pass tangential flow filtration (SPTFF)

Red flag: The CDMO describes PI capabilities but has no commercial campaigns running, only pilot data.

Green flag: The CDMO provides case studies with specific metrics (for example, "80% throughput increase in Suite 3," "six commercial lots produced via perfusion in 2024").

Question 2: Which parts are platform and which are bespoke?
Upstream cell culture archetypes and intensified capture may be platformized, while late polishing and formulation remain molecule-specific. Review all drawings/instruments.

What to expect:

- **Platform elements**: N-1 perfusion protocol, ATF cell retention, Protein A membrane capture, continuous viral inactivation at defined pH and hold time. Biocapacitance, Raman, FT-IR, UV-Vis (Review each equipment drawing)

- **Bespoke elements**: Polishing train (anion exchange [AEX], cation exchange [CEX], hydrophobic interaction chromatography [HIC]), formulation buffer, final UF/DF concentration, and lyophilization where applicable.

Red flag: The CDMO claims a "fully platform PI/CM" offering but every molecule requires extensive process development.

Green flag: The CDMO shows a platform template with decision trees (for example, "mAbs use AEX flow-through; bispecifics add CEX bind–elute").

4.4 Productivity and Capacity Advantages

4.4.1 Space–Time Yield and Annual Throughput

PI/CM's most immediate and measurable benefit is increased volumetric productivity and effective capacity. Upstream intensification via N-1 perfusion, high-inoculation fed-batch, or production perfusion routinely delivers 3–10× higher space–time yields than conventional fed-batch processes. For example, WuXi Biologics' stepwise intensification platform achieved about 35 g/L in intensified fed-batch and cumulative titers over 50 g/L in perfusion, enabling the same annual output from bioreactor volumes roughly 3–5× smaller.

Downstream PI/CM is required to translate these gains into usable throughput. MCC and membrane capture can increase resin productivity by roughly 2–5×, while SPTFF and continuous viral inactivation remove classic hold-time bottlenecks. In practice, organizations implementing hybrid PI flows often report 50–80% increases in annual batches or total output without expanding the qualified facility footprint.

Client impact: If your CDMO runs five conventional campaigns per year in a suite and PI enables nine, you have access to four additional slot opportunities—material when slot scarcity drives timelines.

4.4.2 Reduced Facility Footprint and Capital Efficiency

Higher productivity per liter and per square meter translates into more compact facilities and better capital efficiency. A perfusion-based line capable of replacing a conventional 2,000 L fed-batch train may use only 500–1,000 L bioreactors plus compact modular DSP skids, cutting cleanroom area by an estimated 40–60%. POD-based and hybrid cleanroom designs amplify this effect, enabling regional facilities at roughly 20–50% of the capex and timeline of traditional stainless "cathedrals."

Client impact: Your CDMO can deploy capacity closer to your key markets without requiring 200+ million USD greenfield investments per region, potentially accelerating regional supply strategies by 18–36 months.

4.5 Cost of Goods (CoG) Reductions

4.5.1 Operational Expenditure (OpEx) Savings

PI/CM shifts the CoG structure by attacking multiple cost drivers at once. Typical directions of change are summarized in Table 4-2. Case studies such as the evolution of Bristol Myers Squibb's manufacturing platforms show stepwise CoG reductions as intensification and continuous elements are layered in. Indian PI-based platforms (for example, Enzene Biosciences) report CoG targets of around 40 USD/g for mAb biosimilars using end-to-end PI, which would be challenging with conventional batch processes alone.

Client impact: If your CDMO achieves 40 USD/g for a biosimilar program versus 80 USD/g with conventional processes, you gain pricing headroom to compete in tender markets where 50 USD/g list price is the norm.

4.5.2 Lifecycle Cost Advantages

Lifecycle economics often matter more than per-batch CoGs in portfolio and site decisions. PI/CM accelerates development through robust scale-down models and data-rich lab platforms (for example, Ambr-scale perfusion and intensified DSP), enabling faster design-space definition and more efficient tech transfer. Modular, standardized unit operations then reduce scale-up risk and simplify replication across sites, which is particularly valuable for CDMOs and regional manufacturing strategies.

Client impact:

- Faster process development: Six to nine months to IND-enabling lots instead of 12–15 months with conventional platforms.
- Easier tech transfer: Standardized perfusion protocols and modular skids enable replication at a second site with minimal re-optimization.Ch4_docx.docx
- Lower Phase III/commercial CMC costs: Higher productivity can enable smaller campaign sizes for the same annual output, potentially reducing stability and validation burdens.

4.6 Agility and Flexibility Gains

4.6.1 Multi-Product and Multi-Modality Support

PI/CM architectures are inherently more modular and recipe-driven than classic hard-piped batch trains. Single-use assemblies, configurable skids, and software-defined automation allow a single suite to support mAbs, bispecifics, Fc-fusion proteins, and—in some designs—viral vectors or other modalities with minimal mechanical changes. Continuous and intensified modes further enhance flexibility by allowing campaign duration to be tuned to demand rather than fixed batch counts.

Client impact: If your pipeline includes both mAbs and bispecifics, a PI-enabled CDMO can run both modalities in the same suite with changeover times measured in days rather than weeks, which is typical for traditional stainless lines requiring extensive CIP/SIP.

4.6.2 Regional and Resilient Supply Chains

Compact, modular PI facilities align naturally with regionalization and supply-chain resilience policies that emerged after COVID-19 disruptions. POD clusters or hybrid cleanrooms can be deployed in 6–12 months instead of the 3–5 years typical for large stainless plants, enabling closer-to-patient manufacturing in multiple geographies. This supports lower inventories, reduces cross-border logistics risk, and can qualify for local incentives tied to domestic biomanufacturing capacity.

Client impact: Your CDMO can stand up regional capacity to serve local-for-local tender requirements without forcing you to wait four years for a conventional greenfield facility.

4.7 Quality and Sustainability Benefits

4.7.1 Enhanced Process Control and Product Quality

Intensified and continuous processes generate high-frequency data streams and invite richer PAT deployment. Raman, capacitance, inline UV–Vis, and advanced chromatographic analytics support multivariate models that link CPPs to CQAs in near real time.

Shorter and more controlled residence times can reduce degradation or aggregation for sensitive molecules, enabling equal or better product quality relative to legacy fed-batch.

AstraZeneca and others have demonstrated dynamic perfusion processes that achieve high space–time yields while maintaining CQA profiles within established fed-batch specifications.

Client impact: Real-time PAT data enables tighter CQA control bands, supporting ICH Q8/Q11 enhanced approaches and potentially reducing end-product testing burdens when real-time release testing is validated.

4.7.2 Environmental Impact Reductions

Lifecycle assessments indicate that PI can materially improve environmental performance at a given annual output. Higher titers, smaller equipment, and reduced cleaning translate into lower process mass intensity (PMI), water use, and energy consumption per kilogram of drug substance, with reported reductions of about 30–50% for key metrics. While single-use increases solid waste and extractables/leachables considerations, the overall environmental balance is often favorable in PI scenarios, particularly when utilities are carbon-intensive or water-constrained.

Client impact: PI supports environmental, social, and governance (ESG) commitments and can sometimes qualify for sustainability-linked financing or regulatory incentives in jurisdictions with carbon pricing.

4.8 Key Disadvantages and Risk Mitigation

4.8.1 Technical Complexity and Single Points of Failure

PI’s advantages come with new failure modes and operational complexity. Long perfusion campaigns and connected DSP trains can convert discrete batch risks into campaign-wide risks, with cell-retention fouling, PAT drift, or automation failures potentially impacting large product pools. Managing this requires rigorous failure modes and effects analysis (FMEA), redundancy where justified (for example, dual ATF systems and backup sensors), and clear operational playbooks for fault handling and campaign termination.

Questions to ask your CDMO:

- Have you conducted FMEA for perfusion campaigns, and can you share the top five failure modes and mitigations?
- Do you have redundant cell-retention devices (for example, two ATF systems per bioreactor)?
- What is your protocol if PAT sensors drift mid-campaign—do you terminate or continue with increased off-line sampling?
- How often do you experience unplanned campaign terminations (target <5% of campaigns)?

4.8.2 High Media and Buffer Demands

Perfusion and continuous DSP substantially increase instantaneous media and buffer consumption, even if volume per kilogram improves. Without mitigation via concentrated feeds, BIC, and thoughtful storage and waste design, sites may face logistics bottlenecks, chilled storage shortages, or waste-handling constraints. Early utility and tankage assessments are essential, especially for brownfield retrofits.

Questions to ask your CDMO:

- What is your media consumption per bioreactor per day during perfusion?
- Is concentrated feed validated, or do you dilute on receipt?
- Do you have BIC operational, or are you still batching buffers in preparation tanks?
- What is your cold-chain capacity, and can it support three to four simultaneous perfusion campaigns?

4.8.3 Automation, Digital, and Organizational Dependencies

End-to-end PI is highly dependent on robust automation, data infrastructure, and around-the-clock operational readiness. Industry surveys suggest that only a minority of sites currently achieve full connectivity across equipment, historians, MES, and analytics, and cultural shifts from “batch thinking” to “flow thinking” can be non-trivial. Successful implementations invest early in digital architecture, cross-functional training, and clear governance to avoid brittle, manual workarounds that erode PI’s theoretical benefits.

Questions to ask your CDMO:

- What percentage of your PI workflows are fully automated without manual data transcription?
- Do you use standardized protocols (for example, OPC UA, ISA-95) or proprietary middleware?
- How do you manage data integrity and 21 CFR Part 11 compliance for networked equipment?
- What is your staffing model for 24/7 perfusion campaigns (dedicated operators versus on-call coverage)?
- Have you invested in operator training for perfusion troubleshooting, or do you rely primarily on vendor support?

4.8.4 Capex Front-Loading and ROI Timing

PI generally front-loads investment into equipment, PAT, and digital infrastructure relative to a minimal fed-batch option. Initial capex can be 20–50% higher, particularly when moving directly to hybrid or end-to-end PI, with ROI realized over two to five years through OpEx savings and capacity gains. Stepwise adoption (for example, N-1 perfusion plus one intensified DSP step) often delivers faster payback and can be more acceptable in risk-averse organizations.

Client impact: If your CDMO passes through capex as campaign overhead or depreciation, you should understand how PI investments are allocated across clients; ideally, capex is amortized across the CDMO's full portfolio, not loaded onto your program alone.

4.9 Net Assessment — CDMO–Client Business Case

For CDMO clients, PI delivers the most value in three situations.

4.9.1 High-Volume, Cost-Sensitive Programs (mAbs, Biosimilars)

Hybrid or end-to-end PI enables structurally lower CoGs, supports aggressive pricing strategies, and allows your CDMO to flex capacity as volumes grow or fragment by region.

Decision criteria:

- Annual demand >100 kg at commercial scale.
- Target CoGs <60 USD/g to remain competitive.
- Multi-year supply agreement that justifies the CDMO's PI investment.

4.9.2 Portfolios Requiring Regional or Multi-Market Supply

PI-centric, modular facilities provide options to add capacity near key markets in 6–12 months instead of 3–5 years, which is difficult with conventional stainless expansions.

Decision criteria:

- Need for simultaneous manufacturing in two or more regions (for example, US, EU, China).
- Local-for-local tender or regulatory requirements.
- Portfolio of three or more molecules sharing similar platform processes.

4.9.3 Complex or Fragile Modalities

Perfusion and intensified DSP reduce residence times and hold steps, which can be decisive for unstable proteins and certain viral vector processes.

Decision criteria:

- Molecule shows significant degradation or aggregation under conventional fed-batch hold conditions.
- Yield losses >20% attributable to extended DSP residence times.
- Scientific rationale for continuous harvest supported by forced-degradation studies.

4.10 Key Takeaways for CDMO Clients

1. PI/CM is not a magic bullet; it is a set of levers that, when implemented well, make your CDMO a structurally better manufacturing partner.
2. Ask specific questions about archetype implementation, automation maturity, failure rates, and utility capacity—marketing claims must be backed by operational data.
3. Align incentives through pricing models and risk-sharing structures tied to productivity KPIs, favoring USD/g models when PI delivers higher titers.
4. Match PI adoption to asset stage: early clinical work may favor conventional platforms for flexibility, while late clinical and commercial programs benefit most from PI.
5. Evaluate regional deployment capabilities and prioritize CDMOs with proven modular PI facility designs if your strategy requires multi-region supply.

Chapter 4 References (8)

1. Tsang V, et al. Biomanufacturing evolution from conventional to intensified processes. *Biotechnol Bioeng*. 2020;117(11):3359–3372.
2. Pollock J, et al. Integrated continuous bioprocessing: economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. *Biotechnol Prog*. 2017;33(4):854–866.
3. Walther J, et al. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production. *J Biotechnol*. 2015;213:3–12.
4. Steinebach F, et al. Process intensification in biologics manufacturing. *Chem Eng Process*. 2019;141:107265.
5. Karst N, et al. Reviewing the process intensification landscape through the life cycle lens. *Biotechnol Bioeng*. 2024;121(4):1123–1140.
6. WuXi Biologics. Stepwise cell culture process intensification platform whitepaper. 2024.
7. BioPhorum. Continuous manufacturing in biologics. Position paper. 2023.
8. FDA. *Continuous Manufacturing of Drug Substances and Drug Products*. Draft Guidance. 2023.

FIVE : PI/CM Implementation Roadmap

5.1 Roadmap Overview – Four Phases to Commercial PI

PI works best as a staged program rather than a one-off project. A practical roadmap has four phases that build on each other, with clear decision gates and increasing levels of investment and operational commitment:

Phase 0 – Strategy and Scoping (3–6 months)
Define the business case, select candidate assets, establish baseline metrics, and model PI scenarios to determine expected ROI and capacity impact.

Phase 1 – Lab Development and Scale-Down Models (6–12 months)
De-risk PI in the lab using robust scale-down models (Ambr perfusion, benchtop DSP), define design space via DoE, select PAT tools, and build initial multivariate models.

Phase 2 – Pilot Integration and Demonstration (9–18 months)
Prove that integrated PI flows work at realistic scale (50–500 L), run extended campaigns, implement pilot-level control strategies, execute FMEA, and draft regulatory control strategy aligned with ICH Q13.

Phase 3 – Commercial Deployment and Lifecycle Management (12–24 months, then ongoing)
Build or retrofit facilities, implement integrated automation, qualify the PI process through FAT/SAT/IQ/OQ/PQ, execute tech transfer, train personnel, and establish lifecycle management for continuous improvement.

Each phase has specific deliverables, cross-functional owners, and decision gates. Sponsors should expect to see clear evidence at each gate, not vague progress reports.

5.2 Phase 0 – Strategy and Scoping

Duration: 3–6 months
Goal: Decide where PI helps your program and how success will be measured
Key Cross-Functional Owners: Business Development, Process Development, MSAT, Finance, QA/Regulatory

5.2.1 Core Activities

When a CDMO works with you in Phase 0, they should execute the following activities transparently and with your input:

Clarify objectives and constraints

- What is the primary driver: CoG reduction, capacity unlock, regional supply enablement, or enabling "difficult" modalities?
- What are the constraints: existing facility limitations, timeline to first commercial lot, regulatory commitments already made, budget for CapEx/OpEx?

Select candidate assets

- High-volume mAbs and biosimilars where 3–6× productivity gains materially change economics
- Unstable proteins or viral vectors where continuous harvest and reduced hold times improve yield and quality
- Portfolio molecules that can share a common PI platform to amortize learning curve costs

Build baseline metrics

Document current-state performance so PI benefits can be measured objectively:

- Current titers (g/L), yields (%), and space-time yield (g/L/day)
- Current CoG by category (media, resins, labor, utilities, overhead)
- Facility utilization (campaigns/year, bioreactor occupancy %)
- Regulatory commitments (filed batch definitions, control strategies, comparability protocols)

Model PI scenarios

Use techno-economic models to compare three scenarios:

- **Scenario A (minimal PI):** N-1 perfusion only, conventional N-stage and DSP
- **Scenario B (hybrid PI):** N-1 perfusion + intensified N-stage + membrane capture or MCC + batch polishing
- **Scenario C (end-to-end PI):** Perfusion upstream + continuous capture + continuous viral inactivation + flow-through polishing + SPTFF

For each scenario, model:

- Expected titer improvement (2–10×)
- CoG reduction (20–60%)
- Capacity increase (50–200%)
- CapEx required ($2M–$20M+ depending on greenfield vs. brownfield)
- ROI timeline (12–48 months)

5.2.2 Phase 0 Deliverables and Decision Gate

Key Deliverables:

- Business case document with baseline metrics, PI scenario models, and ROI projections
- Risk assessment covering technical, regulatory, operational, and commercial risks
- Preliminary timeline and budget for Phases 1–3
- Asset selection recommendation with justification

Decision Gate Questions:

- Is the expected ROI acceptable given CapEx/OpEx requirements and timeline?
- Does the selected molecule(s) have sufficient volume and strategic importance to justify PI investment?
- Are facility, utility, and organizational constraints manageable, or do they require major remediation?
- Is leadership committed to the multi-year, cross-functional effort required?

Sponsor Questions for Your CDMO:

- What PI configuration are you proposing for my asset, and why this archetype over alternatives?
- How much CoG and capacity improvement do you expect vs. your current platform, with what confidence level?
- How will this affect my regulatory strategy (e.g., do I need to invoke ICH Q13 continuous manufacturing guidance, or can I stay within conventional batch frameworks)?
- What is the investment required from my program vs. shared across your CDMO portfolio?

Red Flag:
-CDMO cannot provide baseline metrics or CoG breakdown—suggests weak understanding of current-state performance.
-PI business case relies on >6× productivity gains without supporting pilot data
-No risk assessment or mitigation plan for known failure modes (cell retention, PAT, automation)

Green Flag:
-CDMO provides detailed techno-economic model with sensitivity analysis (e.g., "if titer is 30 g/L instead of 40 g/L, ROI extends from 18 to 24 months")
-Clear delineation of which PI investments are shared (platform) vs. molecule-specific (bespoke)
-Transparent discussion of risks and how they've been mitigated in previous PI implementations

5.3 Phase 1 – Lab Development and Scale-Down Models

Duration: 6–1 months
Goal: De-risk PI in the lab and create models that predict pilot and commercial behavior
Key Cross-Functional Owners: Process Development, Analytical Development, QC, PAT/Automation Engineering

5.3.1 Upstream Lab Development

The goal is to establish robust scale-down models for intensified upstream processes and define the design space through systematic experiments.

N-1 perfusion development

- Use Ambr 250 or benchtop stirred-tank bioreactors (0.5–3 L) with integrated ATF or TFF cell retention
- Define inoculation density target (20–50 × 10^6 cells/mL typical)
- Optimize perfusion rate (1–3 reactor volumes/day), bleed rate, and temperature/pH trajectories
- Measure viable cell density (VCD), viability, titer, and key metabolites (glucose, lactate, ammonia) over 7–14 days
- Execute DoE to map design space for CPPs: inoculation density, perfusion rate, bleed rate, temperature shift timing

Intensified N-stage development

- **High-inoculation fed-batch:** Test inoculation at 10–30 × 10^6 cells/mL, optimize feed strategy
- **Intermittent perfusion:** Test periodic media exchange (e.g., 1 reactor volume every 2–3 days) to extend culture duration to 18–21 days
- **Production perfusion:** Operate in continuous mode for 21–30 days, targeting steady-state VCD of 80–150 × 10^6 cells/mL and cumulative titers >30 g/L

Key metrics and acceptance criteria:

- Titer improvement vs. baseline fed-batch (target: 3–10×)
- Product quality (glycosylation, charge variants, aggregates, HCP) comparable to or better than baseline
- Process robustness (CV <15% across 3+ replicate runs)
- Cell retention device performance (no integrity failures, fouling manageable with periodic backflush)

5.3.2 Downstream Lab Development

Intensified DSP must be developed in parallel to match upstream productivity gains, using intensified upstream material (high-titer harvests) as feedstock.

Capture step intensification

- **Multi-column chromatography (MCC):** Test periodic counter-current (PCC) or simulated moving bed (SMB) configurations at lab scale using ÄKTA avant or equivalent systems
- **Membrane capture:** Screen Protein A membranes (e.g., Sartobind) at 10–50 mL scale, measure dynamic binding capacity, yield, and HCP clearance
- Compare MCC vs. membrane on productivity (g resin or membrane area/hour), yield (%), buffer consumption (L/kg), and footprint

Viral inactivation intensification

- Test continuous viral inactivation using lab-scale plug-flow reactors or coiled tubing at pH 3.5, 20–25°C, for 30–60 min validated residence time
- Measure viral clearance (log reduction), product recovery (%), and aggregation vs. batch VI

Polishing intensification

- Screen flow-through AEX and CEX membranes for HCP, DNA, and aggregates clearance
- Test stacked membrane modules in series (capture → VI → AEX FT → CEX FT) to simulate integrated continuous train

Single-pass TFF (SPTFF) and buffer conditioning

- Demonstrate SPTFF concentration from capture eluate (~5 g/L) to final DS concentration (50–100 g/L) in single pass, with simultaneous buffer exchange
- Test buffer inline conditioning (BIC) at lab scale: blend concentrated stock solutions (10× salts, 100× buffers) with WFI to generate process buffers on demand

Key metrics and acceptance criteria:

- Overall DSP yield >70% (target: 75–85%)
- HCP clearance <100 ppm (target: <50 ppm)
- Aggregates <2% (comparable to batch DSP)
- Productivity improvement vs. batch DSP (target: 2–5× higher throughput per unit time or equipment footprint)

5.3.3 PAT and Digital Foundations

PI relies on real-time monitoring and control, so Phase 1 must establish PAT tools and initial multivariate models.

Select and deploy PAT sensors

- **Bioreactor:** Capacitance (online VCD), Raman (glucose, lactate, titer estimation), pH, DO, temperature
- **Downstream:** Inline UV (protein concentration during capture load and elution), conductivity (buffer composition), Raman (protein A elution pool quality)

Build initial MVDA models

- Collect high-frequency data from scale-down runs (every 1–15 min depending on sensor)
- Use PCA, PLS, or hybrid mechanistic-empirical models to link CPPs (perfusion rate, VCD, glucose feed rate) to CQAs (titer, glycosylation, aggregates)
- Validate models by predicting outcomes of new experiments within ±10–15% error

Data infrastructure pilot

- Set up lab-scale data historian (e.g., OSIsoft PI, Rockwell FactoryTalk) to capture PAT streams and correlate with offline analytics
- Establish data integrity protocols (audit trails, electronic signatures, backup/recovery)

5.3.4 Phase 1 Deliverables and Decision Gate

Key Deliverables:

- Scale-down model protocols with documented design space for intensified upstream and DSP
- Comparison of PI archetypes (N-1 perfusion vs. intensified fed-batch vs. perfusion; MCC vs. membrane; continuous VI, etc.) with data-driven recommendation
- Product quality characterization showing comparability to baseline process (or justification for any differences)
- PAT tool selection and initial MVDA models
- Risk assessment update with technical de-risking evidence

Decision Gate Questions:

- Do scale-down models reliably predict performance, and are they robust (CV <15%)?
- Is product quality (CQAs) acceptable and comparable to baseline?
- Which PI archetypes offer the best balance of productivity, CoG, and risk for this molecule?
- Are PAT tools and data models ready to support pilot-scale control strategies?

Sponsor Questions for Your CDMO:

- What lab data show that your PI model is robust for my molecule (titers, CQAs, robustness across replicates)?
- Which intensified DSP steps are in-scope for my program, and what are the trade-offs (yield, cost, complexity)?
- How are you building PAT and MVDA models that will scale to your GMP suites without major re-tuning?
- Can I see raw data and DoE reports, not just summary slides?

Red Flags:

- CDMO cannot provide replicate data or shows high variability (CV >20%)
- Product quality differences dismissed as "within spec" without thorough characterization
- PAT tools selected but no data models or control logic developed
- No clear recommendation on which PI archetype to advance to pilot

Green Flags:

- CDMO provides detailed DoE reports with design space maps and process understanding
- Product quality extensively characterized (glycan profiles, charge variants, aggregates, potency) with comparability justified
- PAT models validated on independent experiments and show predictive accuracy
- Clear go/no-go criteria for advancing to Phase 2 with objective metrics

5.4 Phase 2 – Pilot Integration and Demonstration

Duration: 9–18 months
Goal: Prove that integrated PI flows work at realistic scale and are controllable, with evidence to support regulatory filing
Key Cross-Functional Owners: MSAT, Manufacturing, QA, Engineering, Automation, Regulatory Affairs

5.4.1 Pilot-Scale Execution

Pilot campaigns should be run at 50–500 L bioreactor scale (depending on facility capabilities) to bridge the gap between lab models and commercial manufacturing.

Run integrated campaigns

- **Duration:** 14–21 days for intensified fed-batch, 21–30+ days for production perfusion
- **Integration:** Seed intensification (N-2 → N-1 perfusion → N production) → intensified or continuous DSP (capture → VI → polishing → SPTFF)
- **Objectives:** Demonstrate end-to-end flow, measure productivity and quality, stress-test control strategies

Implement pilot-level control strategies

- **Perfusion control:** Automated perfusion rate adjustments based on VCD, glucose, lactate from PAT sensors
- **MCC switching:** Automated column switching for continuous or semi-continuous capture with load/wash/elute/CIP cycles coordinated
- **Continuous VI:** Plug-flow reactor residence time control via flow rate and temperature monitoring
- **SPTFF:** Concentration and diafiltration controlled via transmembrane pressure (TMP) and permeate flux feedback

Characterize startup, steady-state, and shutdown

ICH Q13 requires understanding of process dynamics across all phases:

- **Startup (0–3 days):** VCD ramp-up, metabolic transitions, titer accumulation begins
- **Steady-state (days 3–21+):** VCD stable within ±10%, metabolite levels controlled, consistent daily titer
- **Shutdown:** Controlled ramp-down, final harvest, CIP/SIP protocols
- **Disturbance handling:** Intentional challenges (media delivery delay, cell retention device fouling simulation, PAT sensor drift) to test robustness and recovery protocols

5.4.2 FMEA and Risk Management

Failure modes and effects analysis (FMEA) is critical for identifying single points of failure in PI processes and designing mitigations.

Conduct FMEA workshops

Cross-functional team (PD, MSAT, QA, Engineering) identifies failure modes, rates severity/probability/detectability, and defines risk priority numbers (RPN):

High-risk examples:

Cell retention device fouling leading to campaign loss (RPN >100), PAT sensor drift causing out-of-spec product, automation communication failure halting continuous DSP.

Design mitigations:

- **Redundancy:** Dual ATF systems, backup PAT sensors, UPS for critical equipment
- **Monitoring:** Real-time alerts for deviations (e.g., VCD drop >15%, pressure increase >20%)
- **Procedures:** Clear decision trees for continue vs. terminate campaigns, rework protocols for out-of-spec intermediates

Stress testing

Intentionally introduce disturbances during pilot runs to validate mitigations:

- Media pump failure simulation → automatic switchover to backup pump
- ATF filter fouling → scheduled backflush restores performance
- MCC column fouling → early regeneration or column replacement mid-campaign

5.4.3 Regulatory and Quality Positioning

By the end of Phase 2, you should have a clear regulatory strategy for your PI process, aligned with ICH Q13 and relevant agency guidances.

Draft control strategy (ICH Q13 Annex III compliant)

- Define batch boundaries for continuous processes (time-based, volume-based, or pool-based)
- Specify control strategy for each phase: startup (monitoring-heavy), steady-state (automated control), shutdown (manual oversight)
- Document CPP–CQA relationships using MVDA models and establish control ranges

Comparability assessment

If transitioning from an existing batch process:

- Execute side-by-side comparability studies (batch vs. PI process) for CQAs, impurity profiles, stability
- Justify any differences (e.g., "glycosylation profile shift within historical range and does not affect potency")

Batch definition and release strategy

- **For continuous upstream:** Define batch as N-day campaign or N-liter harvest pool
- **For continuous DSP:** Pool definition (e.g., "all eluate from continuous capture between t=0 and t=48 h")
- **Release testing:** Discuss real-time release testing (RTRT) potential with agencies, or default to traditional end-product testing

Early agency engagement

Consider pre-IND or Type C meetings (FDA) or scientific advice (EMA) to discuss:

- Proposed batch definition and control strategy
- PAT and RTRT plans
- Comparability approach if transitioning from approved batch process

5.4.4 Phase 2 Deliverables and Decision Gate

Key Deliverables:

- At least 2–3 successful pilot-scale integrated campaigns with full data packages (titers, yields, CQAs, process performance)
- FMEA report with risk mitigation strategies implemented and tested
- Control strategy documented (startup, steady-state, shutdown, disturbance handling)
- Batch definition and release strategy aligned with ICH Q13
- Regulatory strategy finalized with early agency engagement (if needed)
- Tech transfer readiness confirmed

Decision Gate Questions:

- Were pilot campaigns successful with acceptable deviation rates (<10%)?
- Has FMEA identified all critical failure modes with tested mitigations?
- Is the control strategy robust and regulatory-compliant (ICH Q13)?
- Is product quality consistent and comparable to baseline?
- Is the organization ready for commercial-scale deployment?

Sponsor Questions for Your CDMO:

- How many pilot runs were executed, and what was the success rate?
- Can you share FMEA results and how you've mitigated top risks?
- What is your proposed batch definition, and has it been discussed with agencies?
- How will you handle mid-campaign deviations (continue vs. terminate criteria)?
- What is the tech transfer plan and timeline?

Red Flags:

- Only 1 pilot run or >20% failure rate
- No FMEA conducted or high-risk modes not mitigated
- Vague batch definition ("we'll define it later")
- No regulatory engagement plan
- Tech transfer readiness unclear

Green Flags:

- Multiple successful pilots (≥2–3) with CV <10%
- Comprehensive FMEA with tested mitigations and documented risk reductions
- Clear, ICH Q13-aligned control strategy with agency alignment (if applicable)
- Product quality extensively characterized and comparable
- Detailed tech transfer plan with timeline and resource allocation

5.5 Phase 3 – Commercial Deployment and Lifecycle Management

Duration: 12–24 months + ongoing
Goal: Bring PI to commercial operations with qualified facilities, trained personnel, and continuous improvement systems
Key Cross-Functional Owners: Engineering, Digital/Automation, MSAT, Manufacturing, QA, Training

5.5.1 Facility and Infrastructure

Whether building new or retrofitting existing capacity, commercial PI facilities require thoughtful design aligned with intensified process requirements.

Facility design considerations

- **Bioreactor suite:** Sized for extended campaigns (21–60 days); adequate media storage (cold chain, tankage); perfusion-compatible harvest handling
- **DSP suite:** Continuous or semi-continuous skids (MCC, continuous VI, SPTFF); buffer inline conditioning (BIC) systems; reduced hold tank requirements
- **Utilities:** WFI, purified water, compressed gases scaled for continuous operations; waste handling for high-volume perfusion spent media
- **Cleanroom:** Modular POD designs enable faster deployment (6–12 months vs. 3–5 years for traditional builds)

Key infrastructure decisions - See chart below

Decision	Conventional Option	PI-Optimized Option	Trade-offs
Bioreactor platform	2000–5000 L stainless	500–2000 L single-use with perfusion	SUS faster to deploy, stainless lower OpEx at scale
DSP architecture	Batch columns + hold tanks	MCC/membrane + continuous VI + SPTFF	Continuous reduces footprint but increases automation complexity
Buffer Prep	Batch tank preparation	Buffer inline conditioning (ILC)	BIC cuts footprint 40–60%, requires validation
Cleanroom	Ballroom or hard-wall	Modular PODs	PODs enable regional replication, faster deployment

5.5.2 Automation and Digital Backbone

Commercial PI is inseparable from robust automation and data infrastructure.

Automation architecture requirements

- **Equipment-level control:** PLCs for bioreactors, ATF systems, chromatography skids, SPTFF
- **Supervisory control:** SCADA or DCS for campaign-level coordination (perfusion rate adjustments, MCC column switching, material tracing)
- **MES integration:** Batch records, electronic workflows, material genealogy, deviation management
- **Data historian:** Real-time PAT streams, process parameters, alarms stored for CPV and analytics

Communication standards

- **OPC UA:** Industry-standard protocol for equipment interoperability; essential for multi-vendor PI systems
- **ISA-95:** Standardized information models for manufacturing operations management
- Avoid proprietary middleware that locks you into single vendors

Cybersecurity and data integrity

- **21 CFR Part 11 compliance:** Audit trails, electronic signatures, access controls for all automation and data systems
- **Network segmentation:** Isolate GMP automation networks from corporate IT; implement firewalls and intrusion detection
- **Disaster recovery:** Regular backups, tested restore procedures, redundant historians

5.5.3 Tech Transfer and Training

Successful commercial launch depends on thorough tech transfer and operator readiness.

Tech transfer deliverables

- **Process descriptions:** Master batch records (MBRs), standard operating procedures (SOPs), process flow diagrams (PFDs)
- **Equipment specifications:** User requirement specifications (URS), functional specifications, calibration and maintenance schedules
- **Control logic:** Automation sequences, PAT alarm setpoints, diversion criteria, MVDA model parameters
- **Troubleshooting playbooks:** Decision trees for common failure modes (ATF fouling, column breakthrough, PAT drift), escalation procedures

Training program components

- **Classroom training:** PI principles, perfusion fundamentals, continuous DSP concepts, ICH Q13 regulatory framework
- **Hands-on training:** Simulator-based practice (if available), supervised operation of pilot equipment, mock campaigns
- **Competency assessment:** Written exams, practical demonstrations, documented sign-offs by qualified trainers
- **Ongoing training:** Annual refreshers, cross-training for backup roles, updates when processes or equipment change

Staffing for 24/7 operations

Long perfusion campaigns require continuous oversight:

- **Operators:** 3–4 shifts (day/night/weekend coverage), 2–3 operators per shift depending on facility size
- **Engineers:** On-call support for automation troubleshooting, PAT sensor maintenance
- **QA:** Real-time review of deviations, approval of continue/terminate decisions

5.5.4 Continuous Process Verification (CPV) and Lifecycle Management

Commercial PI requires ongoing monitoring and continuous improvement to maintain performance and realize long-term benefits.

CPV implementation

- **Control charts:** Track key CPPs (VCD, perfusion rate, titer) and CQAs (purity, aggregates, potency) over time using statistical process control (SPC)
- **Trending analysis:** Detect gradual drifts (e.g., declining resin capacity, cell retention fouling patterns) before they cause failures
- **Out-of-trend investigations:** Root cause analysis when parameters exceed control limits; CAPA implementation

PAT model maintenance

- **Sensor calibration:** Raman, capacitance, UV sensors require periodic recalibration (quarterly to annually depending on sensor type)
- **Model retraining:** MVDA models updated when cell line, media, or equipment change; validation against new data sets
- **Model drift monitoring:** Track prediction errors over time; retrain if error increases >15%

5.5.5 Phase 3 Deliverables and Ongoing Accountability

Key Deliverables:

- Commercial facility commissioned and qualified (FAT/SAT, IQ/OQ/PQ complete)
- Automation architecture operational with validated data integrity and cybersecurity controls
- Tech transfer complete (process descriptions, control logic, PAT setup, troubleshooting playbooks, training records)
- Engineering batches successful (≥2 runs demonstrating process performance and operator competency)
- CPV plan established with control charts and trending protocols
- KPI dashboard tracking CoG, capacity, quality, sustainability vs. original business case

Decision Gate Questions (Launch Readiness Review):

- Are all critical systems qualified and operational (bioreactors, ATF, MCC, SPTFF, BIC, automation)?
- Have utilities been stress-tested (media supply, WFI, waste handling, power backup)?
- Are operators, engineers, and QA staff trained and competent for 24/7 PI operations?
- Are tech transfer documents complete, and have engineering batches validated process robustness?
- Is the organization prepared for lifecycle management (CPV, PAT maintenance, continuous improvement)?

Sponsor Questions for Your CDMO (Commercial Readiness):

- How have you qualified the line for long campaigns (21–30 days) and PI-specific risks (cell retention, continuous DSP)?
- What is your plan for CPV—how will you monitor process performance over time and detect trends early?
- How will you maintain PAT models and sensors (recalibration frequency, model retraining triggers)?
- What KPIs will you track and share with me to demonstrate that PI benefits are actually realized for my program (CoG, capacity, quality)?
- How do you handle continuous improvement—will you incrementally add more intensification, or is this the final configuration?
- What is your staffing model for 24/7 perfusion campaigns, and how do you ensure continuity and competency?

Red Flags:

- Qualification incomplete (e.g., "IQ/OQ done, but PQ delayed pending commercial campaign")
- No engineering batches run, or engineering batches show significant deviations
- Training records incomplete or competency assessments not documented
- No CPV plan or KPI dashboard in place
- CDMO cannot articulate lifecycle management strategy (PAT maintenance, model updates, continuous improvement)

Green Flags:

- All qualifications complete with no major deviations or CAPAs outstanding
- Engineering batches successful (≥2) with performance meeting or exceeding pilot-scale results
- Comprehensive training records with documented operator competency for all PI-specific tasks
- CPV plan detailed, with control charts live and trending protocols operational
- KPI dashboard shared transparently with sponsor, showing CoG, capacity, quality metrics vs. targets
- Clear continuous improvement roadmap with plans to add further intensification or optimize existing processes

5.6 Timeline and Resource Planning

5.6.1 Typical Timeline (Greenfield Scenario)

For a CDMO building new PI capability:

- **Phase 0 (Strategy):** 3–6 months
- **Phase 1 (Lab development):** 6–12 months (can overlap Phase 0)
- **Phase 2 (Pilot):** 9–18 months (overlaps Phase 1 end)
- **Phase 3 (Commercial deployment):** 12–24 months (overlaps Phase 2 end)

Total elapsed time: 24–36 months from kickoff to first commercial campaign

Critical path items:

- Lab scale-down model development (Phase 1)
- Pilot campaign execution and FMEA (Phase 2)
- Facility design, construction, and qualification (Phase 3)
- Automation integration and testing (Phase 3)

5.6.2 Accelerated Timeline (Brownfield / Existing Capability)

If CDMO already has PI platform established:

- **Phase 0 (Asset-specific scoping):** 1–3 months
- **Phase 1 (Molecule adaptation):** 3–6 months (streamlined DoE)
- **Phase 2 (Validation runs):** 6–9 months (fewer pilot campaigns needed)
- **Phase 3 (Tech transfer to existing line):** 6–12 months

Total elapsed time: 12–24 months from kickoff to first commercial campaign

Advantage of established platforms: CDMO has proven scale-down models, qualified equipment, trained personnel, and regulatory precedent—dramatically reducing risk and timeline.

5.6.3 Resource Requirements

Phase 1 (Lab development):

- 2–3 FTE process scientists (upstream and downstream)
- 1 FTE analytical scientist (product characterization)
- 0.5 FTE automation/PAT engineer
- Lab equipment: Ambr or benchtop bioreactors with ATF/TFF, ÄKTA systems, PAT sensors (~$500K–$1M investment if not already available)

Phase 2 (Pilot):

- 3–5 FTE MSAT engineers (campaign execution, troubleshooting)
- 1–2 FTE QA (sampling, deviation management, documentation)
- 0.5–1 FTE automation engineer (control strategy implementation)
- Pilot equipment: 50–500 L bioreactors, ATF systems, DSP skids (~$2M–$5M if building new pilot suite)

Phase 3 (Commercial):

- $10M–$50M CapEx depending on greenfield vs. brownfield, single-use vs. stainless, level of automation
- 10–20 FTE operations staff (operators, engineers, QA/QC) for 24/7 coverage
- Ongoing: 1–2 FTE for PAT/MVDA model maintenance and continuous improvement

CHAPTER FIVE References (5)

Tsang V, et al. "Biomanufacturing evolution from conventional to intensified processes." *Biotechnol Bioeng*. 2020;117(11):3359-3372. PMC7531520[2]

Karst N, et al. "Continuous bioprocessing: the future has arrived." *Chem Eng Process*. 2021;168:108584

ICH Q13. "Continuous Manufacturing of Drug Substances and Drug Products." Final guideline. Jan 2023

FDA. "Continuous Manufacturing of Drug Substances and Drug Products." Draft Guidance. Apr 2023

BioPhorum Operations Group. "Continuous manufacturing in biologics." Dec 2023

SIX: Case Studies and Scenarios

6.1 Introduction: From Theory to Verified Performance

Theoretical benefits are one thing; verified operational data is another. This chapter provides composite case studies drawn from recent industry implementations by innovators, CDMOs, and biosimilar manufacturers. These snapshots validate the productivity, cost, and timeline claims made in previous chapters and offer concrete benchmarks you can use to validate your own business cases and probe CDMO partners more effectively.

Rather than presenting these as idealized success stories, the cases are framed to highlight the business constraints, technical choices, implementation timelines, and actual outcomes—including the gaps between initial projections and realized performance. The goal is to give senior leaders a realistic picture of what process intensification delivers in practice, across different organizational profiles and facility contexts.

We conclude with a cross-case comparison table that summarizes what is realistically achievable across different PI archetypes, providing benchmarks you can use to evaluate internal proposals or CDMO offerings.

6.2 Case 1: Large Innovator – N-1 Perfusion Retrofit (Brownfield)

6.2.1 The Strategic Challenge

A top-10 pharmaceutical company faced a classic capacity constraint: growing demand for a blockbuster monoclonal antibody was approaching the limit of an existing legacy stainless-steel facility with 12,000 L production bioreactors. The asset was approaching loss of exclusivity within 5–7 years, making a greenfield build economically unattractive. Forecasts indicated the need for a 50% increase in annual output to meet expanding indications and geographic markets.

Traditional options included:

- **Building a new facility:** 4–5 years, >$500M capital, but with LOE uncertainty
- **Outsourcing additional capacity to a CDMO:** Feasible but expensive at scale, with supply-chain and tech-transfer risks
- **Incremental debottlenecking:** Limited upside, already exhausted standard optimization levers

The leadership team needed a solution that could unlock meaningful capacity within existing walls, on a timeline consistent with near-term supply commitments, without betting hundreds of millions on long-term demand beyond patent expiry.

6.2.2 The PI Solution: N-1 Perfusion Seed Train

The company implemented **N-1 perfusion**—a high-density seed train strategy—to inoculate production bioreactors at 10× standard density, significantly shortening the production phase and increasing annual batch throughput.[2]

Implementation details:

- Retrofitted existing seed bioreactors (500 L scale) with alternating tangential flow (ATF) cell retention systems
- Upgraded media preparation systems to handle concentrated feeds and higher perfusion volumes
- Validated scale-down models using Ambr 250 perfusion to de-risk the approach before pilot
- Executed integrated pilot runs at 50 L scale, then scaled to commercial 500 L N-1 stage

Timeline:

- Concept to GMP campaign: **18 months**
- Phase breakdown: 6 months lab/scale-down, 9 months pilot + tech transfer, 3 months first commercial validation

Investment:

- Total capital: ~**$30M** (primarily seed train upgrades, media utility debottlenecking, and PAT integration)
- Minimal disruption to existing production operations during retrofit

6.2.3 Verified Results

Throughput:

- Production bioreactor duration reduced from **14 days to 9 days** (36% reduction)
- Annual batch count increased from **26 batches/year to ~40 batches/year** (55% increase)
- Effective capacity unlock: **equivalent to adding a second 12,000 L line** without new facility construction

Productivity:

- Peak titers increased by ~**20%** due to healthier, higher-viability seed cells entering production stage
- More consistent batch-to-batch titer performance (CV reduced from 18% to 12%)

Return on Investment:

- Breakeven achieved in **<12 months** of commercial operation vs. the cost of outsourcing or building new capacity
- Avoided capital: **>$400M** (net present value of greenfield alternative)
- Operational cost per gram: **15% reduction** due to higher titers and throughput

6.2.4 Lessons and Limitations

What worked:

- N-1 perfusion proved to be the lowest-risk, highest-return retrofit for existing stainless capacity
- Minimal regulatory friction—treated as process optimization within existing control strategy
- Operations team adapted quickly; no major deviations in first year of commercial use

What required active management:

- Media logistics: perfusion seed trains consumed 5× more media than conventional seed, requiring cold-chain and storage upgrades
- ATF filter management: fouling required proactive monitoring and predictive maintenance protocols
- Scale-down model robustness: early Ambr models over-predicted performance by ~15%; required refinement with additional DoE work

Sponsor Takeaway:

N-1 perfusion is the lowest-risk, highest-return retrofit for existing stainless capacity. If your CDMO has large legacy assets, ask them if N-1 is an option to increase slot availability and reduce your waiting times. Insist on seeing data from at least 5–10 commercial campaigns, not just pilot runs.

6.3 Case 2: CDMO – Hybrid Continuous Platform (Greenfield)

6.3.1 The Strategic Challenge

A mid-sized CDMO wanted to build a new commercial-scale facility optimized for **flexibility and speed-to-market**. Their target clients included biotech innovators and biosimilar manufacturers with widely varying volume demands (10 kg to 500 kg per year). Traditional facility archetypes forced an unpalatable trade-off:

- **Large stainless plant:** High capital, long lead times (3–5 years), inflexible for multi-product use
- **Conventional single-use:** Better flexibility, but CoG remained high and footprint still substantial

The CDMO's leadership recognized that a differentiated technical platform—delivering both flexibility and structural CoG advantage—would be a competitive moat in an increasingly commoditized CDMO market.

6.3.2 The PI Solution: Hybrid Continuous Platform

The CDMO designed a **Hybrid PI facility** using single-use perfusion bioreactors (500 L and 2,000 L) coupled with intensified fed-batch capability and membrane-based intensified downstream processing.

Implementation details:

- **POD-based cleanroom design:** Modular, prefabricated cleanroom pods for upstream, downstream capture, polishing, and formulation
- **Dual-mode upstream:** Each line capable of running either intensified fed-batch or production perfusion, depending on client molecule and business case
- **Intensified DSP:** Multicolumn chromatography (MCC) capture skids, continuous viral inactivation, flow-through polishing, single-pass TFF
- **Buffer inline conditioning (BIC):** Eliminated large ready-to-use buffer tanks; real-time buffer generation from concentrates
- **Integrated automation:** Unified DCS controlling upstream + DSP with time- and volume-based batching logic

Timeline:

- Ground-breaking to first engineering run: **18 months** (vs. 36+ months for traditional stainless facility)
- Commercial qualification: **24 months** total
- First client GMP campaign: **Month 26**

Footprint:

- Total GMP cleanroom area: **2,500 m²** (estimated 40% reduction vs. fed-batch-equivalent capacity)
- Modular expansion: additional 500 m² pod can be added in **6 months** for capacity scale-out

6.3.3 Verified Results

CapEx:

- Initial capital spend: ~**50% lower** than stainless facility of equivalent annual output
- Modular design enabled phased investment: Phases 1–2 funded from operating cash flow rather than requiring full upfront debt

Flexibility:

- Changeover time reduced from **7 days** (stainless standard) to **<2 days** (single-use + pod segregation)
- Capable of running 4 different client molecules in parallel across 4 upstream suites without cross-contamination risk
- Tech transfer time for new molecules: **4–6 months** (vs. 9–12 months conventional)

Cost of Goods:

- Achieved **$50–70/g** for standard mAbs at 500 L perfusion scale
- Competitive with 10,000 L stainless fed-batch economics, but at 1/20th the scale
- Enabled viable commercial manufacturing for clients with 50–200 kg/year demand (previously uneconomic)

Utilization:

- Year 1: **65% utilization** (8 campaigns across 4 suites)
- Year 2: **85% utilization** (14 campaigns, adding 2 new client programs)
- Effective capacity: **~180 kg/year** total mAb output from 2,500 m² facility

6.3.4 Lessons and Limitations

What worked:

- Modular pod design proved highly effective for parallel multi-client operations
- BIC eliminated a major source of batch delays and reduced buffer prep labor by 60%
- Clients valued speed-to-market and flexibility over absolute lowest CoG

What required active management:

- **Digital integration complexity:** Initial commissioning revealed interoperability issues between vendor skids; required 3 months of additional software work to achieve unified control
- **PAT sensor calibration drift:** Raman probes required more frequent recalibration than anticipated in continuous operation; implemented predictive maintenance algorithms
- **Client expectation management:** Some clients initially expected "fully continuous" end-to-end processing; education required to clarify hybrid model and benefits

Sponsor Takeaway:

A PI-centric CDMO can offer "big pharma" economics at "biotech" scales. You don't need to order 20 kg batches to get a good price per gram if the facility is designed this way. When auditing a CDMO's hybrid PI platform, focus on **digital integration maturity** and **actual campaign data**, not just equipment lists.

6.4 Case 3: Biosimilar Manufacturer – Full End-to-End (E2E) PI/CM

6.4.1 The Strategic Challenge

An emerging-markets biosimilar manufacturer needed to produce monoclonal antibodies at **<$40/g** to compete in price-sensitive global tender markets (Latin America, Southeast Asia, Eastern Europe). Traditional batch processes yielded CoG in the $80–120/g range at their target scale (100–300 kg/year), making competitive pricing impossible while maintaining acceptable margins.

The company's leadership recognized that **CoG was the existential constraint**—not speed, not modality complexity, but pure unit economics. Incremental improvements would not close the gap; a fundamentally different manufacturing architecture was required.

6.4.2 The PI Solution: Fully Continuous End-to-End Process

The company developed a **fully continuous end-to-end platform** modeled on approaches pioneered by Enzene Biosciences and similar innovators, with perfusion upstream directly feeding continuous downstream processing in a closed, integrated loop.

Implementation details:

- **Continuous perfusion upstream:** 500 L single-use bioreactors operated for 30–60 day campaigns at steady-state VCD of 80–120 × 10^6 cells/mL
- **Continuous capture:** Precipitation-based capture or membrane affinity chromatography (continuous loading)
- **Continuous viral inactivation:** Plug-flow reactor with automated pH control
- **Flow-through polishing:** Stacked AEX/mixed-mode membranes operated in continuous flow mode
- **Single-pass TFF:** Concentration and buffer exchange directly into drug substance pool
- **Fully integrated automation:** Single master batch record spanning 30–60 days, with time-based sub-batch definitions for release testing

Timeline:

- Platform development: **3 years** (first-of-kind implementation with significant technical risk)
- Subsequent molecule tech transfer: **<6 months** (platform proven, new molecules leverage existing knowledge)
- Regulatory approval: **First biosimilar approval 18 months post-commercial campaign**

Footprint:

- Complete manufacturing suite: **~140 m²** (~1,500 ft²) per line
- Entire facility (2 lines + support): **<500 m²** GMP space

6.4.3 Verified Results

Productivity:

- Cumulative titers: **>50 g/L** (vs. 4–5 g/L conventional fed-batch)
- Space-time yield: **~1.5 g/L/day** sustained over campaign
- Annual output per 500 L line: **~150 kg/year** (equivalent to ~5,000 L fed-batch line at 20% higher utilization)

Cost of Goods:

- Realized CoG: **$35–45/g** at commercial scale (100–200 kg/year production volumes)
- CoG breakdown: Media/buffers 30%, consumables 25%, labor 20%, utilities 10%, overhead/depreciation 15%
- Enabled tender pricing at **$60–80/g** with >40% gross margins

Market Impact:

- Won tenders in 6 countries where conventional CoG would have been non-competitive
- Established regional manufacturing hubs (India, Brazil) using replicated 500 m² facilities
- Reduced time-to-market for new biosimilar launches by **12–18 months** vs. traditional scale-up

6.4.4 Lessons and Limitations

What worked:

- End-to-end PI delivered transformational CoG and space efficiency, validating the business case
- Platform approach enabled rapid tech transfer for subsequent biosimilar molecules
- Continuous operation proved more robust than anticipated; deviation rates lower than batch comparators after first year

What required active management:

- **High automation dependency:** Any DCS or PAT failure risked entire campaign; required 24/7 monitoring and rapid vendor response protocols
- **Regulatory narrative:** Required substantial pre-filing engagement with regulators to establish control strategy and batch definition; not all agencies equally receptive
- **Media supply chain:** High daily consumption (>1,000 L/day for 500 L reactor) required robust supplier agreements and logistics planning
- **Cultural shift:** Operations team required extensive retraining; took ~18 months to fully transition from batch to continuous mindset

Sponsor Takeaway:

For cost-sensitive assets like biosimilars, end-to-end PI/CM is a game changer. It breaks the "economy of scale" rule, allowing low costs even at modest total volumes. However, **this archetype demands high organizational maturity** in automation, PAT, regulatory strategy, and operations. Not suitable for risk-averse early adopters or molecules with unstable processes.

6.5 Case 4: Viral Vector CDMO – Modality-Specific PI/CM

6.5.1 The Strategic Challenge

An AAV (adeno-associated virus) manufacturer faced two compounding problems:

1. **Low yields:** Fed-batch upstream yields were highly variable (0.5–2 × 10^{13} vg/L), with significant batch-to-batch inconsistency
2. **Product degradation:** Long hold times (12–48 hours) between harvest and purification led to substantial loss of "full" (functional) capsids, with empty capsid percentages climbing to 40–60%

Traditional batch processing was fundamentally misaligned with AAV biology: the vector is produced intracellularly, released upon cell lysis, and begins degrading immediately upon exposure to proteases and pH shifts in the culture medium. Longer residence times directly translated to lower functional yields and higher impurity burdens downstream.

6.5.2 The PI Solution: Modality-Specific Continuous Harvest

The CDMO implemented a **modality-specific PI approach** focused on minimizing residence time and maintaining product quality through continuous or near-continuous operations.

Implementation details:

- **Perfusion upstream for continuous harvest:** Maintained adherent or suspension cells in perfusion mode, with daily or continuous harvest of vector-containing medium
- **Inline lysis and clarification:** Immediate cell lysis (chemical or mechanical) and depth filtration to remove cell debris
- **Membrane chromatography capture:** Anion-exchange or affinity membrane capture of AAV directly from clarified lysate
- **Minimal hold times:** Target <4 hours from harvest to capture, <12 hours harvest to drug substance pool
- **Integrated control:** PAT-driven harvest timing based on vector titer and cell viability, not fixed batch schedules

Timeline:

- Process development and optimization: **12 months**
- Pilot demonstration (50 L scale): **6 months**
- Commercial tech transfer and validation: **9 months**

6.5.3 Verified Results

- **Functional capsid recovery increased by ~10×** compared to conventional batch processing with 24–48 hour holds
- Empty capsid percentage reduced from 45–60% (batch) to **15–25%** (continuous harvest)
- More consistent lot-to-lot full/empty ratios (CV <20% vs. >40% for batch)

Speed:

- Downstream processing time reduced from **6 days** (batch with multiple hold steps) to **1 day** (continuous flow with minimal holds)
- Campaign-to-campaign turnaround improved by 40%

Footprint and Infrastructure:

- Eliminated need for large -80°C storage freezers for intermediate harvest hold (saved **~50 m²** per suite)
- Reduced cold-chain logistics burden and freeze-thaw cycle risks

Economics:

- Cost per dose (gene therapy): Reduced by **30–40%** primarily through yield improvement, not OpEx reduction
- Enabled viable manufacturing at clinical and small-commercial scales (10–100 L bioreactor range)

6.5.4 Lessons and Limitations

What worked:

- PI solved a fundamental quality problem (degradation) that batch processing could not address
- Continuous harvest proved more robust and reproducible than anticipated
- Modality-specific design attracted clients with challenging AAV, lentiviral, and oncolytic virus programs

What required active management:

- **Lysis optimization:** Inline lysis required significant process development to avoid clogging depth filters
- **Membrane fouling:** High cell density and debris loads challenged membrane capture; required frequent changeouts until optimized
- **Regulatory precedent:** Limited prior approvals for continuous viral vector processing; required extensive agency pre-engagement

Sponsor Takeaway:

For unstable molecules (viral vectors, certain enzymes, labile fusion proteins), PI/CM is a **quality and yield necessity**, not just a cost play. When evaluating a CDMO's viral vector capabilities, ask specifically about **hold time management** and whether they have implemented perfusion + continuous harvest. Batch-only platforms will struggle to deliver competitive yields for degradation-prone modalities.

Metric	N-1 Perfusion (Retrofit)	Hybrid PI (Greenfield)	End-to-End Continuous
Titer/Yield Increase	1.5–3× (volumetric)	3–6× (cumulative)	5–10× (cumulative)
CoG Reduction	10–20%	30–50%	50–70%
Footprint Reduction	Neutral (uses existing)	30–50%	60–80%
CapEx Savings	High (avoids new build)	40–50%	>60% (but higher CapEx/m^2)
Implementation Timeline	12–18 months	18–30 months	30–48 months (first-of-kind)
Implementation Risk	Low	Medium	High (requires high automation & org maturity)
Regulatory Complexity	Low (process optimization)	Medium (hybrid batch definition)	High (ICH Q13, batch definition, agency pre-engagement)

Best Fit For...	Capacity unlock in legacy stainless plants	CDMOs requiring flexibility; innovators with diverse portfolios	Biosimilars; high-volume, cost-sensitive commercial products
Typical Use Cases	Blockbuster mAbs in late lifecycle; brownfield capacity expansion	Multi-client CDMO platforms; regional manufacturing hubs	Biosimilar mAbs; cost-driven emerging-market supply

Key Observations:

1. **Risk-reward spectrum is real:** N-1 perfusion delivers modest gains with minimal risk; end-to-end continuous delivers transformational gains but demands high organizational maturity and longer timelines
2. **Hybrid PI is the "sweet spot" for many organizations:** Captures 60–80% of the benefit of full continuous at 30–50% of the implementation complexity
3. **Modality matters more than scale:** Viral vector and unstable protein PI implementations prioritize quality and yield over CoG; mAb implementations prioritize CoG and capacity
4. **Footprint and CapEx savings are consistent:** Across all archetypes, PI delivers material space efficiency, which translates to capital avoidance or faster regional deployment

6.7 Comparative Insights: When to Choose Which Archetype

The four case studies illustrate that the "right" PI approach depends on your specific business constraint, organizational readiness, and asset characteristics. **Table 6-2** provides a decision matrix to guide archetype selection.

Table 6-2: PI Archetype Selection Matrix

Primary Constraint	Organizational Profile	Recommended Archetype	Why
Capacity	Large innovator, legacy stainless assets	N-1 perfusion retrofit	Fastest capacity unlock, lowest risk, leverages existing infrastructure
Capital efficiency	CDMO, greenfield build	Hybrid PI platform	Balances flexibility, CoG, and speed-to-operation
Cost of goods	Biosimilar manufacturer, emerging markets	End-to-end continuous	Only path to <$40/g target; justifies higher complexity
Product quality/yield	Viral vector, unstable proteins	Modality-specific PI (continuous harvest)	Solves degradation problem batch cannot address
Speed to market	Biotech, early commercial	Hybrid PI with modular DSP	Fast tech transfer, flexible capacity scaling
Portfolio diversity	Multi-product innovator or CDMO	Hybrid PI with platform design	Supports multiple molecules without full redesign

- **Strategic Implications:**

  Don't force one model: Case 1 (N-1 perfusion) and Case 3 (end-to-end continuous) represent opposite ends of the risk-reward spectrum. Match the archetype to your specific business constraint (capacity vs. cost) and organizational readiness.
- **Modality dictates architecture:** Case 4 demonstrates that for some modalities (AAV, lentivirus, labile proteins), PI is not optional—it's required to achieve acceptable quality and yield.
- **Speed is real:** Case 2 validates that PI facilities can be brought online **2–3× faster** than traditional stainless plants, a massive strategic advantage for CDMOs and their clients in fast-moving markets.

6.8 Red Flags and Green Flags: Evaluating PI/CM Claims

When reviewing internal PI proposals or CDMO offerings, use these indicators to separate credible implementations from marketing narratives.

Red Flags (High Risk of Underperformance):

- CDMO describes PI capabilities but has no commercial campaigns running—only pilot data
- Business case relies on >6X productivity gains without supporting pilot data at realistic scale
- No FMEA or Risk assessment for known failure modes (cell retention, PAT drift, automation failures)
- Digital architecture is "TBD" or relies on manual data transcription between systems
- Regulatory strategy assumes PI is "just like batch" with no explicit ICH Q13 alignment
- No baseline metrics provided for current-state CoG, throughput, or deviation rates
- Claims of "fully continuous" but actual implementation is batch with one or two continuous steps

Green Flags (High Confidence in Execution)

- CDMO provides detailed Case Studies with specific metrics (e.g., "80% throughput increase in Suite 3, 12 commercial lots produced via perfusion in 2024")
- Clear delineation of platform versus bespoke elements with decision trees for molecule-specific choices
- Transparent discussion of risks and mitigations, including actual deviation rates and FMEA outcomes
- Robust Digital Architecture with OPC UA, unified DCS/MES, and validated 21 CFR Part 11 compliance
- Techno-economic model with sensitivity analysis (e.g., "if titer is 30 g/L instead of 40 g/L, ROI extends from 18 to 24 months")
- Evidence of regulatory precent: prior submissions using PI/CM, or active pre-IND/pre-BLA meetings with agencies
- Operational Data: median campaign duration, deviation rates, PAT uptime, changeover times from actual GMP operations

6.9 Practical Next Steps: Using These Cases in Your Organization

For Innovators:

1. **Map your portfolio** to the four archetypes—which molecules are capacity-constrained (Case 1), cost-sensitive (Case 3), or quality-challenged (Case 4)?
2. **Model scenarios** using the benchmarks in Table 8-1 to quantify PI impact on your specific assets
3. **Engage CDMOs early**—ask them which case study most resembles their platform and request supporting data

For CDMOs:

1. **Position your platform** explicitly against these archetypes—avoid vague "we do PI" claims
2. **Build case study library** with client permission, showing actual campaign metrics and ROI realized
3. **Develop decision tools** (like Table 8-2) that help clients self-assess fit for your PI platform

For Technical Leaders:

1. **Use Table 6-1 as a benchmark** when evaluating internal or external PI proposals
2. **Demand operational data**, not just pilot data—insist on at least 5–10 commercial campaigns before committing
3. **Apply the Red Flag/Green Flag checklist** in vendor audits and internal gate reviews

6.10 Summary: Evidence Supports Staged, Pragmatic Adoption

The four case studies presented in this chapter validate the core themes of this ebook:

1. **PI delivers measurable gains** across productivity (2–10×), CoG (10–70% reduction), and footprint (30–80% reduction), with outcomes matching or exceeding initial business cases when well-executed
2. **Risk scales with ambition:** N-1 perfusion retrofits deliver quick wins with minimal risk; end-to-end continuous delivers transformational benefits but requires high organizational maturity, longer timelines, and robust digital infrastructure
3. **Hybrid PI is the pragmatic path for most organizations:** Captures 60–80% of the benefit at 30–50% of the complexity, making it the preferred starting point for CDMOs and innovators with diverse portfolios
4. **Modality can dictate architecture:** For unstable molecules (viral vectors, labile proteins), PI is not a cost optimization—it's a quality and yield necessity
5. **Speed matters:** PI facilities (especially hybrid greenfield designs) can be operational **2–3× faster** than traditional stainless plants, enabling faster time-to-market and more agile regional deployment strategies

For senior leaders evaluating PI, the key message is this: **PI is no longer experimental**. Hundreds of commercial campaigns have been executed across multiple archetypes, delivering verified benefits. The challenge is not whether PI works, but **how to select the right archetype for your context** and **how to execute it with the discipline these cases demonstrate**.

The next chapter turns from case evidence to forward-looking topics: how PI integrates with automation, PAT, and the digital backbone that makes intensified and continuous manufacturing operationally viable at scale.

Chapter SIX References (8)

Sartorius PI Forum. "Case studies in process intensification." 2024.

BioPhorum. "Continuous manufacturing implementation benchmarks." 2023.

Xu S, et al. High cell density perfusion seed train for monoclonal antibody production. *Biotechnol Bioeng*. 2020;117(3):683-694.

Yang WC, et al. N-1 perfusion enables flexible capacity in existing facilities. *Biotechnol Prog*. 2018;34(5):1123-1135.

WuXi Biologics. "Scale-out vs scale-up economics." White Paper. 2023.

Enzene Biosciences. "EnzeneX 2.0 Case Study." 2024.

Cytiva. "Intensified viral vector manufacturing." 2024.

Bausch M, et al. Continuous processing improves AAV vector quality. *Mol Ther Methods Clin Dev*. 2021;23:337-353.



Chapter 7:
Brains of the Facility – Automation, PAT, and the Digital Backbone

7.1 Introduction: Why Digital Infrastructure Is Non-Negotiable for PI

Process intensification transforms biologics manufacturing into a data-rich, flow-driven activity that cannot be reliably operated with manual, paper-centric systems. Digital infrastructure, automation architecture, and process analytical technology (PAT) are not "nice-to-have" add-ons—they are the core enablers that make PI scalable, compliant, and economically attractive at commercial scale.

This fundamental reality creates an organizational challenge: many biologics manufacturers have treated digital and automation capabilities as support functions that respond to process requirements after they are defined. In PI, that sequence must reverse. **Automation, PAT, and data architecture must be specified in Phase 0 and integrated from Phase 1 onward**, not bolted on during commissioning or after equipment procurement.

When digital infrastructure lags or is under-specified, the theoretical benefits of PI—higher productivity, real-time control, reduced CoG, faster tech transfer—fail to materialize. Instead, organizations encounter brittle manual workarounds, data silos, unvalidated control loops, and operational complexity that erodes rather than enhances performance.

This chapter describes the essential technology stack, integration patterns, and practical implementation steps required to operate intensified and continuous bioprocessing at commercial scale. It is structured for two audiences:

- **Senior technical and operations leaders** who must approve digital architecture investments and ensure automation requirements are built into facility and equipment decisions
- **CDMO clients** who need to assess whether a partner's digital maturity matches their PI claims

The content is organized around three core questions:

1. **What automation architecture is required** to control intensified upstream, continuous downstream, and integrated PI trains?
2. **What PAT tools and models are essential**, and how do they enable real-time control and quality oversight?
3. **What data platforms and integration standards are needed** to avoid vendor lock-in, ensure data integrity, and support continuous process verification?

7.2 The Four-Layer Automation Stack for PI/CM

7.2.1 Architecture Overview

Most successful PI facilities converge on a **four-layer automation architecture** that separates concerns while enabling coordinated control across unit operations:

Level 1: Skid-Level Control (PLCs and Local HMIs)

- Local programmable logic controllers (PLCs) embedded in bioreactor systems, ATF/TFF skids, MCC/membrane chromatography modules, buffer inline conditioning (BIC) systems, and SPTFF units
- Each skid operates autonomously with local alarms, safety interlocks, and human-machine interfaces (HMIs)
- Responsibility: Equipment suppliers (validated as part of FAT)

Level 2: Supervisory Control (DCS/SCADA)

- Distributed control system (DCS) or SCADA platform that coordinates recipes, sequences, and interlocks across multiple skids
- Manages process phases: startup (ramp to steady-state), steady-state operation (maintain targets), shutdown (controlled ramp-down), and disturbance handling (recovery sequences)
- Implements time-based or volume-based batch logic for continuous operations
- Responsibility: Site engineering + automation integrator

Level 3: Manufacturing Execution System (MES)

- Manages electronic batch records (eBRs), workflow execution, material genealogy, and quality events
- Handles hybrid batch definitions (e.g., 24-hour time windows, pooled volumes, campaign-level batches)
- Interfaces with QMS for deviations, CAPA, and batch release workflows
- Responsibility: Site IT/OT + MES vendor

Level 4: Analytics and Digital Twin

- Aggregates contextualized data from Levels 1–3 for multivariate data analysis (MVDA), soft sensors, process optimization, and simulation
- Supports continuous process verification (CPV), trend analysis, and predictive maintenance
- May include digital twin models for scenario planning and operator training
- Responsibility: Process development + data science + digital MSAT

This layered approach ensures that **continuous or hybrid PI flows can be controlled consistently from seed train to drug substance pool**, with clear separation of real-time control (Levels 1–2), batch/workflow management (Level 3), and analytics (Level 4).

7.2.2 ISA-88 and ISA-95 Extensions for Continuous Processing

ISA-88 (batch control) and ISA-95 (enterprise-control integration) remain foundational standards, but PI requires explicit extensions to handle continuous and hybrid operations:

ISA-88 Extensions:

- **Time-sliced or volume-based batch definitions:** Batches defined as fixed time windows (e.g., 24-hour periods) or volumetric pools (e.g., 500 L harvest pools) rather than discrete reactor runs
- **Phase-aware logic:** Explicit encoding of startup, steady-state, ramp, transition, and shutdown phases with different control strategies for each
- **Material traceability:** Residence time distribution (RTD) models to track material segments through connected unit operations

ISA-95 Extensions:

- **Contextualized data models:** Mapping time-series data (Level 1–2) to production orders, batches, and materials (Level 3) using consistent ontologies
- **Real-time KPI propagation:** Feeding process performance metrics (titer, VCD, CQA predictions) up to MES and ERP systems for supply chain visibility

A well-designed PI DCS configuration **encodes these concepts explicitly** in equipment recipes and control modules, rather than burying them in vendor-specific scripts or relying on manual operator interpretation.

PI relies on **continuous or high-frequency measurement** of critical process parameters (CPPs) to enable real-time control and reduce reliance on offline analytics. A pragmatic PAT starter set includes:

PAT Tool	Primary Measurement	PI Role	Implementation Priority
Raman spectroscopy	Nutrients (glucose, glutamine), metabolites (lactate, ammonia), sometimes titer estimation	Feed control, perfusion rate optimization	High (upstream intensification)
Capacitance probes	Viable cell density (VCD)	Cell bleed control, steady-state density targets	High (perfusion, N-1)
Inline UV/VIS	Protein concentration (280 nm), turbidity	Capture load/elution monitoring, breakthrough detection	High (continuous DSP)
Conductivity	Buffer composition, salt concentration	Buffer blending verification, pool control	Medium (BIC, SPTFF)
Multi-parameter probes	pH, dissolved oxygen (DO), temperature, pressure	Basic closed-loop control, safety interlocks	High (all processes)
Offline/at-line analytics	HPLC (product titer, aggregates), CE-SDS (purity), LC-MS (glycans, charge variants)	CQA confirmation, MVDA model training and validation	High (model calibration)

These tools provide the **data foundation for model-based control** and enable risk-based approaches to batch release, including real-time release testing (RTRT) where supported by robust control strategies.

7.2.3 From Monitoring to Closed-Loop Control

In early PI deployments, PAT is often used for **monitoring only**—generating data streams that operators review but do not act upon automatically. Leading PI facilities push further, implementing **closed-loop control** where PAT signals drive automated process adjustments:

Upstream closed-loop examples:

- **VCD-based perfusion control:** Capacitance signal automatically adjusts perfusion rate and cell bleed to maintain target VCD (e.g., 80–100 × 10^6 cells/mL) within ±10%
- **Raman-based feed control:** Real-time glucose and lactate measurements adjust concentrated feed rates to maintain metabolic balance and prevent overflow metabolism

Downstream closed-loop examples:

- **UV-based MCC switching:** Inline UV at column outlet triggers automated valve switching (load → wash → elute → CIP) when breakthrough or peak-end thresholds are reached
- **Conductivity-based buffer blending:** BIC systems adjust concentrate flow rates in real-time to maintain target conductivity ±0.5 mS/cm

The shift from "seeing the data" to "acting on the data automatically within validated control strategies" is the operational hallmark of mature PI programs.

7.2.4 PAT Model Lifecycle Management

PAT-based control strategies depend on **multivariate models** (e.g., PLS, PCA, hybrid mechanistic-empirical) that link sensor signals to process states and CQAs. These models require explicit lifecycle management:

Model development (Phase 1):

- Train initial models using lab-scale data (Ambr perfusion, bench DSP)
- Validate predictive accuracy on independent experiments (target: 10–15% error for titer, VCD)

Model deployment (Phase 2–3):

- Transfer models to pilot/commercial DCS with version control and change tracking
- Implement model monitoring: track residuals, prediction intervals, and input data quality

Model maintenance (Phase 3+):

- **Quarterly recalibration:** Update models with recent campaign data to account for sensor aging, cell line drift, media lot changes
- **Annual retraining:** Re-optimize model structures if process conditions evolve (new cell banks, media formulations, equipment)
- **Change control:** Treat model updates as process changes requiring impact assessment and QA approval

Critical success factor: Model lifecycle procedures must be documented in SOPs and integrated into site change control workflows from Phase 2 onward, not treated as IT maintenance activities.

7.3 Integrating Skids, DCS, and MES: Interoperability and Standards

7.3.1 The Interoperability Challenge

PI lines typically integrate **equipment from multiple vendors** (bioreactor from Vendor A, ATF from Vendor B, MCC skid from Vendor C, SPTFF from Vendor D, DCS from Vendor E). Without enforced interoperability standards, integration becomes a custom engineering project for every molecule and site, eroding PI's economic and timeline advantages.

Common integration failures:

- Proprietary communication protocols requiring custom middleware for each vendor pair
- Inconsistent tag naming (e.g., Vendor A uses "PV_TEMP_01", Vendor B uses "Temp_Bioreactor_Suite3_degC")
- Non-standard data types (integers vs. floats, different timestamp formats)
- Lack of standardized alarm and event structures
- Equipment cannot expose internal state variables needed for advanced control (e.g., ATF transmembrane pressure, MCC column utilization)

These issues delay commissioning, increase validation burden, and create long-term maintenance risk.

7.3.2 Best-Practice Standards for PI Integration

Leading PI facilities enforce the following standards from URS stage onward:

Communication protocols:

- **OPC UA (IEC 62541)** as the mandatory standard for all Level 1 (skid) → Level 2 (DCS) communication
- DNP3 or Modbus TCP acceptable for simple devices (sensors, pumps) but not for complex skids
- **No proprietary protocols** without vendor-provided OPC UA wrappers validated at FAT

Data modeling:

- **Unified tag naming conventions:** Site-level standard specifying equipment_location_parameter_unit format (e.g., BIOR_Suite3_VCD_E6cellsPerML)
- **Standard data types and scaling:** Agreement on float precision, engineering units, and scaling factors before equipment procurement
- **Event and alarm taxonomies:** Consistent alarm priority levels (critical, high, medium, low) and event types (state changes, setpoint adjustments, faults) across all vendors

Interface specifications:

- Clear **setpoint/status/mode** structures for each unit operation: what the DCS can command, what the skid reports back, what interlocks exist
- **Handshake protocols** for coordinated sequences (e.g., upstream signals downstream to prepare for harvest)

Contractual enforcement:

- Interoperability requirements in equipment purchase orders with **penalties for non-compliance**
- FAT includes **integration testing** with DCS simulator, not just standalone skid operation
- Vendor provides OPC UA **information models** (tag lists, data types, method signatures) 90 days before equipment delivery

7.4 Sponsor Question for CDMOs:
"What communication standards do you mandate for PI skids, and can you show me a recent FAT report demonstrating OPC UA compliance testing?"

7.5 PI-Specific DCS Features and Control Strategies

7.5.1 Capabilities Legacy Batch Systems Lack

Standard fed-batch DCS configurations often struggle with PI-specific requirements. Your PI DCS must natively support:

Event- or time-based batching:

- Defining batches by **time windows** (e.g., 24-hour periods within a 30-day perfusion campaign) or **pooled volumes** (e.g., 500 L harvest pools) rather than single reactor run start-to-end events
- Generating sub-batch identifiers automatically (e.g., Campaign_C001_Day01, Campaign_C001_Day02...)

Coordinated multi-skid recipes:

- **Linked recipe execution:** Upstream perfusion rate changes automatically trigger coordinated capture column flow rate adjustments in downstream MCC
- **Phase synchronization:** Ability to define "steady-state upstream + steady-state capture" as a coordinated multi-skid phase

Disturbance handling:

- **Predefined recovery sequences:** If feed pump fails, DCS automatically switches to backup pump, logs event, alerts operator
- **Fault-tolerant control:** If Raman probe fails, DCS switches from Raman-based feed control to capacitance-based proxy control until probe is restored
- **Campaign termination logic:** Clear decision rules for when to terminate (e.g., VCD drops >30% and cannot be recovered within 12 hours) vs. continue with increased monitoring

Advanced alarm management:

- **Context-aware alarms:** Different alarm limits during startup vs. steady-state vs. shutdown phases
- **Alarm shelving protocols:** Ability to temporarily suppress nuisance alarms (e.g., high flow rate during CIP) with QA-approved justification and automatic re-enablement
- **Predictive alarming:** Trending CPPs to alert operators *before* hard limits are breached (e.g., "VCD trending 10% below target over past 6 hours")

7.5.2 Control Strategy Alignment with ICH Q13

Your DCS configuration must implement the **state of control** and **material traceability** expectations defined in ICH Q13:

State of control demonstration:

- Continuous monitoring of CPPs with statistical process control (SPC) charts showing process is "in control" within validated ranges
- Real-time calculation of process capability indices (Cpk) for critical parameters
- Automated documentation of deviations with timestamps, root cause categories, and corrective actions

Material traceability:

- **Residence time distribution (RTD) tracking:** DCS calculates and records the age distribution of material at each unit operation based on flow rates and equipment volumes
- **Batch boundary enforcement:** Material entering the process after a defined batch start time is automatically assigned to the next batch identifier
- **Diversion logic:** Predefined rules for when to divert material (e.g., startup material before steady-state achieved, material produced during PAT failures) with automated valve control and pool segregation

Sponsor Question for CDMOs:
"Can your DCS generate an ICH Q13-compliant batch record showing material traceability, state-of-control evidence, and phase-specific control strategies for a 30-day perfusion campaign?"

7.6 Data Architecture: From Raw Signals to Actionable Insights

7.6.1 The PI Data Volume Challenge

PI generates **orders of magnitude more data** than traditional fed-batch processing, especially when logging PAT at sub-minute intervals:

Typical data volumes:

- **Conventional fed-batch (14-day run):** ~50,000 data points (process parameters logged every 5 minutes, offline analytics 2× daily)
- **Intensified fed-batch with PAT (9-day run):** ~500,000 data points (PAT every 15 seconds, process parameters every 1 minute)
- **Perfusion campaign (30-day run):** ~5,000,000 data points (PAT every 15 seconds, process parameters every 30 seconds, continuous harvest analytics)

Without a scalable architecture, stakeholders **"drown in data and starve for insight"**—unable to extract process understanding, troubleshoot deviations, or demonstrate process control to regulators.

7.6.2 Three-Layer Data Architecture

A scalable PI data platform requires three functional layers:

Layer 1: Raw Time-Series Historian

- High-frequency data capture from all Level 1 (skids) and Level 2 (DCS) sources
- Typical platforms: OSIsoft PI System, Rockwell FactoryTalk Historian, Honeywell PHD, AVEVA Historian
- Requirements:
  - Data compression algorithms to reduce storage (5–10× compression typical without information loss)
  - Redundant servers for 99.9%+ uptime
  - Tag counts sized for PI: 5,000–20,000 tags per line (vs. 1,000–3,000 for fed-batch)
  - Retention policies: 7 years hot storage for GMP data, offline archival for older campaigns

Layer 2: Contextualization Engine

- Maps raw time-series data to production context: which batch, which phase, which equipment, which materials
- Implements ISA-88/ISA-95 hierarchies: Enterprise → Site → Area → Line → Unit → Equipment Module
- Annotates data with events: batch start/end, phase transitions, alarms, operator interventions, material additions
- Typical platforms: OSIsoft PI Asset Framework (AF), Seeq, TrendMiner, Augury
- Critical capability: **Unified data model** across upstream, downstream, and utilities so cross-functional analysis is possible

Layer 3: Analytics and Visualization

- MVDA tools for process understanding and soft sensors (SIMCA, Umetrics MODDE, Python scikit-learn)
- Interactive dashboards for real-time operations and historical trending (Tableau, Power BI, Grafana, Seeq Workbench)
- Statistical process control (SPC) and CPV tools (JMP, Minitab, PI ProcessBook + custom SPC)
- Digital twin and simulation platforms (gPROMS, MATLAB Simulink, custom Python models)

7.6.3 Data Integrity and 21 CFR Part 11 Compliance

All three layers must comply with **21 CFR Part 11 and EU Annex 11** requirements for electronic records and signatures:

Electronic record requirements:

- **Audit trails:** All data changes, deletions, and configuration modifications logged with user ID, timestamp, reason
- **Data immutability:** Raw historian data cannot be edited or deleted; any corrections require annotation with justification
- **Secure timestamping:** NTP-synchronized clocks across all systems (±1 second accuracy)
- **Backup and recovery:** Validated disaster recovery procedures with tested restoration (annual DR drills)

Electronic signature requirements:

- **Role-based access control (RBAC):** Operators can view/acknowledge alarms; engineers can adjust setpoints within validated ranges; QA must approve model changes
- **Multi-factor authentication:** For high-risk actions (batch record approval, diversion decisions)
- **Signature workflows integrated into MES:** eBR approval chains with embedded context (what was signed, when, under what process state)

Cybersecurity:

- **Network segmentation:** OT (operational technology) networks for Level 1–3 physically or logically isolated from IT networks
- **Intrusion detection:** Monitoring for unauthorized access attempts, unusual data traffic patterns
- **Vendor patch management:** Coordinated updates to PLC firmware, DCS software, MES with validation protocols
- **Incident response plans:** Defined procedures for ransomware, equipment compromise, data breach scenarios

Sponsor Question for CDMOs:
"Can you provide a data integrity CAPA-free audit report from your last regulatory inspection covering PI lines with continuous data streams?"

7.7 Use Cases for PI Analytics and Digital Twins

7.7.1 Soft Sensors for Real-Time Quality Prediction

Problem: Offline CQA analytics (glycosylation, charge variants, aggregates, HCP) take 24–72 hours, too slow for real-time control or early deviation detection in continuous processes.

Solution: MVDA-based soft sensors that predict CQAs from PAT signals in real-time:

- **Titer prediction from Raman spectra:** PLS models correlating Raman spectral features with offline HPLC titer measurements (typical accuracy: ±10–15%)
- **Glycan profile prediction from VCD, pH, lactate trends:** Hybrid mechanistic-empirical models linking culture conditions to glycosylation outcomes
- **Aggregation risk scoring:** Logistic regression models flagging high-risk periods based on pH excursions, temperature spikes, residence time in DSP hold steps

Implementation requirements:

- Training datasets: ≥10 campaigns with paired PAT and offline CQA data
- Model validation: Independent test set showing <20% prediction error
- Deployment: Real-time calculation in Level 4 analytics, with alerts triggered when predictions exceed action limits
- Lifecycle: Quarterly model recalibration, annual revalidation

Business impact: Enables **earlier intervention** (adjust process before CQA drifts out of spec) and supports **real-time release testing (RTRT)** strategies where regulators accept PAT-based predictions as primary evidence of quality.

7.7.2 Rapid Deviation Investigation

Problem: In a 30-day perfusion campaign with 5M data points, manually reconstructing events during a deviation (e.g., VCD drop on Day 18) is time-consuming and error-prone.

Solution: Contextualized search and automated root cause tools:

- **Event timeline reconstruction:** Query historian + MES to visualize all process parameters, alarms, operator actions, and material additions in 2-hour window around deviation
- **Golden batch comparison:** Overlay current campaign data against historical "golden batch" envelopes to identify parameters trending outside normal range *before* hard limits were breached
- **Correlation analysis:** Automated identification of parameters with high correlation to the observed deviation (e.g., media flow rate dropped 15% six hours before VCD decline)

Implementation requirements:

- Contextualization engine (Layer 2) operational with event annotations
- Dashboard tools (Seeq, TrendMiner) configured with PI-specific templates
- Training for QA and manufacturing engineers on search and visualization workflows

Business impact: Reduces deviation investigation time from **days to hours**, accelerates CAPA closure, and supports continuous improvement cycles.

7.7.3 Continuous Process Verification (CPV) Automation

Problem: Manual CPV (reviewing control charts quarterly, writing reports annually) does not scale to high-frequency PI data and continuous operations.

Solution: Automated CPV with real-time SPC and trending:

- **Automated control charts:** X-bar/R, CUSUM, or EWMA charts updated every batch (or daily for continuous campaigns) for all CPPs and CQAs
- **Out-of-trend detection:** Automated alerts when parameters drift outside warning limits (2σ) even if within specification limits (3σ)
- **Performance degradation trending:** Track process capability indices (Cpk) over time to detect slow drift (e.g., cell line aging, equipment fouling)
- **Automated reporting:** Quarterly CPV reports generated from historian + MES data with minimal manual compilation

Implementation requirements:

- Level 4 analytics platform with SPC libraries (JMP, Minitab, custom Python)
- Integration with MES for batch metadata (product, lot, phase)
- Validated report templates aligned with ICH Q10 and site CPV procedures

Business impact: Maintains **state of control** required by ICH Q13, detects process drift earlier, reduces manual CPV labor by 60–80%.

7.7.4 Digital Twins for Scenario Planning and Training

Problem: Testing process changes (new cell bank, media optimization, increased perfusion rate) in GMP campaigns is risky and resource-intensive.

Solution: Digital twin models that simulate process behavior under different scenarios: See page below.

- **Mechanistic models:** ODE-based representations of cell growth, metabolism, and product formation (gPROMS, MATLAB Simulink)
- **Hybrid models:** Combine mechanistic frameworks with ML-based parameter fitting for improved accuracy
- **Use cases:**
    - *In silico DoE:* Test 20 process scenarios to narrow design space before wet-lab experiments
    - *Operator training:* Simulate normal operations, deviations, and recovery procedures in safe environment
    - *Capacity planning:* Model impact of longer campaigns, higher VCD targets, or additional lines on annual throughput

Implementation requirements:

- Validated models with demonstrated predictive accuracy (±15–20% for key outputs)
- Integration with control systems for "what-if" scenario testing
- Change control procedures for model updates

Business impact: Accelerates process optimization, de-risks scale-up, and supports regulatory submissions with *in silico* evidence of design space robustness.

7.8 Phased Implementation Roadmap for Digital and Automation

Digital and automation work must **track the overall PI roadmap** from Chapter 5, not arrive as an afterthought during commissioning.

Phase 0: Strategy and Standards Definition (0–6 months)

Activities:

- Define **communication standards** (mandate OPC UA, specify tag naming conventions)
- Select **target automation platforms** (DCS, MES, historian vendors)
- Establish **data governance policies** (retention, backup, access control, cybersecurity baseline)
- Define **digital roles** needed (automation engineers, data scientists, digital MSAT)

Deliverables:

- Digital Architecture Blueprint (1-page schematic of 4-layer stack)
- Equipment URS template with interoperability requirements
- Vendor engagement plan (which suppliers must provide OPC UA wrappers, when)

Phase 1: Lab PAT Integration and Initial Models (6–18 months)

Activities:

- Integrate PAT sensors into lab-scale systems (Ambr perfusion, bench DSP)
- Collect high-frequency data for model training (every 1–15 minutes depending on sensor)
- Build initial MVDA models (PLS, PCA for titer, VCD, CQA prediction)
- Set up lab-scale historian pilot (OSIsoft PI, simple dashboard)
- Prototype control logic in miniature (simulated perfusion control, MCC switching)

Deliverables:

- PAT tool selection report with performance benchmarks
- MVDA models with validation statistics (R^2, RMSEP, Q^2 values)
- Lab data infrastructure proof-of-concept
- Control strategy draft (v1.0) aligned with ICH Q13

Critical success factor: Do not skip this phase. Organizations that deploy PAT and automation "cold" at pilot scale without lab-scale learning experience major delays and rework.

Phase 2: Pilot DCS Integration and Control Validation (12–30 months)

- Deploy integrated pilot DCS instance coordinating 50–500 L bioreactor + DSP skids
- Implement **time/volume-based batching logic** for hybrid PI campaigns
- Validate **closed-loop PAT control** (VCD-based perfusion, UV-based MCC switching)
- Test **disturbance handling** (simulated pump failures, sensor dropouts, manual overrides)
- Execute FMEA on digital/automation systems (identify single points of failure, design redundancy)

Deliverables:

- Commissioned pilot DCS with validated recipes for ≥2 campaigns
- PAT control validation report (setpoint accuracy, response time, deviation handling)
- FMEA with automation-specific mitigations (backup sensors, UPS, failover logic)
- Control strategy draft (v2.0) incorporating pilot learnings

Phase gate question: *"Can the pilot DCS generate a complete electronic batch record for a 21–30 day hybrid campaign with full material traceability and ICH Q13 compliance?"*

Phase 3: Commercial Automation Scale-Up (≥24 months)

- Scale DCS/MES/historian to commercial tag counts (5,000–20,000 tags per line)
- Implement **production-grade redundancy** (redundant historians, UPS, backup PAT sensors)
- Finalize **alarm strategies** (context-aware limits, shelving protocols, escalation trees)
- Integrate **MES workflows** for eBR approval, deviation management, batch release
- Deploy **automated CPV dashboards** and reporting
- Validate **cybersecurity controls** (network segmentation, intrusion detection, DR procedures)

Deliverables:

- Fully qualified commercial automation system (IQ/OQ/PQ complete)
- Validated eBR templates for all PI campaigns
- 21 CFR Part 11 / EU Annex 11 compliance validation report
- CPV automation operational with first trending reports
- Digital twin operational (if in scope)

Phase gate question: *"Have you executed ≥1 engineering batch demonstrating end-to-end automation, data integrity, and operator workflows, with no major CAPAs?"*

7.9 Organizational Requirements: New Roles and Skills

7.9.1 Hybrid Skill Sets PI Demands

PI requires **hybrid roles** that bridge process understanding and digital/automation expertise:

Process Automation Engineers:

- Understand both control theory (PID loops, feedforward/feedback) *and* bioprocess specifics (cell metabolism, chromatography behavior)
- Can translate process scientist requirements into DCS logic and vice versa
- Typical background: ChE or BiE degree + 3–5 years automation experience (not pure IT or pure bioprocess)

Data Scientists / MVDA Specialists:

- Embedded close to MSAT and manufacturing, not in IT department
- Skilled in PLS/PCA, hybrid modeling, and *interpretable* ML (not just black-box neural nets)
- Comfortable working with messy process data (missing values, sensor drift, batch-to-batch variability)

Digital MSAT Roles:

- Interface between plant operations and IT/OT teams
- Own PAT model lifecycle (calibration, retraining, change control)
- Support deviation investigations using data analytics tools
- Train operators on dashboard interpretation and alarm response

Staffing gap: These roles are in short supply. Organizations must invest in **proactive hiring** (recruit from adjacent industries: oil/gas, chemicals) and **internal development** (cross-train bioprocess engineers in automation, IT staff in GMP/biologics).

7.9.2 Training and Change Management

Operators and QA staff must shift from **batch documentation mindset** to **flow oversight mindset**. Training should focus on:

For Operators:

- Interpreting real-time dashboards and trend visualization (not just alarm acknowledgement)
- Understanding PAT basics (what Raman measures, why capacitance drifts, when to escalate)
- Responding to **automated recovery sequences** (when to trust the system, when to intervene manually)
- **Campaign thinking:** managing 30-day perfusion runs vs. 14-day fed-batch runs (fatigue management, handover protocols for shift changes)

For QA/QC Staff:

- Continuous process sampling strategies (time-based, volume-based, phase-based)
- Reviewing **high-frequency data streams** for trending and state-of-control evidence
- **Deviation management** for long campaigns (when to investigate mid-campaign vs. wait for campaign end)
- Understanding **RTRT concepts** and PAT-based quality oversight

For Maintenance:

- **Preventive maintenance schedules** specific to PI (ATF membrane replacement every 20–30 days, PAT sensor recalibration quarterly)
- Troubleshooting **automation failures** (PLC faults, communication dropouts, sensor drift)

Training metrics to track:

- % operators qualified for PI campaigns (target: 100% of shift leads, 75% of all operators by commercial launch)
- Mean time to escalate PAT sensor issues (target: <30 minutes)
- Deviation rate for first 5 commercial campaigns vs. pilot (target: <2× pilot baseline)

7.10 Vendor Management, FAT, and SAT for PI Automation

7.10.1 Factory Acceptance Testing (FAT) Must Reflect PI Realities

Standard FAT protocols test equipment in isolation with simple "step input → measure output" sequences. **PI FAT must simulate realistic campaign dynamics**:

FAT requirements for PI/CM skids:

- **Simulate 14–30 day campaigns** with realistic process profiles (not just 2-hour steady-state tests)
- Test **PAT sensor integration:** Verify Raman, capacitance, UV signals are correctly transmitted via OPC UA with proper scaling and units
- Test **communication failures:** Disconnect OPC UA, observe skid behavior (does it fail-safe? alarm appropriately? buffer data?)
- Test **coordinated control:** If upstream and downstream skids are from different vendors, test coordinated recipe execution (e.g., harvest trigger → capture load sequence)
- Verify **time/volume batching logic** works as designed (can DCS correctly track material through 30-day campaign?)

Acceptance criteria:

- All OPC UA tags accessible with <1 second latency
- No communication dropouts during 72-hour stress test
- Alarm and event logs correctly populated in historian
- Batch record generated with complete material genealogy

Red flag: Vendor resists extended FAT or insists "integration testing happens at site." This signals inadequate preparation and will cause SAT delays.

7.10.2 Site Acceptance Testing (SAT) and Commissioning

SAT focuses on **integrated system performance** in the actual GMP environment:

SAT test scenarios:

- **End-to-end dry run:** Execute full PI campaign with water/buffer (no cells/product) for 21–30 days
- **Utility stress test:** Verify WFI, compressed air, chilled water, power backup can sustain continuous operation without interruptions
- **Cybersecurity validation:** Penetration testing, DR drill, intrusion detection verification
- **Operator workflow validation:** Execute all SOPs (startup, routine monitoring, deviation response, shutdown) with operators who will run commercial campaigns

IQ/OQ/PQ considerations:

- **Installation Qualification (IQ):** Verify all hardware, wiring, network infrastructure matches design specifications
- **Operational Qualification (OQ):** Test each unit operation independently (bioreactor control loops, ATF backflush, MCC column switching, SPTFF TMP control)
- **Performance Qualification (PQ):** Demonstrate integrated performance over ≥1 full-duration engineering batch (21–30 days) meeting all acceptance criteria (titer, yield, CQA, data integrity)

Common SAT pitfalls:

- Under-scoped PQ (only 7-day test for 30-day commercial campaigns)
- Inadequate utility testing (WFI runs out on Day 12 of 30-day test)
- Operators not involved until qualification complete (discover workflow issues during first GMP campaign)

7.11 Future Directions: Autonomous and AI-Enabled PI

As digital maturity increases, leading PI facilities are exploring **next-generation capabilities**:

Self-Tuning Controllers:

- AI/ML-based control algorithms that **automatically adjust PID parameters** to maintain optimal performance across molecules and campaigns
- Example: Reinforcement learning agents that optimize perfusion rate, feed timing, and cell bleed to maximize cumulative titer while maintaining CQA targets

Edge Computing:

- **Local MVDA and anomaly detection** running directly on skid PLCs or edge servers (not centralized historian)
- Enables sub-second response times for critical control loops and reduces dependence on network connectivity

Federated Digital Twins:

- **Combined upstream + downstream models** used for:
  - Scenario planning ("What if we increase VCD target from 80M to 100M cells/mL?")
  - Operator training (simulate deviations and recovery in safe environment)
  - Control refinement (optimize setpoints across full process, not just individual units)

Predictive Maintenance:

- ML models analyzing equipment vibration, pressure trends, flow rates to **predict failures before they occur**
- Example: ATF membrane fouling prediction 12 hours in advance, triggering proactive backflush

Organizations that invest now in clean data, interoperable automation, and robust PAT will be best positioned to adopt these capabilities as they mature from R&D pilots to commercial deployment.

7.12.2 CDMO Digital Maturity Audit Questions

When evaluating a CDMO's PI/CM capabilities, probe digital readiness with these questions:

Automation Architecture:

1. What DCS/MES platforms do you use, and do they natively support time/volume-based batching for continuous processes?
2. What communication standard do you require from equipment vendors (OPC UA, other)?
3. Can you show me a DCS configuration for a 30-day perfusion campaign with material traceability?

PAT Integration:

4. Which PAT tools are operational in your PI lines (Raman, capacitance, inline UV)?
5. Do you use PAT for monitoring only, or do you have closed-loop control validated?
6. How do you manage PAT model lifecycle (recalibration frequency, retraining triggers)?

Data Management:

7. What is your data historian platform, and what is your tag count per PI line?
8. How do you contextualize data (ISA-88/95 models, manual tagging, or ad-hoc)?
9. Can you generate automated CPV reports from historian data, or is CPV manual?

Compliance & Cybersecurity:

10. Can you provide a 21 CFR Part 11 validation summary for your PI data systems?
11. What is your cybersecurity posture (network segmentation, intrusion detection, DR drills)?
12. Have you had a data integrity CAPA in the past 2 years related to PI operations?

Organizational:

13. How many process automation engineers and data scientists support your PI platform?
14. What is your operator training program for PI (duration, competency assessment)?
15. Can you share a recent FAT report showing OPC UA integration testing?

Red Flags:

- CDMO cannot answer basic architecture questions (DCS vendor, communication standards)
- No closed-loop PAT control operational in commercial campaigns
- Manual data transcription between systems
- No dedicated automation or data science staff
- Cybersecurity policies outdated or not validated
- Training program <40 hours for operators transitioning to PI/CM

Green Flags:

- Clear four-layer architecture with OPC UA enforced across all vendors
- Multiple PAT tools in closed-loop control with validated model lifecycle procedures
- Unified data platform with contextualization and automated CPV operational
- 21 CFR Part 11 validation current with zero data integrity CAPAs
- Dedicated digital MSAT team (≥2 FTE per site)
- Comprehensive operator training with documented competency assessments
- Recent FAT reports demonstrating integration testing and extended campaign simulation

The next chapter examines how PI aligns with sustainability imperatives and policy tailwinds, providing additional strategic justification for the digital and automation investments described here.

Chapter 7 References: (9)

Arnold L, et al. Digital infrastructure requirements for continuous bioprocessing. *Biotechnol Prog*. 2021;37(2):e3098.

BioPhorum. Continuous manufacturing in biologics: Automation and data. White paper. December 2023.

Rathore AS, et al. Roadmap for implementation of quality by design (QbD) for biotechnology products. *Trends Biotechnol*. 2009;27(9):546-553.

O'Brien L, et al. Automation of high CHO cell density seed intensification via online Raman spectroscopy. *Biotechnol Prog*. 2021;37(5):e3172.

Kornecki M, et al. PAT as key-enabling technology for QbD in pharmaceutical manufacturing. *Pharm Eng*. 2020;40(4):24-32.

Narayanan H, et al. Hybrid models for intensified downstream bioprocessing. *Biotechnol Bioeng*. 2021;118(9):3452-3465.

ISA-88. Batch Control Part 1: Models and Terminology. International Society of Automation. 2010.

ISA-95. Enterprise-Control System Integration. International Society of Automation. 2018.

Waldron C, et al. Control systems for continuous biopharmaceutical manufacturing. *Curr Opin Chem Eng*. 2020;27:87-94.

EIGHT: Yes, a lot to do on Monday !!

8.1 From Understanding to Action

By this point in the book, you have seen why Process Intensification and Continuous manufacturing (PI/CM) matter strategically, what archetypes exist and where they fit, how they change economics and capacity , how to implement them in phases, how to organize cross-functional teams, what facility designs enable them, what peers have achieved, and how digital infrastructure supports them.

The remaining question is: After reading this e-book and placing it on the bookshelf on Sunday to collect dust....**What do you actually do on Monday morning?**

This chapter provides actionable decision frameworks, governance templates, and question sets you can use immediately to:

1. **Assess your current position** relative to PI readiness and competitive pressure
2. **Choose your entry point** from realistic PI archetypes based on your specific constraints
3. **Structure internal discussions** with cross-functional teams and executive leadership
4. **Evaluate CDMO partners** using targeted questions that reveal true PI maturity
5. **Build momentum** through quick wins and phased governance milestones

Unlike earlier chapters that explained concepts, this chapter is organized as **executable checklists and decision aids** designed to be lifted into steering committee decks, board updates, and internal playbooks.

8.2 Self-Assessment: Where Are You Today?

8.2.1 The PI/CM Readiness Matrix

Before committing resources, leadership teams should honestly assess current organizational readiness across **four dimensions**: strategic urgency, technical capability, digital maturity, and organizational alignment.

Dimension 1: Strategic Urgency (Why PI matters for your portfolio)

Signal	Low Urgency	Medium Urgency	High Urgency
LOE/biosimilar pressure	Products protected >5 years	2–5 years to LOE on key assets	<2 years to LOE; biosimilar competition active
Capacity constraint	<60% utilization; ample headroom	70–85% utilization; debottlenecking considered	>85% utilization; rejecting opportunities or planning greenfield
CoG competitiveness	CoG at market benchmark (80–150 $/g mAb)	CoG 10–20% above biosimilar targets	CoG structurally uncompetitive (>150 $/g); cannot serve emerging markets
Portfolio fragmentation	1–3 major products; stable demand	5–10 products; multi-indication portfolios	>10 products; orphan drugs, regional variants, frequent changeovers
Modality complexity	Standard IgG mAbs	Bispecifics, fusion proteins, unstable formats	Viral vectors, cell therapies, next-gen modalities with short half-lives

Dimension-1 Score:

- **Low urgency (0–1 high signals):** PI/CM is optional watch-and-learn mode defensible
- **Medium urgency (2–3 high signals):** PI/CM should be on strategic roadmap; Phase 0 scoping justified
- **High urgency (4–5 high signals):** PI/CM is strategically essential; delay increases late-mover risk

NOTES:

DATE:

Dimension 2: Technical Capability
(Do you have process development and MSAT capacity?)

Capability	Absent	Developing	Mature
Perfusion expertise	No perfusion experience	N-1 perfusion pilots completed; limited production perfusion	Multiple perfusion campaigns at commercial scale
DSP intensification	Conventional batch chromatography only	MCC or membrane capture pilots	MCC + continuous VI + SPTFF operational
PAT integration	Offline analytics only	Raman/capacitance deployed; data logged but not used for control	Real-time feedback control; MVDA models deployed
Scale-down models	Fed-batch only	Ambr or benchtop perfusion models	Robust mini-bioreactor perfusion + scaled-down DSP integrated
Regulatory experience	No continuous or intensified filings	One ICH Q13-aligned submission (approved or in review)	Multiple PI processes approved; established agency relationships

Dimension-2 Score:

- **Absent (0–1 mature):** High technical risk; consider CDMO partnership or substantial PD investment before PI commitment
- **Developing (2–3 mature):** Moderate risk; Phase 1 lab models feasible with 3–5 PD/MSAT FTE and vendor support
- **Mature (4–5 mature):** Low technical risk; ready for Phase 2 pilot integration

NOTES: DATE:

Dimension 3: Digital Maturity
(Can you support PAT, automation, and data integration?)

Capability	Absent	Developing	Mature
Automation infrastructure	Manual batch records; minimal DCS	DCS/SCADA for unit ops; limited MES integration	Integrated DCS-MES-historian; OPC UA connectivity
Data historians	No structured timeseries storage	Historian deployed; data stored but not contextualized	Contextualized data; automated reports and dashboards
PAT portfolio	pH, DO, temperature only	Raman, capacitance available; used for monitoring	PAT feeding real-time control loops; soft sensors deployed
Analytics capability	Spreadsheet-based manual analysis	MVDA tools available; ad-hoc modeling	Dedicated data science team; lifecycle model management
Interoperability standards	Vendor-locked proprietary protocols	Moving toward OPC UA; some multivendor integration	OPC UA standard; all skids interoperable

Dimension-3 Score:

- **Absent (0–1 mature):** Critical blocker; PI will fail without digital investment. Begin Phase 0 with digital strategy parallel to process scoping
- **Developing (2–3 mature):** Moderate risk; can proceed but must front-load digital specifications in Phase 1 equipment selection
- **Mature (4–5 mature):** Ready for advanced PI with real-time control and autonomous features

NOTES:

DATE:

Dimension 4: Organizational Alignment (Do you have governance and resources?)

Element	Absent	Developing	Mature
Executive sponsorship	PI awareness but no explicit commitment	VP-level champion identified; budget discussions underway	COO/Head of Tech Ops actively sponsors; Board-level support
Cross-functional governance	Siloed functions; no PI steering committee	Ad-hoc PI working group; irregular meetings	Formal PI steering committee with all 7 functions; monthly governance
MSAT resourcing	MSAT <1 FTE available for PI	2–3 FTE allocated; hiring in progress	3–5 FTE dedicated PI team with pilot experience
Finance alignment	No PI business case developed	Preliminary business case; NPV positive but not approved	Approved multi-year PI CapEx and OpEx budget
Cultural readiness	Risk-averse; batch-centric mindset dominates	Growing awareness; pockets of PI advocacy	Change agents across functions; flow-thinking embedded

Dimension-4 Score:

- **Absent (0–1 mature):** Organizational blockers will derail technical progress. Focus Phase 0 on governance and business case before lab work
- **Developing (2–3 mature):** Moderate risk; can proceed with Phase 0 scoping and explicit governance structure
- **Mature (4–5 mature):** Organizational readiness high; can execute phased roadmap with confidence

NOTES: DATE:

8.2.2 Interpreting Your Self-Assessment

Strategic Urgency	Technical + Digital + Organizational Readiness	Recommended Action
High	Mature (9–15 mature scores across Dimensions 2–4)	**Aggressive PI roadmap**: Phase 0 immediately → Phase 1 in parallel → target Phase 2 pilot within 18 months. High probability of success.
High	Developing (5–8 mature)	**Accelerated capability build**: Invest in PD/MSAT hiring, digital infrastructure, and governance WHILE scoping PI. Consider hybrid approach: CDMO partnership for first PI asset while building internal capability.
High	Absent (0–4 mature)	**CDMO partnership essential**: Strategic urgency demands PI, but internal capability gaps are critical. Partner with mature PI CDMO for first 1–2 assets; learn by observing; build internal capability in parallel.
Medium	Mature	**Opportunistic PI adoption**: Begin Phase 0 for highest-value assets. Leverage existing capability to derisk. Position as competitive differentiator.
Medium	Developing	**Phased capability build**: Phase 0 scoping for 1–2 target molecules. Invest selectively in capability gaps (e.g., perfusion expertise, digital architecture). Timeline: 2–3 years to commercial PI.

Medium	Absent	**Watch and learn**: PI is not urgent; capability gaps are significant. Focus on monitoring industry progress, attending conferences, building awareness. Reassess annually.
Low	Any readiness	**PI optional**: Current strategy defensible. Maintain awareness; revisit when strategic pressure increases or new modalities enter portfolio.

Example application:

A biosimilar manufacturer scores:

- **Strategic urgency:** HIGH (biosimilar competition, CoG pressure, regional markets)
- **Technical capability:** DEVELOPING (N-1 perfusion pilots, MCC experience, no production perfusion)
- **Digital maturity:** DEVELOPING (DCS present, limited MES, no historians)
- **Organizational alignment:** MATURE (executive sponsor, budget approved, governance in place)

Total readiness: 6 mature scores (2 technical + 2 digital + 2 organizational) = DEVELOPING

Recommended action: Accelerated capability build. Invest in 2 FTE PD/MSAT with perfusion expertise, deploy historian and OPC UA standards in Phase 0–1, and proceed with ambitious PI roadmap targeting hybrid PI (N-1 perfusion + MCC) within 24 months. Consider engaging PI-experienced CDMO as tech transfer partner to accelerate learning.

8.3 Choosing Your Entry Point: The PI Decision Tree

8.3.1 Match Archetype to Constraint

Not every organization should aim for end-to-end continuous manufacturing as a first move. The optimal PI entry point depends on your **dominant constraint**:

Decision Tree:

START: What is your #1 constraint?
↓
├─ CAPACITY (existing facility >80% utilized, rejecting demand)
│ ├─ Have stainless bioreactors? → N-1 PERFUSION RETROFIT
│ │ - Fastest capacity unlock (18 months)
│ │ - Lowest CapEx ($20–50M)
│ │ - 50–80% throughput increase
│ │ - Low regulatory risk (no production process change)
│ │
│ └─ Single-use or greenfield? → HYBRID PI (PERFUSION + INTENSIFIED DSP)
│ - 3–6× productivity gain
│ - 40–60% smaller footprint
│ - 24–36 months to commercial
│ - Moderate CapEx ($80–150M for new facility)
│
├─ COST OF GOODS (CoG >100 $/g mAb; biosimilar pressure)
│ ├─ High-volume single product (>1,000 kg/year)? → END-TO-END PI
│ │ - 50–70% CoG reduction
│ │ - Platform investment justified by volume
│ │ - 36–48 months to commercial
│ │ - High CapEx but lowest CoG/kg
│ │
│ └─ Multi-product portfolio? → HYBRID PI PLATFORM
│ - 30–50% CoG reduction
│ - Multi-product flexibility retained
│ - 24–36 months
│ - Balanced CapEx and CoG
│
├─ MODALITY COMPLEXITY (unstable proteins, viral vectors, bispecifics)
│ └─ Quality/yield driver? → MODALITY-SPECIFIC PI
│ - Perfusion for short residence time
│ - Membrane-based DSP (gentle, fast)
│ - Continuous VI (minimize hold)
│ - CoG benefit follows yield improvement
│ - 18–30 months
│
├─ SPEED TO MARKET (late-stage pipeline; need rapid capacity)
│ └─ Need facility <18 months? → MODULAR POD + HYBRID PI

│ - Pre-fabricated POD cleanrooms
│ - Single-use perfusion or high-density fed-batch
│ - MCC + BIC + SPTFF
│ - 12–18 months facility deployment
│ - Premium CapEx but fastest timeline
│
└─ MULTI-CONSTRAINT (capacity + CoG + flexibility)
└─ Best balanced approach? → PHASED HYBRID PI
- Phase 1: N-1 perfusion (capacity unlock)
- Phase 2: Add MCC + continuous VI (CoG reduction)
- Phase 3: Perfusion for select products (full PI)
- 24–48 months phased deployment
- Derisk by proving value at each phase

Selection criteria:

1. **Capacity first:** If capacity is the acute constraint, choose **N-1 perfusion retrofit** or **intensified fed-batch** for fastest relief
2. **CoG second:** If CoG competitiveness is the driver, choose **hybrid PI** or **end-to-end** depending on product volumes and portfolio diversity
3. **Modality third:** If product stability or yield is limiting, choose **modality-specific PI** to unlock quality first, cost second
4. **Risk tolerance fourth:** If organization is risk-averse, start with **N-1 perfusion** or **intensified fed-batch**; if change-ready, consider **hybrid PI**
5. **Timeline fifth:** If speed is essential (pipeline launch, competitive threat), prioritize **modular POD + hybrid PI** or **N-1 perfusion** for fastest deployment

8.4 Internal Decision Framework: The Monday Morning Conversation

8.4.1 Governance Kickoff: The 90-Minute PI Scoping Session

Purpose: Align leadership on whether to proceed with Phase 0 PI scoping and establish governance structure.

Attendees: COO or Head of Tech Ops (chair), VP-level leaders from PD, MSAT, QA/QC, Regulatory, Engineering, Digital/Automation, Finance/Strategy.

Agenda (90 minutes):

1. Strategic context (15 min) – Finance/Strategy lead

- Review LOE cliffs, capacity utilization, CoG benchmarks
- Present competitive landscape: which peers have deployed PI?
- Articulate "do nothing" baseline scenario and financial trajectory

2. Self-assessment results (20 min) – All functions contribute

- Present PI Readiness Matrix scores (Section 9.2)
- Discuss capability gaps and resource constraints
- Identify highest-risk dimensions (technical, digital, organizational)

3. Entry point recommendation (20 min) – PD/MSAT lead

- Propose 2–3 candidate PI archetypes using Decision Tree (Section 9.3)
- Map to 1–3 target molecules/indications
- Present preliminary business case ranges (NPV, IRR, CoG impact)

4. Governance structure proposal (15 min) – COO

- Propose PI Steering Committee composition and cadence
- Identify PI Champion candidate (typically MSAT or Engineering VP-level)
- Outline Phase 0 scope, budget, and timeline (0–6 months)

5. Phase 0 go/no-go decision (15 min) – All

- Go: Approve Phase 0 budget ($200K–500K for consulting, vendor assessments, preliminary business case)
- No-go: Defer pending [specific trigger: capacity crunch, LOE date, new modality]
- Parking lot: Table concerns and assign owners to resolve by [date]

6. Next steps and commitments (5 min)

- Phase 0 kickoff meeting scheduled (within 2 weeks)
- PI Champion named
- Monthly PI Steering Committee meetings calendared

Outputs:

- [ ] Phase 0 approved with budget and timeline
- [ ] PI Steering Committee roster finalized
- [ ] PI Champion named and empowered
- [ ] Monthly governance cadence established
- [ ] Communication plan: how/when will broader organization learn about PI initiative?

8.4.2 Phase 0 Deliverables: The 6-Month Scoping Package

By end of Phase 0, leadership should have:

1. Business case with scenarios (Finance + PD + MSAT):

- Baseline: Do nothing (conventional fed-batch trajectory)
- Scenario A: N-1 perfusion retrofit
- Scenario B: Hybrid PI (greenfield or retrofit)
- Scenario C: End-to-end PI (if high-volume asset justifies)
- Each scenario modeled for: NPV, IRR, CoG ($/g), capacity (kg/year), CapEx, timeline, risk score

2. Target molecule selection (PD + MSAT + Commercial):

- Prioritized list of 3–5 molecules ranked by:
  - Strategic value (revenue, pipeline position)
  - Technical feasibility (expression, stability, analytics)
  - Capacity urgency (demand forecast, current utilization)
  - Regulatory pathway (new vs. supplement, comparability strategy)

3. CDMO landscape assessment (Sourcing + MSAT):

- Screened 5–10 CDMOs for PI capability
- Shortlist of 2–3 CDMOs with deep PI experience
- Preliminary capacity/pricing quotes
- Red/green flag summary for each CDMO

4. Capability gap analysis (All functions):

- Technical: PD/MSAT perfusion expertise, DSP intensification experience
- Digital: Automation architecture, historian, PAT integration
- Regulatory: ICH Q13 familiarity, agency relationship strength
- Organizational: Resource availability, training needs

5. Phase 1 plan and budget (PD + MSAT + Engineering + Digital):

- Phase 1 scope: scale-down model development, PAT integration, preliminary control strategy
- Resource plan: FTE by function, vendor support, equipment needs
- Budget: $2M–5M typical (lab equipment, consumables, vendor fees, FTE costs)
- Timeline: 6–18 months
- Phase 1 go/no-go criteria defined

Phase 0 review gate:

- Steering Committee reviews full package
- Go/no-go decision to proceed to Phase 1
- If go: approve Phase 1 budget and resource plan
- If no-go: document reasons and conditions for revisit

8.5 CDMO Evaluation Framework

8.5.1 The 20 Questions That Reveal True PI Maturity

When evaluating CDMO partners for PI capability, most organizations rely on marketing decks and facility tours. These questions cut through positioning to reveal operational reality.

Process Capability (Questions 1–5):

1. **Which PI archetypes do you operate commercially today—not at pilot scale?**
    - Green flag: N-1 perfusion, production perfusion, MCC capture, continuous VI, SPTFF operational across ≥3 commercial products
    - Red flag: "We can do anything" without specific examples or only pilot-scale demonstrations
2. **For perfusion: What is your longest commercial perfusion campaign duration, and for which molecule?**
    - Green flag: 30–60 days sustained; multiple campaigns completed; documented learnings
    - Red flag: <14 days; only pilot data; reluctance to share specifics
3. **How do you handle cell retention device failures mid-campaign?**
    - Green flag: Dual ATF systems with automated switching; documented procedures; <5% campaign failure rate
    - Red flag: Single ATF per reactor; "hasn't happened"; no FMEA or mitigation plan
4. **What is your approach to concentrated media: on-site dilution or ready-to-use?**
    - Green flag: 10–20× concentrates with validated inline dilution; media vendor partnerships for scale
    - Red flag: Only ready-to-use; "we haven't needed concentrates"; undersized media storage
5. **For DSP: Do you operate multicolumn chromatography (MCC) and buffer inline conditioning (BIC) as standard platform elements?**
    - Green flag: MCC + BIC deployed across multiple products; URS templates available; >10 commercial campaigns
    - Red flag: Single-column batch only; BIC "under consideration"; no commercial MCC experience

NOTES: DATE:

Facility Design (Questions 6–10):

1. **Describe your upstream suite layout for perfusion. How many parallel perfusion lines can you run?**
    - Green flag: ≥2 parallel lines with independent media/waste systems; clear floor plan provided
    - Red flag: Single line; shared utilities; layout not optimized for perfusion flow rates
2. **What percentage of your cleanroom space is designated as flex space for future process evolution?**
    - Green flag: 20–30% flex space pre-plumbed and powered; explicit expansion plan
    - Red flag: 0% flex; "we'll cross that bridge when we get there"
3. **How are your utilities sized for perfusion: media delivery, waste handling, gas supply?**
    - Green flag: 5–10× conventional flow rates; dedicated high-flow WFI and waste systems; documented capacity
    - Red flag: Conventional utility sizing; "we'll upgrade if needed"
4. **Do you use modular POD cleanrooms or hard-wall construction?**
    - Green flag: PODs with documented deployment timeline <12 months; replicable across sites
    - Red flag: Traditional construction only; 3–5 year facility builds
5. **Show me your DSP flow path from perfusion harvest to drug substance pool. How many hold tanks?**
    - Green flag: ≤2 hold tanks (post-capture surge, pre-formulation); direct flow architecture; short residence time
    - Red flag: >4 hold tanks; meandering flow; long product residence times (>24 hours)

NOTES: DATE:

Digital & Automation (Questions 11–15):

1. What DCS/MES/historian stack do you use, and how do systems communicate?
    - Green flag: Named vendors (e.g., DeltaV, Syncade, OSIsoft PI) with OPC UA connectivity; integrated architecture diagram provided
    - Red flag: "Proprietary system"; vendor-locked; no interoperability standards
2. How do you define and track batches for continuous or perfusion campaigns?
    - Green flag: Time-volume hybrid batch definitions; MES configured for continuous flows; genealogy maintained
    - Red flag: "We treat it like a long batch"; manual records; unclear traceability
3. What PAT sensors are integrated into your process control strategy?
    - Green flag: Raman, capacitance, inline UV; real-time feedback to DCS; soft sensors deployed
    - Red flag: pH/DO/temperature only; PAT data logged but not used for control
4. Can you provide an example dashboard from a recent perfusion campaign?
    - Green flag: Live dashboard with VCD, metabolites, feed rate, CQA trends; automated alerts; historical comparison
    - Red flag: "We can build that"; no examples; manual data export to Excel
5. How do you manage model lifecycle for PAT-based control (Raman, MVDA)?
    - Green flag: Documented procedures for model training, validation, update; version control; periodic re-calibration
    - Red flag: "Models are static"; no lifecycle plan; unclear who owns model updates

NOTES: DATE:

Regulatory & Quality (Questions 16–18):

1. **How many ICH Q13-aligned submissions have you filed, and how many are approved?**
    - Green flag: ≥2 submissions filed; ≥1 approved; clear regulatory strategy documentation
    - Red flag: "We're preparing our first"; no approved precedents; unfamiliar with ICH Q13 Annex III
2. **Describe your sampling and release strategy for a 30-day perfusion campaign.**
    - Green flag: Stratified time-based sampling; pooled batch concept; pre-defined CQA control limits; RTRT roadmap
    - Red flag: "We sample every day"; unclear pooling strategy; no documented batch definition
3. **What is your QA review process for high-frequency PAT data (e.g., Raman every 15 minutes for 30 days)?**
    - Green flag: Automated data review with exception-based human oversight; trending dashboards; pre-defined alert thresholds
    - Red flag: "QA reviews all data manually"; overwhelming data volume; no automation

NOTES:

DATE:

Commercial Experience (Questions 19–20):

1. **For your most mature PI product: What is the realized CoG compared to your original business case projection?**
    - Green flag: Realized CoG within 10% of projection; transparent sharing of learnings and adjustments
    - Red flag: Reluctance to share; "still ramping"; large variance (>30%) unexplained
2. **What continuous improvement or troubleshooting has been required post-launch?**
    - Green flag: Specific examples (e.g., ATF backflush optimization, MCC cycle tuning, media lot variability mitigation); documented improvements
    - Red flag: "Everything went perfectly"; no examples; defensiveness

NOTES: DATE:

8.5.2 CDMO Red Flags and Green Flags Summary

Critical red flags (disqualify or proceed with caution):

❌ No commercial PI experience (only pilot-scale demonstrations)
❌ Vague/evasive answers about batch definition, sampling, data mgmt
❌ Undersized utilities or no flex space for process evolution
❌ No OPC UA or interoperability standards
❌ Zero ICH Q13 submissions filed
❌ Reluctance to share performance data or lessons learned
❌ Single points of failure (e.g., one ATF per reactor, no redundancy)
❌ Manual data handling for PAT-intensive processes

Strong green flags (high confidence partner):

✅ ≥3 commercial PI products across multiple archetypes
✅ 30+ day perfusion campaigns with documented success rates
✅ Dual ATF systems, MCC + BIC operational, integrated PAT
✅ OPC UA-compliant automation with MES-DCS-historian integration
✅ ICH Q13 submissions approved; transparent regulatory strategy
✅ Flex space designed into facility (20–30%)
✅ Utilities sized for perfusion (5–10× conventional flow)
✅ Willing to share detailed dashboards, SOPs, and performance data
✅ Documented continuous improvement examples post-launch

8.6 Building Momentum: The 12-Month PI Roadmap

8.6.1 Months 1–3: Phase 0 Foundation

Week 1–2:

- [ ] Convene 90-minute PI Scoping Session (Section 9.4.1)
- [ ] Name PI Champion and establish Steering Committee
- [ ] Approve Phase 0 budget ($200K–500K)

Month 1:

- [ ] Complete PI Readiness Self-Assessment (Section 9.2)
- [ ] Finance builds preliminary business case scenarios
- [ ] PD/MSAT identifies 3–5 candidate molecules
- [ ] Sourcing screens 5–10 CDMOs for PI capability

Month 2:

- [ ] Vendor assessments: site visits to 2–3 shortlisted CDMOs
- [ ] Apply 20 Questions framework (Section 9.5)
- [ ] PD develops preliminary scale-down model concepts
- [ ] Digital/Automation assesses current infrastructure gaps

Month 3:

- [ ] Phase 0 Deliverables Package assembled (Section 9.4.2)
- [ ] Steering Committee reviews and approves/rejects Phase 1
- [ ] If approved: initiate Phase 1 hiring (2–3 FTE PD/MSAT)
- [ ] If rejected: document reasons and set revisit triggers

8.6.2 Months 4–9: Phase 1 Lab Development

Month 4–5:

- [ ] Lab equipment procurement (Ambr, benchtop STR, ATF/TFF systems)
- [ ] Baseline characterization of target molecule (titer, yield, CQAs)
- [ ] Initiate N-1 perfusion scale-down model development
- [ ] Digital: deploy pilot historian and PAT integration testbed

Month 6–7:

- [ ] Execute N-1 perfusion DoE at lab scale
- [ ] Develop DSP intensification options (MCC vs. membrane screening)
- [ ] QA drafts sampling and batch definition strategy
- [ ] Regulatory: prepare ICH Q13 alignment memo and agency engagement plan

Month 8–9:

- [ ] Integrated lab-scale demonstration (perfusion seed → intensified DSP)
- [ ] Refine CPP-CQA relationships; preliminary control strategy
- [ ] Phase 1 review: Steering Committee evaluates data
- [ ] Phase 2 go/no-go decision and pilot site selection

8.6.3 Months 10–12: Phase 2 Planning and Pilot Prep

Month 10:

- [ ] Select pilot scale (50–500 L) and location (internal vs. CDMO)
- [ ] Equipment URS development (bioreactor, ATF, MCC, PAT, automation)
- [ ] MSAT hired to full pilot team strength (3–5 FTE)
- [ ] Engineering: facility fit assessment and utility sizing

Month 11:

- [ ] Equipment procurement initiated (6–12 month lead times)
- [ ] Digital: DCS/MES configuration for pilot scale
- [ ] QA: pilot batch record templates and deviation procedures
- [ ] Regulatory: Type C meeting request filed with FDA/EMA

Month 12:

- [ ] Pilot protocol finalized (robustness testing, FMEA scenarios)
- [ ] Governance: Year 1 retrospective and Year 2 planning
- [ ] Communication: Internal update to broader organization
- [ ] Budget: Phase 2 capital approved ($5M–15M typical)

Success metrics for Year 1:

- Phase 0 completed on time and budget
- Phase 1 lab models demonstrate ≥2× productivity improvement vs. baseline
- Phase 2 pilot plan approved with clear go/no-go criteria
- Cross-functional team aligned and resourced
- No organizational surprises or governance failures

8.7 Board and Executive Communication

8.7.1 The PI/CM One-Pager for Board Updates

Template structure:

Strategic Context (2–3 sentences):
"Our portfolio faces LOE cliffs for Products X and Y within 3 years, with biosimilar competition intensifying. Current CoG of $120/g is structurally uncompetitive for post-LOE markets requiring $40–60/g. Process intensification offers a pathway to 40–60% CoG reduction and 3–6× capacity increase within 30 months."

Business Case Summary (table):

Scenario	CoG ($/g)	Capacity (kg/yr)	CapEx ($M)	NPV ($M)	Timeline (months)
Baseline (do nothing)	120	500	0	Baseline	N/A
N-1 perfusion retrofit	95	800	35	+85	18
Hybrid PI greenfield	55	1,200	120	+240	30

Key Risks and Mitigations (bullets):

- **Technical risk:** Limited perfusion experience → Mitigation: Hire 2 FTE with perfusion background; partner with PI-experienced CDMO for first asset
- **Regulatory risk:** No ICH Q13 submissions → Mitigation: Early agency engagement (Type C meeting Q3 2026); leverage CDMO's approved precedents
- **Digital risk:** Immature automation → Mitigation: Deploy OPC UA standards in Phase 0; allocate $2M for historian and MES upgrade

Decision Request:
"Approve $4.5M Phase 1 budget to develop lab-scale PI models for Product X and initiate pilot planning, targeting commercial deployment by Q2 2028."

Next Update:
"Board review at Month 9 (Phase 1 results) with Phase 2 go/no-go recommendation."

8.7.2 Quarterly Steering Committee Agenda Template

PI Steering Committee – Quarterly Review

Attendees: COO (chair), VPs of PD, MSAT, QA/QC, Regulatory, Engineering, Digital, Finance
Duration: 90 minutes
Frequency: Quarterly

Standing Agenda: See Below

1. **Phase status and milestones (20 min) – PI Champion**
    - Current phase progress vs. plan (Gantt chart)
    - Completed milestones since last meeting
    - Upcoming milestones and critical path items
2. **Cross-functional updates (30 min) – All functions (5 min each)**
    - PD: Scale-down model status, CQA strategy
    - MSAT: Pilot preparation, resource status
    - QA/QC: Sampling strategy, batch definition progress
    - Regulatory: Agency interactions, submission planning
    - Engineering: Facility design, utility sizing, CapEx tracking
    - Digital: Automation architecture, PAT integration, data platform
    - Finance: Business case updates, realized vs. projected metrics
3. **Risk review and mitigation (15 min) – PI Champion**
    - Top 5 risks from risk register
    - New risks identified since last meeting
    - Mitigation actions and owners

4. **Phase gate decision (if applicable) (15 min) – COO**
    - Review gate criteria and evidence
    - Go/no-go/conditional decision
    - If go: approve next phase budget and resources
5. **Strategic alignment (10 min) – Finance + COO**
    - Portfolio changes affecting PI priorities
    - Competitive intelligence updates
    - Organizational capacity and resource constraints
6. **Action items and next steps (5 min) – PI Champion**
    - Review action items from previous meeting
    - Assign new action items with owners and dates
    - Set date for next quarterly review

8.8 Common Pitfalls and How to Avoid Them

1. **Failure: "PI as science project" – No business case or executive sponsor**
    - Symptom: PD develops impressive lab models, but no path to pilot or commercial; fades when key scientist leaves
    - Prevention: Require approved business case and named executive sponsor before Phase 1 begins
2. **Failure: Digital as afterthought – Automation deferred to Phase 3**
    - Symptom: Equipment procured without OPC UA; manual data handling; PI benefits unrealized
    - Prevention: Digital/Automation full participant from Phase 0; interoperability standards in all URS
3. **Failure: QA engaged too late – Batch definition improvised at pilot**
    - Symptom: Pilot data unusable for regulatory submission; rework required; 6–12 month delay
    - Prevention: QA drafts sampling and batch strategy in Phase 1, reviewed by Regulatory
4. **Failure: Under-resourced MSAT – Expecting miracles with <2 FTE**
    - Symptom: Pilot campaigns poorly executed; tech transfer incomplete; commercial launch struggles
    - Prevention: Budget 3–5 FTE MSAT for Phase 2–3; hire experienced perfusion/PI engineers
5. **Failure: Siloed workstreams – Upstream, DSP, automation working independently**
    - Symptom: Integration failures at pilot scale; equipment incompatibilities discovered late
    - Prevention: Weekly cross-functional stand-ups from Phase 1; single integrated project plan
6. **Failure: No PI Champion – Distributed accountability**
    - Symptom: Coordination failures, missed milestones, scope creep, blame-shifting
    - Prevention: Name PI Champion in Phase 0 with explicit authority and budget control
7. **Failure: Ignoring facility constraints – PI designed for greenfield but deploying in legacy plant**
    - Symptom: Utility shortfalls (media, waste, gas); layout doesn't support flow; expensive retrofits required
    - Prevention: Engineering assesses facility fit in Phase 0; realistic retrofit vs. greenfield decision

8. **Failure: Regulatory surprise – Assuming agencies will accept PI without engagement**
    - Symptom: Submission questions, inspection findings, delayed approval
    - Prevention: Early agency engagement (Type C meetings); transparent control strategy and comparability
9. **Failure: Vendor lock-in – Single-source proprietary systems**
    - Symptom: Unable to scale, switch products, or replicate across sites; high ongoing costs
    - Prevention: Specify open standards (OPC UA, ISA88, ISA95) in all URS; multi-vendor competition
10. **Failure: Scope creep – Attempting end-to-end continuous as first PI project**
    - Symptom: Overwhelming complexity; long timelines; budget overruns; failure to deliver
    - Prevention: Start with N-1 perfusion or hybrid PI; prove value; expand scope in Phase 2–3

8.8.2 Red Flag Early Warning Signs

If you observe these patterns in your PI program, intervene immediately:

PI discussed for >12 months with no Phase 1 lab work initiated
Business case shows >5× NPV but leadership "not ready to commit"
PD developing models in isolation; MSAT/QA not engaged
Digital team unaware of PI program or "will be involved later"
MSAT allocated <2 FTE for Phase 2 pilot execution
No PI Steering Committee meetings held in past 6 months
Equipment URS lack OPC UA or interoperability requirements
QA batch definition strategy still "TBD" at start of Phase 2
Regulatory strategy is "we'll figure it out at submission"
Engineering says "we'll make it fit" without facility assessment

Intervention playbook:

- Escalate to COO/Head of Tech Ops immediately
- Conduct rapid diagnostic using Section 9.2 readiness assessment
- Identify root cause (governance, resources, capability, leadership commitment)
- Mandate corrective action plan with 30-day milestones
- Consider external advisory support (consultant, industry expert) to reset program

8.9 Chapter Summary: Your Monday Action Plan

What you should do this week:

Day 1 (Monday):

- [ ] Read this chapter and mark 3–5 highest-priority actions for your organization
- [ ] Schedule quick 1:1 with COO/ Head of Tech Ops to discuss PI/CM readiness

Day 2–3 (Tuesday–Wednesday):

- [ ] Complete PI/CM Readiness Self-Assessment (Section 9.2) with input from functional leads
- [ ] Identify dominant constraint (capacity, CoG, modality) and recommended PI/CM archetype (Section 9.3)

Day 4 (Thursday):

- [ ] Draft 90-minute PI/CM Scoping Session agenda (Section 9.4.1)
- [ ] Invite functional VPs and secure date within 2 weeks

Day 5 (Friday):

- [ ] Prepare preliminary business case skeleton (baseline + 2 PI scenarios)
- [ ] Identify 2–3 candidate molecules for PI evaluation
- [ ] Prepare PI Champion candidate short-list (typically MSAT or Engineering VP)

What you should have by Month 3:

Phase 0 approved with $200K–500K budget
PI Steering Committee meeting monthly
PI Champion named and empowered
Self-assessment completed identifying capability gaps
Entry point selected (which PI archetype for which constraint)
3–5 candidate molecules prioritized
CDMO landscape screened (5–10 vendors assessed)
Phase 1 plan drafted with go/no-go criteria

What you should have by Month 12:

Phase 1 lab models demonstrating ≥2× productivity improvement
Integrated scale-down demonstration completed
QA sampling and batch definition strategy documented
Regulatory alignment memo and agency engagement plan
Phase 2 pilot site selected and equipment URS drafted
MSAT team hired and trained (3–5 FTE)
Digital architecture plan with OPC UA standards
Phase 2 budget approved ($5M–15M)

What makes PI Programs Succeed (TOP-10)

1. **Executive sponsorship** – COO/Head of Tech Ops actively champions; Board-level support
2. **Business case discipline** – NPV positive across realistic scenarios; approved budgets
3. **Cross-functional from Day 1** – All 7 functions engaged in Phase 0, not bolted on later
4. **Named PI Champion** – Single accountable leader with authority and resources
5. **Digital early** – Automation and PAT specified in equipment selection, not retrofitted
6. **QA upfront** – Sampling and batch strategy drafted in Phase 1, not improvised at pilot
7. **Phased de-risking** – Start with N-1 perfusion or hybrid PI; prove value; expand scope
8. **Realistic timelines** – 18–36 months for first commercial PI; avoid over-promising
9. **Con't improvement mindset** – Expect and embrace learnings; document and iterate
10. **Governance rigor** – Monthly cross-functional reviews; quarterly executive gates; disciplined decision-making

The strategic imperative:

Process intensification and Continuous Manufacturing have moved from experimental to proven. Organizations that implement PI strategically—with clear governance, phased roadmaps, cross-functional alignment, and integrated digital foundations—will gain structural competitive advantages in cost, capacity, flexibility, and sustainability that will compound over the next decade.

The challenge is not whether PI/CM works, but **how to execute it credibly in your context**.

What will you do on Monday?

Chapter 8 References (10)

Tsang V, et al. Biomanufacturing evolution from conventional to intensified processes. *Biotechnol Bioeng*. 2020;117(11):3359-3372.

BioPhorum Operations Group. Operational roadmap for PI adoption. White paper. 2024.

Markarian J. Cross-functional coordination in continuous manufacturing. *Pharm Technol*. 2018;42(10):20-25.

PMBOK Guide. *Project Management Body of Knowledge*. 7th ed. PMI. 2021.

Langer ES. Biopharmaceutical manufacturing scale and technologies. BioPlan Associates. 2024.

Croughan MS, et al. The future of industrial bioprocessing: Batch or continuous? *Biotechnol Bioeng*. 2015;112(4):648-651.

Farid SS. Economic drivers for continuous bioprocessing. *Curr Opin Chem Eng*. 2019;26:1-9.

Walther J, et al. The business case for continuous biomanufacturing. *BioProcess Int*. 2019;17(2):20-26.

Konstantinov KB, Cooney CL. White paper on continuous bioprocessing. *J Pharm Sci*. 2015;104(3):813-820.

Steinebach F, et al. Design and operation of a continuous integrated monoclonal antibody production process. *Biotechnol Prog*. 2017;33(5):1303-1313.



Chapter 9: The Evidence Base — Verified Success in PI/CM

9.1 From Theory to Verified Performance

Chapters 1 through 9 have laid out the strategic case for process intensification (PI)—why it matters now, what archetypes exist, how they change economics, how to implement them in phases, what organizational structures enable success, what facility and digital investments are required, how PI integrates into GMP operations, and how automation underpins continuous bioprocessing. All of this rests on a fundamental assumption: **that PI actually delivers the gains claimed**.

This chapter provides the proof. It consolidates **ten validated success stories** from commercial implementations, industry surveys, pilot-scale demonstrations, and independent third-party analyses published between 2022 and 2026. These stories translate abstract productivity claims into concrete operational data—actual cost-of-goods figures, verified footprint reductions, confirmed campaign durations, and adoption trends across innovators, CDMOs, and biosimilar manufacturers.

Why this matters for decision-makers:

Leadership teams evaluating PI proposals—whether internal programs or CDMO partnerships—need benchmarks to separate credible plans from vendor marketing. The evidence presented here serves three purposes:

1. **Validate your business case assumptions.** Compare your PI scenarios against the performance ranges documented in Stories 1–10 to ensure projections are realistic, not aspirational.
2. **Interrogate CDMO claims.** When a CDMO promises 5× productivity gains or $40/g cost-of-goods, these stories provide the data standards to probe whether their claims are credible and their platforms are proven.
3. **Build board-level confidence.** The stories consolidate peer-reviewed publications, conference presentations, independent analyses, and market surveys into slide-ready proof points that counter "wait and see" arguments.

Each story follows a consistent structure: **Headline → Evidence bullets → Citations**. Stories 1–7 document specific platforms and technical validations. Stories 8–10 capture industry momentum—conference agendas, market projections, and independent economic analyses that signal PI has moved from niche experimentation to mainstream practice.

The chapter closes with a **cross-story benchmark table** (Section 10.3) that summarizes productivity, CoG, footprint, and CapEx ranges by PI archetype, and a **practical guide** (Section 10.4) for using this evidence in internal business cases, CDMO evaluations, and executive updates.

A note on evidence quality: All ten stories are drawn from publicly accessible sources—peer-reviewed journals, industry white papers, conference proceedings, market surveys, and third-party analyses. Where possible, citations include direct URLs or DOI identifiers. Some data points (particularly vendor-specific performance claims) reflect self-reported information presented at industry forums; these are marked as such and should be validated through due diligence when evaluating specific partners.

9.2 The Ten Validated Success Stories

Story 1: EnzeneX Platform — Breaking the $40/gram Barrier

Headline: Fully integrated continuous mAb platform demonstrates biosimilar-competitive cost-of-goods in commercial facility.

Evidence:

- **EnzeneX platform** (Enzene Biosciences, India) achieves **5–10× higher productivity** vs. legacy fed-batch platforms through end-to-end continuous architecture: perfusion bioreactors (40–50 g/L cumulative titers), continuous capture-polishing (multicolumn chromatography and membrane-based DSP), and fully automated control systems[1][2].
- Public case presentations indicate credible pathway to **CoG ≤ $40/g for monoclonal antibodies**, positioning the platform as cost-competitive with biosimilar requirements in tender markets (typically $50–60/g target pricing)[1].
- Facility footprint reported at **~1,500 sq ft for 10–15 kg/month output**, representing **~10× productivity per m²** compared to conventional fed-batch layouts and validating claims of 40–60% smaller facilities for equivalent throughput[2][3].

Why this matters:

EnzeneX demonstrates that end-to-end PI is not a theoretical concept—it is operational at commercial scale in a GMP facility, delivering cost structures that enable aggressive biosimilar competition in price-sensitive markets. The platform validates Chapter 4's economic modeling and Chapter 7's facility design principles for POD-based, continuous manufacturing.

Citations:

[1] Enzene Biosciences. "Breaking the $40/gram Barrier." NIIMBL e-poster presentation. 2025.

[2] CPHI Online. "Breaking the 40 per gram barrier" video presentation. 2025. https://www.cphi.com

[3] BioProcess International. *Process Intensification: Driving Efficiencies in Bioprocessing* eBook. 2024.

Story 2: Repligen Perfusion ROI — From Fed-Batch to Perfusion

Headline: Switching to perfusion unlocks 5–10× volumetric capacity with positive ROI despite higher consumable costs.

Evidence:

- **2025 Repligen/XCell ATF white paper** models the economics of converting commercial mAb manufacturing from fed-batch to perfusion using N-1 perfusion seed intensification and production perfusion modes[4].
- Analysis finds **5–10× volumetric productivity increase** and substantial capacity unlocking in existing facilities without greenfield expansion, enabling CDMOs to add 4–5 additional campaign slots per year in the same manufacturing suite[4].
- Despite **20–30% higher media and cell-retention filter costs**, total CoG can **decrease by 20–25%** in modeled scenarios due to improved asset utilization, reduced bioreactor capital per kg output, and faster campaign turnaround[4].

Why this matters:

Perfusion is often perceived as expensive (higher media, filters, complexity). This techno-economic analysis—conducted by a leading vendor but grounded in client data—demonstrates that perfusion delivers **net positive ROI** in capacity-constrained brownfield settings. The findings support Chapter 4's capacity-unlock business case and Chapter 11's entry-point decision tree for N-1 perfusion retrofits.

Citations:

[4] Repligen/XCell ATF. "From Fed-Batch to Perfusion: Unlocking ROI and Capacity in Monoclonal Antibody Manufacturing." White paper. September 2025. https://www.repligen.com/resources

Story 3: Industry Adoption Survey — 40% Planning Continuous Upstream

Headline: Nearly 40% of biomanufacturers actively evaluating continuous upstream processing, with CDMOs leading adoption.

Evidence:

- **2025 BioPlan Associates survey** reports that **~40% of surveyed biomanufacturers** plan to evaluate continuous upstream processing (primarily perfusion) by 2025–2026, up from <20% in 2020[5].
- Adoption intent is **even higher among CDMOs (45–50%)**, where PI is viewed as a competitive differentiator for flexible, multi-client capacity offerings[5].
- Survey respondents cite **automation and data integration** as both the primary enabler and the primary bottleneck for adoption, reinforcing Chapter 9's emphasis on digital infrastructure as foundational to PI success[5].

Why this matters:

PI is no longer niche—it has moved into mainstream strategic planning across innovators, CDMOs, and biosimilar manufacturers. The 40% adoption intent signals a tipping point: organizations that delay PI risk being structurally disadvantaged relative to peers who move earlier. This data counters "wait and see" arguments by demonstrating that competitors are already committing.

Citations:

[5] BioPlan Associates/BioProcess Online. "Report: Nearly 40% of Biomanufacturers Eyeing Continuous Processing." 2025. https://www.bioprocessonline.com

Story 4: Hybrid vs. End-to-End — Do We Really Need Full Continuous?

Headline: Hybrid PI configurations capture most economic benefits of full end-to-end continuous with lower implementation risk.

Evidence:

- **2025 peer-reviewed perspective** in *Biotechnology and Bioengineering* argues that **hybrid PI architectures**—intensified upstream (N-1 perfusion or high-inoculation fed-batch) + continuous capture (MCC or membrane) + batch polishing—deliver **80–90% of the economic benefit** of fully end-to-end continuous systems[6].
- Analysis highlights that hybrid configurations are **easier to implement, validate, and operate** within existing brownfield facilities, require less organizational change (operators comfortable with batch polishing), and carry lower technical risk (fewer single points of failure)[6].
- Authors conclude that end-to-end continuous may be justified for specific use cases (e.g., ultra-unstable proteins, very high volume biosimilars), but **hybrid PI is the pragmatic default** for most commercial applications[6].

Why this matters:

The "all-or-nothing" perception—that PI means fully continuous or nothing—discourages adoption. This analysis validates the book's central premise (Chapter 3) that PI is a **modular toolbox**, not a binary choice. Organizations can start with N-1 perfusion or hybrid DSP, prove value, and expand scope incrementally. This de-risks adoption and accelerates time-to-benefit.

Citations:

[6] Steinebach, F., et al. "Do We Really Need End-to-End Continuous Bioprocessing?" *Biotechnology and Bioengineering*. 2025. DOI: 10.1002/bit.28xxx

Story 5: Single-Pass TFF — Shrinking Downstream Volume and Hardware

Headline: Single-pass tangential flow filtration (SPTFF) reduces hold-tank volumes by up to 25% and enables inline DSP intensification.

Evidence:

- Detailed **SPTFF operational studies** (2022–2025) demonstrate that single-pass TFF can **reduce hold-tank volumes by 20–25%** compared to traditional multi-pass batch UFDF operations, simplifying buffer logistics and reducing stainless-steel capital requirements[7][8].
- SPTFF enables **inline concentration and diafiltration** in intensified downstream trains, matching the continuous or semi-continuous flow from perfusion bioreactors or multicolumn chromatography without accumulating large intermediate pools[7][8].
- Technology supports modular DSP skids that are **30–40% more compact** than traditional batch DSP suites, reinforcing Chapter 7's facility design emphasis on flow-through polishing and buffer inline conditioning (BIC)[7][8].

Why this matters:

SPTFF addresses a common DSP bottleneck—hold times and buffer preparation—that often limits the benefit of upstream intensification. By enabling continuous flow through concentration/diafiltration steps, SPTFF is a **core enabling technology** for hybrid and end-to-end PI trains. This validates Chapter 3's DSP toolbox and supports the technical feasibility of integrated continuous manufacturing.

Citations:

[7] Orbit DTU. "Single-Pass Tangential Flow Filtration: Critical Operational Variables." Study report. 2022. https://backend.orbit.dtu.dk

[8] Orbit DTU. "SPTFF in Intensified Downstream Processing." 2025 update. https://orbit.dtu.dk

Story 6: Integrated Continuous Bioprocessing — 150× Scale-Up Proof

Headline: Pilot-scale integrated continuous train demonstrates 150× scale-up with maintained control strategy and product quality.

Evidence:

- **Pilot-scale ICB study** (published 2022, presented at 2024–2025 conferences) demonstrated stable, multi-week operation of an integrated PI train: perfusion bioreactor → periodic counter-current chromatography (PCC) → continuous viral inactivation → continuous polishing[9].
- Study achieved **150× scale-up from development (ambr/bench scale) to pilot (50–200 L)** while reusing the same downstream equipment configurations and maintaining control strategy continuity—no major redesign required[9].
- Product quality attributes (glycosylation, aggregates, HCP, charge variants) remained **within established fed-batch specifications** throughout extended campaigns, with high cell densities (50–80 × 10^6 cells/mL) sustained for 3–4 weeks[9].

Why this matters:

A common concern is that PI works in the lab but fails at scale or in integrated configurations. This pilot study proves that **integrated PI trains can scale predictably** and operate robustly at commercially relevant scales (50–500 L range typical for clinical and small-commercial programs). The 150× scale-up with equipment reuse validates Chapter 5's phased roadmap—robust scale-down models developed in Phase 1 translate reliably to Phase 2 pilots.

Citations:

[9] Vogel, J.H., et al. "Integrated Continuous Bioprocessing: Pilot-Scale Demonstration and 150× Scale-Up." *Biotechnology Progress*. 2022. PMC9541590. https://pmc.ncbi.nlm.nih.gov/articles/PMC9541590

Story 7: Conference Agendas — PI as Mainstream, Not Niche

Headline: ICB VII (2025) and major bioprocessing summits feature PI as core themes with commercial case studies from large innovators and CDMOs.

Evidence:

- **Integrated Continuous Biomanufacturing (ICB) VII conference** (2025) dedicated majority of technical sessions to perfusion, multicolumn chromatography, continuous viral inactivation, SPTFF, and PI-centric facility design—no longer relegated to side tracks[10].
- Presenters included **large innovators (AstraZeneca, BMS, Amgen), leading CDMOs (Lonza, Samsung Biologics, WuXi), and technology vendors**, with emphasis on **real commercial campaigns and lessons learned** rather than purely conceptual or bench-scale work[10].
- Similar trends observed at **2025 BioProcessing Summit Continuous Processing Track**, where PI platforms were positioned as **repeatable, validated offerings** marketed to sponsors, not experimental pilots[11].

Why this matters:

Conference agendas are a leading indicator of where the industry is investing. The shift from PI as a niche side topic (pre-2020) to **central conference themes with commercial case studies** signals that PI has crossed the chasm from early adopters to mainstream practice. For leadership teams, this reduces "first-mover risk"—you are no longer pioneering unproven technology; you are catching up to an emerging competitive standard.

Citations:

[10] Engineering Conferences International. "Integrated Continuous Biomanufacturing VII — Final Program." 2025. https://www.engconf.org/icb-vii

[11] BioProcessing Summit. "Intensified and Continuous Bioprocessing Track." 2025. https://www.bioprocessingsummit.com

Story 8: CPI Independent Analysis — 30% CoG Reduction, Major Footprint Savings

Headline: Neutral third-party analysis confirms 30% cost-of-goods reduction and significantly smaller facility footprints vs. fed-batch benchmarks.

Evidence:

- **UK Centre for Process Innovation (CPI)**, a neutral, non-vendor public-private research organization, published **2025 techno-economic analysis** comparing intensified/continuous biologics facilities to conventional fed-batch stainless baselines[12].
- Analysis reports **~30% CoG reduction** for hybrid PI configurations (N-1 perfusion + intensified DSP) and **significantly smaller footprints** (40–60% reduction in cleanroom area for equivalent annual output)[12].
- Study emphasizes **modular POD-based facilities and integrated single-use processes** as key enablers of both cost reduction and accelerated deployment (6–18 months vs. 3–5 years for traditional stainless facilities)[12].

Why this matters:

CPI is an **independent, government-backed research center**—not a vendor or CDMO with commercial incentives to overstate benefits. Their validation of 30% CoG reduction and major footprint savings provides **neutral, third-party credibility** for the economic ranges cited throughout Chapters 4, 7, and 11. Use CPI data when presenting to skeptical CFOs, board members, or finance committees who discount vendor claims.

Citations:

[12] UK Centre for Process Innovation. "Smarter, Smaller, Stronger: The Economics of Intensified Biologics Manufacturing." Blog and technical report. December 2025. https://www.uk-cpi.com

Story 9: Market Growth Projections — 20% CAGR for Continuous/PI Solutions

Headline: Bioprocess equipment and automation market projections show 20% annual growth for continuous/PI solutions through late 2020s, driven by perfusion and digital enablers.

Evidence:

- **2025–2026 bioprocess market analyses** project **~20% compound annual growth rate (CAGR)** for continuous and intensified bioprocessing solutions (perfusion systems, multicolumn chromatography, inline monitoring, automation platforms) through 2028–2030[13][14].
- Growth is **largely driven by perfusion bioreactors, intensified DSP equipment (MCC, SPTFF), and enabling automation/PAT technologies**—the exact PI toolbox described in Chapter 3[13][14].
- Market surveys highlight **automation and data integration as primary bottlenecks and enablers** for PI adoption, reinforcing that **PI and digital transformation are inseparable** for sustainable competitive advantage (Chapter 9)[13][14].

Why this matters:

Market growth rates reflect where capital is flowing. A 20% CAGR for PI-enabling technologies signals that **vendors, CDMOs, and innovators are collectively betting on PI as the future**. For leadership teams, this means:

- **Vendor ecosystems will mature rapidly** — more robust equipment, better integration, competitive pricing.
- **Talent pools will shift** — engineers and scientists will increasingly expect to work with PI platforms, not legacy batch.
- **Competitive pressure will intensify** — rivals adopting PI will gain structural cost and capacity advantages that cannot be closed through incremental optimization.

Citations:

[13] American Pharmaceutical Review. "The Bioprocess Revolution: How Technology and Trends are Reshaping Pharmaceutical Manufacturing." 2025. https://www.americanpharmaceuticalreview.com

[14] AspenAlert (LinkedIn). "Biotech and Bioprocess Activity Trends." 2026. https://www.linkedin.com/company/aspenalert

Story 10: WuXi Biologics Stepwise Platform — 3–5× Titer Gains in Intensified Fed-Batch

Headline: Stepwise cell culture intensification platform achieves 3–5 g/L in intensified fed-batch and >50 g/L cumulative titers in perfusion, enabling 3–5× smaller bioreactor volumes for equivalent output.

Evidence:

- **WuXi Biologics** publicly presented a **stepwise intensification platform** that progresses from conventional fed-batch (5–8 g/L) → intensified fed-batch with high-inoculation (IFB, 20–35 g/L) → production perfusion (cumulative titers >50 g/L)[15].
- Platform demonstrates that **same molecule can be progressively intensified** as program matures and volumes increase, avoiding all-or-nothing commitment to perfusion at early clinical stages[15].
- Enables **3–5× reduction in required bioreactor volume** for a given annual output target, unlocking capacity in existing facilities or enabling regional facilities with smaller footprints (500–1,500 L instead of 2,000–10,000 L)[15].

Why this matters:

WuXi's stepwise approach validates the **phased adoption strategy** advocated throughout this book. Organizations do not need to commit to end-to-end continuous from Day 1. Start with intensified fed-batch (lower risk, modest gains), prove value, then escalate to perfusion for high-volume or cost-sensitive programs. This de-risks PI adoption and aligns with Chapter 11's entry-point decision framework.

Chapter 9 references (15)

[1] WuXi Biologics. "Stepwise Cell Culture Process Intensification Platform." White paper and conference presentations. 2024–2025. https://www.wuxibiologics.com

[2] CPHI Online. "Breaking the 40 per gram barrier" video presentation. 2025. https://www.cphi.com

[3] BioProcess International. *Process Intensification: Driving Efficiencies in Bioprocessing* eBook. 2024.

[4] Repligen/XCell ATF. "From Fed-Batch to Perfusion: Unlocking ROI and Capacity in Monoclonal Antibody Manufacturing." White paper. September 2025. https://www.repligen.com/resources

[5] BioPlan Associates/BioProcess Online. "Report: Nearly 40% of Biomanufacturers Eyeing Continuous Processing." Industry survey. 2025. https://www.bioprocessonline.com

[6] Steinebach, F., Müller-Späth, T., & Morbidelli, M. "Do We Really Need End-to-End Continuous Bioprocessing? A Techno-Economic Perspective." *Biotechnology and Bioengineering*. 2025;122(4):xxx–xxx. DOI: 10.1002/bit.xxxxx

[7] Orbit DTU. "Single-Pass Tangential Flow Filtration: Critical Operational Variables for Intensified Downstream Processing." Technical study. 2022. https://backend.orbit.dtu.dk

[8] Orbit DTU. "SPTFF Applications in Continuous Biomanufacturing." Study update. 2025. https://orbit.dtu.dk

[9] Vogel, J.H., Walther, J., Lu, Y., et al. "Integrated Continuous Bioprocessing: Pilot-Scale Demonstration of Perfusion with Continuous Capture and Polishing." *Biotechnology Progress*. 2022;38(6):e3290. PMC9541590. https://pmc.ncbi.nlm.nih.gov/articles/PMC9541590

[10] Engineering Conferences International. "Integrated Continuous Biomanufacturing VII — Final Program and Posters." Conference proceedings. 2025. https://www.engconf.org/icb-vii

[11] BioProcessing Summit. "Intensified and Continuous Bioprocessing Track: Session Summaries." Conference agenda. 2025. https://www.bioprocessingsummit.com/continuous-track

[12] UK Centre for Process Innovation (CPI). "Smarter, Smaller, Stronger: The Economics of Intensified Biologics Manufacturing." Technical blog and analysis. December 2025. https://www.uk-cpi.com/blog/intensified-biologics

[13] American Pharmaceutical Review. "The Bioprocess Revolution: How Technology and Trends are Reshaping Pharmaceutical Manufacturing." Market analysis. 2025. https://www.americanpharmaceuticalreview.com/featured-articles/bioprocess-revolution

[14] AspenAlert (LinkedIn). "Biotech and Bioprocess Equipment Activity Trends Q4 2025 – Q1 2026." Market commentary. 2026. https://www.linkedin.com/company/aspenalert

[15] WuXi Biologics. "Stepwise Cell Culture Process Intensification Platform: From Fed-Batch to Perfusion." White paper and conference presentations. 2024–2025. https://www.wuxibiologics.com/resources

APPENDIX A

BIOTECH RESOURCES GROUP
GENERAL INFORMATION

Appendix A: Biotech Resources Group Information

BRG LinkedIn Page
BRG Web
Locations: Maryland, Boston, Basel, Shanghai
Author: bobV@biotech-1.com | 202.738.338six
Author: johnV@biotech-1.com

Appendix B: BRG E-Book #2

Due: Q2 / 2027

Intent: Let's put PI/CM (book#1) to work with some LOE biosimilars



APPENDIX B

BIOTECH RESOURCES GROUP'S
EBOOK #2 : CONCEPT ONLY


Biosimilars by Design:
Facility Design Considerations for Intensified & Continuous Biologics Manufacturing
SITE SELECTION
☑ BUSINESS DRIVERS / BIOSIMILAR SELECTION
☑ FACILITY CONCEPTUAL DESIGN APPROACH (CD)
BASIC DESIGN / TYPE-C
DETAILED DESIGN
PROCURE
QUALIFY / OPERATE
REMEDY PERSISTENT CHALLENGES
RETROFIT / EXPAND
CDMO AUDIT / OUTSOURCING
FACILITY FOCUS
USTEKINUMAB
E-BOOK 2
www.biotech-1.com
Robert Valdes
Biotech Resources Group, LLC

APPENDIX C

BIOTECH RESOURCES GROUP
SERVICES BROCHURE

Biotech Resources Group (BRG) exists to help small to medium-sized biologics companies solve capacity constraints. As an independent **GMP** biologics capacity advisors and owners-reps, we help biologics manufacturing companies solve capacity constraints in **3 different ways**:

1 Support **GMP** clients* as they select, engage, and work externally with a large (EPCM), high-horsepower engineering and design team.
OUTCOME: New Facility, Capacity Increase

2 Support **GMP** clients with internal audit(s) that uncovers internal capacity without an expansion or new facility.
OUTCOME: Increased Capacity, Agility

3 Support **GMP** clients as they search, score, audit, award, and manage a DS/DP CDMO.
OUTCOME: Increased Capacity, Expertise



*NEWCO, SMALL, & MEDIUM-SIZED COMPANIES
USA EU APAC

POWER-UP YOUR CAPACITY WITH OUR GMP SERVICES ECOSYSTEM BRIDGEONE

BRIDGEONE

BIOTECH RESOURCES GROUP, LLC
www.biotech-1.com | zoe@biotech-1.com

BRG
BIOTECH RESOURCES GROUP

Resolving Capacity Constraints & Driving GMP Batch Success

As independent GMP biologics capacity advisors and owner's representatives, we help GMP biomanufacturing companies resolve capacity constraints in 3 ways:

1 Support **GMP** clients* as they select, engage, and work externally with a large (EPCM), high-horsepower engineering and design team.
OUTCOME: New Facility, Capacity Increase

2 Support **GMP** clients with internal audit(s) that uncovers internal capacity without an expansion or new facility.
OUTCOME: Increased Capacity, Agility

3 Support **GMP** clients as they search, score, audit, award, and manage a DS/DP CDMO.
OUTCOME: Increased Capacity, Expertise

TECHNICAL SKILLS REQUIRED	Site Selection / Incentives Vendor Qualification, Award, PM Conceptual Design Support Basic Design Support Detail Design Support BFD, PFD, Time & Motion	+ Equipment URS/Datasheets Constructability Review Procure: Design/Fab/FAT/SAT/ Stainless Superskids Single-Use Systems Process Intensification
MANUFACTURING SKILLS REQUIRED	Facility Audits (All Departments) Facility Design Review Equipment Qualification Time-Motion/Process Staffing, Expertise, Experience	
OPS, QUALITY SKILLS REQUIRED	Facility Audits CDMO Qualification, Award, PM Start-Up, Comm, Qual TYPE-C / NMPA Meetings	



BRIDGEONE **POWER-UP YOUR CAPACITY WITH OUR GMP SERVICES ECOSYSTEM BRIDGEONE**

BRG
BIOTECH RESOURCES GROUP

GMP CAPACITY CHALLENGES

As independent GMP biologics capacity advisors and owner's representatives, we help GMP biomanufacturing companies resolve capacity constraints in **3** different ways:

1 BRG supports GMP clients as they select, engage, and work externally with a large (EPCM), high-horsepower engineering and design team.

2 Support GMP clients with internal audit(s) that uncovers internal capacity without an expansion or new GMP facility.

3 Support GMP clients as they search, score, audit, award, and manage a DS/DP CDMO.

BRIDGEONE
GMP SERVICES ECOSYSTEM

Working alongside Biotech Resources Group (BRG), we'll work shoulder-to-shoulder to help your teams resolve your capacity constraints through a phased approach that reduces decision risk and builds confidence early.

If you're wrestling with: Untapped/Hidden capacity, persistent contamination, or a GMP Capacity Increase decision, let's connect to discuss solutions and options.

- CDMO OUTSOURING
- NEW GMP FACILITY / EXPANSION
- INTERNAL AUDIT / CAPACITY HUNT

DOING NOTHING IS NOT AN OPTION

1 2 3

DESIRED OUTCOMES

1 NEW FACILITY / EXPANSION (EPCM Partner)
- Facility Design that fits CQA's / Modalities
- Layouts, Segregation aligned with FDA/Annex-1
- Fewer late design changes and surprises
- Steer and Challenge the EPCM Partner

2 EXTERNAL CDMO CAPACITY
- Shortlisted CDMO's screened for technical fit, maturity, and real capacity
- Strong Governance and Expectation Management

3 INTERNAL CAPACITY AUDIT
- GMP Capacity Remediation Roadmap
- Review Design, Equipment, Processes, and Operations
- Defer capex if recoverable internal capacity is high

POWER-UP YOUR CAPACITY WITH OUR GMP SERVICES ECOSYSTEM BRIDGEONE

BRIDGEONE

Robert Valdes (Bob) | GMP Capacity Advisor, Consultant | | bobv@biotech-1.com | www.biotech-1.com

APPENDIX D

BIOTECH RESOURCES GROUP
PROJECT DASHBOARD SAMPLER

3 SMART WAYS TO RESOLVE GMP CAPACITY CONSTRAINTS

As GMP Biologics Capacity Advisors, BRG helps small-medium sized biologics manufacturing companies resolve their capacity constraints in 3 ways:

1 BRG supports GMP clients as they select, engage, and work externally with a large (EPCM), high-horsepower engineering and design team.

2 Support GMP clients with internal audit(s) that uncovers internal capacity without an expansion or new GMP facility. Audit also serves to assess, roadmap, and remedy a dysfunctional facility

3 Support GMP clients as they Search, Qualify, Audit, Score, Award and Manage a DS/DP CDMO.

PROJECT SAMPLER

GEO	ENTITY	SCALE (L)	MODALITY	SITE	CD	BD	DD	OPS	AUDIT	TYPE
USA	CDMO	4 X 2000	mAb/Cytokine	★						1
USA	CDMO	10 x 15,000	mAb/Cytokine	★						1
ASIA	CDMO	4 x 5000	mAb/Cytokine	★	★	★	★	★		1
ASIA	CDMO	4 X 300	PLASMID	★	★	★	★	★		1
USA	CDMO	3 X 2000	AAV/LV		★	★	★	★		1
ASIA	CDMO	4 x 2000	mAb/Cytokine		★	★	★	★		1
USA	CDMO	4 X 6000	mAb/Cytokine		★	★		★		1
USA	INNOV	CAMPUS	FF-WHS		★			★		1
ASIA	CDMO	3 X 20,000	mAb/Cytokine		★			★		1
ASIA	CDMO	3 X 30,000	Incl. body		★			★		1
ASIA	CDMO	4 X 2000	AAV / AdV		★			★		1
ASIA	CDMO	10 x 15,000	mAb/Cytokine		★			★		1
ASIA	INNOV	COMM'L	CELL THERAPY		★			★		1
EU	INNOV	4 x 6000	COVID				★	★		1
EU	INNOV	4 x 2000	COVID				★	★		1
Asia	CDMO	2 X 30,000	E.coli/Incl Body						★	2
INDIA	CDMO	4 X 4000	COVID						★	2
USA	INNOV	1000	Enzyme						★	2
ASIA	CDMO	10 x 60,000	Antibiotics						★	2
ASIA	CDMO	6 x 2000	mAb/Cytokine						★	3
USA	INNOV	Pilot	mAb						★	3
USA	CDMO	200 VPM	Fill Finish						★	3

DOING NOTHING IS VERY COSTLY

"Biologics manufacturing is entering a decade in which cost, capacity, and flexibility will determine who remains competitive, particularly as originator products lose exclusivity and biosimilars reshape global price expectations. Traditional fed-batch platforms and incremental debottlenecking can no longer reliably deliver the economics and agility that portfolios of mid-volume biologics, biosimilars, and regionally supplied products require. Process intensification and continuous manufacturing have moved from interesting pilots to proven options in commercial settings, yet many organizations remain in a sustained "wait and see" posture.

"The expectation is not that every reader will become a subject-matter expert in process intensification and/or continuous manufacturing. Rather, by the end of the book, a COO or technical leader should be able to articulate why PI/CM is strategically relevant to their own portfolio and network, distinguish between incremental optimization and step-change redesign, identify a small number of credible starting points, and ask sharper questions of internal teams and external partners. In short, this e-book is designed to move leadership from general awareness to a deliberate, defensible decision about when and how to act. It should make you think a little differently."

Robert and John Valdes

GMP IS IN OUR DNA®

Driving GMP Batch Success, Capacity, and Consistency/Equivalency at Global Scale

BRG
BIOTECH RESOURCES GROUP